

Prof. Madhukar Pai, MD, PhD, FCAHS, FRSC

Inaugural Chair, Department of Global and Public Health, McGill School of Population and Global Health
Canada Research Chair in Epidemiology & Global Health
Professor of Epidemiology, McGill University
Former Director, McGill International Tuberculosis Centre

Date of Last Revision: 29 Jan 2025

A. Contact Information

Address	McGill University Department of Global and Public Health School of Population and Global Health 2001 McGill College Avenue, Suite 1200 Montreal QC H3A 1G1
Telephone	514-398-5422
Fax	514-398-4503
Email	madhukar.pai@mcgill.ca
Website	http://www.paitbgroup.org/

B. Education

Medical

1993	MB BS Stanley Medical College, Chennai, India Dr MGR Medical University, Chennai, India
1997	MD (Community Medicine) Christian Medical College, Vellore, India Dr MGR Medical University, Chennai, India

Graduate/Doctoral

2004	PhD (Epidemiology) University of California, Berkeley, CA, USA Dissertation: Evaluation of Newer Diagnostic Tests for Tuberculosis Supervisor: Professor John M Colford, Jr.
------	---

Postgraduate/Post-Doctoral

2005 – 2006	Postdoctoral fellowship University of California, San Francisco & University of California, Berkeley, CA Focus: tuberculosis epidemiology Supervisors: Professor Philip C Hopewell & Professor Arthur L Reingold
-------------	---

Postgraduate Clinical Training

1993 – 1994	Rotating Internship Stanley Medical College Hospital, Chennai, India
1994 – 1997	Community Medicine Residency Program Christian Medical College, Vellore, India
1997 – 2000	Consultant in Community Medicine Sundaram Medical Foundation Hospital, Chennai, India

Professional Certifications

1994 – Present	Unrestricted medical license, Indian Medical Council, India
1998 – Present	Diplomate of the National Board of Examinations (Board certification in Preventive & Social Medicine), National Board of Examinations, India
2008 – Present	Member, Council of Physicians, Dentists and Pharmacists (CPDP), McGill University Health Centre, Montreal

C. Appointments

University

2015 – Present	Full Professor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal
2011 – 2015	Associate Professor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal
2006 – 2011	Assistant Professor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal
2024 – Present	Director, McGill Global Health Programs, McGill University, Montreal
2023 – Present	Inaugural Chair, Department of Global and Public Health, McGill University, Montreal
2013 – Present	Associate Director, McGill International TB Centre, McGill University, Montreal
2006 – Present	Associate Member, Department of Medicine, McGill University, Montreal
2020 – 2023	Associate Director, McGill International TB Centre, McGill University, Montreal
2018 – 2020	Director, McGill International TB Centre, McGill University, Montreal
2014 – 2020	Director, McGill Global Health Programs, McGill University, Montreal
2007 – 2012	Member, McGill Centre for the Study of Host Resistance, McGill University, Montreal

Hospital

2019 – Present	Senior Scientist, Research Institute of the McGill University Health Centre (MUHC)
2006 – Present	Member, Respiratory Epidemiology & Clinical Research Unit (RECRU), Montreal Chest Institute, Montreal
2014 – 2016	Associate Program Leader, Program on Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre (MUHC).
2006 – 2019	Senior Scientist, McGill University Health Centre (MUHC), Divisions of Respiriology and Infectious Diseases
2006 – 2008	Assistant Director for Global Health Research, Research Institute of the McGill University Health Centre (MUHC-RI), Montreal

Visiting Professorships and external positions

2018 – Present	Visiting Professor, Chinese Academy of Medical Sciences, Beijing, China
2017 – Present	Adjunct Professor, Indian Council of Medical Research, New Delhi, India
2014 – Present	TMA Pai Endowment Chair in Translational Epidemiology & Implementation Science, Manipal University, Manipal, India
2013 – Present	Honorary International Visiting Faculty, Translational Health Science and Technology Institute, New Delhi, India
2012 – Present	Adjunct Faculty, Department of Pulmonary Medicine, Christian Medical College, Vellore, India
2009 – Present	Honorary Professor, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
2000 – Present	Visiting Faculty, Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India
2014 – 2015	Co-Director, Axe en Santé Mondiale, Réseau de recherche en santé des populations du Québec (RRSPQ), Quebec, Canada
2008 – 2012	Professor Extraordinary, Department of Community Health, Faculty of Health Sciences, Stellenbosch University, South Africa

D. Special Honors, Awards, Recognition

Honors

2012	Chanchlani Global Health Research Award, McMaster University
2014	Membership, Royal Society of Canada [College of New Scholars, Artists and Scientists]
2015	Haile T. Debas Prize, Faculty of Medicine, McGill University
2017	David Johnston Faculty & Staff Award, McGill Alumni Association
2017	Fellow, Canadian Academy of Health Sciences

2018	Honoree, 75 most influential public health alumni, School of Public Health, University of California, Berkeley
2019	Principal's Prize for Public Engagement Through Media, McGill University
2019	Named to REACH 50 list 2019, Recognizing Excellence Around Champions of Health (REACH) Awards
2023	Fellow, Royal Society of Canada

Career (Salary) Awards

2007 – 2012	CIHR New Investigator Award Canadian Institutes of Health Research (CIHR)	\$300,000
2007 – 2011	FRQS Chercheur Boursier – Junior 1 Fonds de la recherche du Québec – Santé (FRQS)	Declined
2007 – 2010	Établissement de jeunes chercheurs Fonds de la recherche du Québec – Santé (FRQS)	\$45,000
2012 – 2014	FRQS Chercheur Boursier – Junior 2 Fonds de la recherche du Québec – Santé (FRQS)	\$128,472
2014 – 2015	FRQS Chercheur Boursier – Senior Fonds de la recherche du Québec – Santé (FRQS)	\$211,962
2015 – 2022	Canada Research Chair (Tier 1) Canadian Institutes of Health Research (CIHR)	\$1,400,000
2022 – 2029	Canada Research Chair (Tier 1), renewal Canadian Institutes of Health Research (CIHR)	\$1,400,000

Research Awards

1994	Dr. Rangarajan Memorial Award in Community Health Christian Medical College, Vellore, India
2005	Warren Winkelstein Award for Excellence in Epidemiology University of California, Berkeley, USA
2006	Millennium Research Award Research Institute of the McGill University Health Centre, Montreal, Canada
2007	Union Scientific Prize International Union Against Tuberculosis and Lung Disease, France
2011	Canadian Rising Stars in Global Health, Grand Challenges, Canada
2013	Stars in Global Health, Grand Challenges, Canada

Teaching and Mentorship Awards

2002	Outstanding Graduate Student Instructor Award, University of California, Berkeley
------	---

2007	Core Teaching Award, Epidemiology, Biostatistics and Occupational Health Students' Society (EBOSS), McGill University
2007	Student Advocacy Award, Epidemiology, Biostatistics and Occupational Health Students' Society (EBOSS), McGill University
2008	Core Teaching Award, Epidemiology, Biostatistics and Occupational Health Students' Society (EBOSS), McGill University
2009	Core Teaching Award, Epidemiology, Biostatistics and Occupational Health Students' Society (EBOSS), McGill University
2009	Certificate of Merit award for teaching excellence from the Canadian Association for Medical Education (CAME)
2011	Core Teaching Award, Epidemiology, Biostatistics and Occupational Health Students' Society (EBOSS), McGill University
2012	Core Teaching Award, Epidemiology, Biostatistics and Occupational Health Students' Society (EBOSS), McGill University
2013	Faculty Honour List for Educational Excellence, Faculty of Medicine, McGill University

E. Teaching

E1. McGill Courses

Year/term	Course title	Course number	Credits	Role	# of students	In class hours
Fall 2006	Substantive Epidemiology 2	EPIB642	1	Instructor	23	13
Winter 2007	Practicum	EPIB640	1	Co-instructor	21	13
Summer 2007	Systematic reviews & meta-analysis	EPIB672	2	Instructor	20	26
Fall 2007	Fundamentals of Epidemiology 1	EPIB601	4	Instructor	22	52
Summer 2008	Systematic reviews & meta-analysis	EPIB672	2	Instructor	22	26
Fall 2008	Fundamentals of Epidemiology 1	EPIB601	4	Instructor	33	52
Summer 2009	Systematic reviews & meta-analysis	EPIB672	2	Instructor	25	26
Fall 2009	Fundamentals of Epidemiology 1	EPIB601	4	Instructor	34	52
Summer 2010	Systematic reviews & meta-analysis	EPIB672	2	Instructor	27	26
Fall 2010	Fundamentals of Epidemiology 1	EPIB601	4	Instructor	30	52
Summer 2011	Systematic reviews & meta-analysis	EPIB619	2	Instructor	28	26
Fall 2011	Fundamentals of Epidemiology	EPIB601	4	Instructor	30	52
Summer 2012	Systematic reviews & meta-analysis	EPIB619	2	Co-instructor	36	26

Summer 2013	Systematic reviews & meta-analysis	EPIB619	2	Co-instructor	24	26
Fall 2013	Knowledge Synthesis	EPIB677	3	Instructor	15	39
Summer 2014	Systematic reviews & meta-analysis	EPIB619	2	Co-instructor	25	39
Fall 2014	Knowledge Synthesis	EPIB668	2	Instructor	8	26
Winter 2015	Global health: epidemiology research	EPIB681	3	Co-instructor	13	39
Summer 2015	Systematic reviews & meta-analysis	EPIB619	2	Co-instructor	28	39
Fall 2015	Fundamentals of Global Health	PPHS511	3	Instructor	49	39
Fall 2016	Fundamentals of Global Health	PPHS511	3	Instructor	46	39
Fall 2017	Fundamentals of Global Health	PPHS511	3	Instructor	55	39
Fall 2018	Fundamentals of Global Health	PPHS511	3	Instructor	59	39
Fall 2019	Fundamentals of Global Health	PPHS511	3	Instructor	69	39
Fall 2020	Fundamentals of Global Health	PPHS511	3	Instructor	147	39
Fall 2021	Fundamentals of Global Health	PPHS511	3	Instructor	161	39
Fall 2022	Fundamentals of Global Health	PPHS511	3	Instructor	154	39
Fall 2023	Fundamentals of Global Health	PPHS511	3	Instructor	171	39
Winter 2024	Knowledge translation, communications, and evidence-informed public health leadership	PPHS614	3	Instructor	33	39
Winter 2024	MDCM PIAT Selective on Global Health	INDS 426	2	Instructor	20	18
Fall 2024	Fundamentals of Global Health	PPHS511	3	Instructor	178	39
Winter 2025	Knowledge translation, communications, and evidence-informed public health leadership	PPHS614	3	Co-Instructor	41	39
Winter 2025	MDCM PIAT Selective on Global Health	INDS 426	2	Instructor	30	18

E2. Research Trainees Supervised

Graduated

- 2006 – 2009 Yasmin Akcikir
MSc (epidemiology)
Co-supervisor
Thesis: *Correlates of treatment outcomes of Multidrug-Resistant Tuberculosis (MDR-TB): a systematic review and meta-analysis*
Primary supervisor: Dick Menzies
Funding: MUHC-RI studentship
- 2007 – 2010 Kelty-Anne Hillier
MSc (epidemiology)
Primary supervisor
Thesis: *The impact of increasing antiretroviral therapy use on trends in pediatric admissions and in-hospital mortality at a large South African referral hospital*
Funding: MUHC-RI studentship
- 2008 – 2010 Jessica Lee Minion
MSc (epidemiology)
Primary supervisor
Thesis: *Evaluating light-emitting diode fluorescent microscopy for the diagnosis of active tuberculosis*
Co-supervisor: Dick Menzies
Funding: Quebec Respiratory Health Training Fellowship
- 2008 – 2010 Laurence Brunet
MSc (epidemiology)
Primary supervisor
Thesis: *Tobacco smoking in South African patients with suspected tuberculosis*
Funding: European Commission, EU-FP7 Award
- 2009 – 2011 Caroline Chartrand
Msc (epidemiology)
Primary supervisor
Thesis: *Rapid diagnostic tests for influenza*
Funding: CHU Sainte-Justine Hospital Foundation
- 2009 – 2011 Ioana Nicolau
Msc (epidemiology)
Primary supervisor
Thesis: *Urine-based Rapid Tests for Smoking and Isoniazid Treatment Adherence in Adult Patients in a Tuberculosis Clinic Setting*
Funding: European Commission, EU-FP7 Award
- 2010 – 2012 Lancelot Pinto
Msc (epidemiology)
Primary supervisor

- Thesis: *Chest radiograph scoring systems for the diagnosis of active tuberculosis*
Funding: European Commission, EU-FP7 Award
- 2010 – 2012 Anurag Bhargava
Msc (epidemiology)
Co-supervisor
Thesis: *Nutrition and tuberculosis*
Funding: Quebec Respiratory Health Training Program (QRHTP) fellowship
- 2008 – 2012 Alice Anne Zwerling
PhD (epidemiology)
Primary supervisor
Thesis: *Evaluating interferon-gamma release assays for routine screening of healthcare workers for tuberculosis infection*
Funding: MUHC-RI studentship & Frederick Banting & Charles Best CIHR Doctoral Award
- 2008 – 2012 Daphne Ling
PhD (epidemiology)
Primary supervisor
Thesis: *Alternative approaches to TB diagnostics research: methods for estimating the incremental value of new tests*
Funding: MUHC-RI studentship & Harrison Watson Scholarship, Faculty of Medicine, McGill University & Canadian Lung Association Fellowship
- 2012 – 2014 Claudia M. Denkinge
Postdoctoral fellow
Primary supervisor
Funding: Richard Tomlinson Postdoctoral Fellowship, McGill University & Burroughs –Wellcome Fellowship from the American Society of Tropical Medicine and Hygiene
- 2013 – 2014 Sandra Vivian Kik
Postdoctoral fellow
Primary supervisor
Funding: Bill & Melinda Gates Foundation QuTUB grant
- 2011 – 2015 Samuel Schumacher
PhD (epidemiology)
Primary supervisor
Thesis: *Epidemiology of diagnostic delays in tuberculosis*
Funding: MUHC-RI studentship & Quebec Respiratory Health Training Program (QRHTP) fellowship & Harrison Watson Scholarship, Faculty of Medicine, McGill University
- 2014 – 2015 Zhi Zhen Qin
MSc (epidemiology)
Primary supervisor
Thesis: *Delays in diagnosis and treatment of pulmonary tuberculosis, and patient care-seeking pathways in China: a systematic review and meta-analysis*

- Funding: FRQS fellowship
- 2014 – 2016 Andrew McDowell
Postdoctoral fellow
Primary supervisor
Funding: Bill & Melinda Gates Foundation QuTUB grant
- 2014 – 2016 Marzieh Ghiasi
MSc (epidemiology)
Primary supervisor
Thesis: *Tuberculosis among healthcare trainees in South India*
Funding: CIHR Graduate Studentship
- 2009 – 2016 Hojoon Sohn
PhD (epidemiology)
Primary supervisor
Thesis: *Impact and cost-effectiveness of point-of-care tests for tuberculosis*
Funding: European & Developing Countries Clinical Trials Partnership
- 2013 – 2016 Srinath Satyanarayana
PhD (epidemiology)
Primary supervisor
Thesis: *Quality of tuberculosis care in India*
Funding: MUHC-RI studentship & Canadian Thoracic Society fellowship
- 2016 – 2018 Toyin Togun
Postdoctoral Fellow
Primary supervisor
Thesis: *Improving the diagnosis of childhood tuberculosis*
Funding: Steinberg Postdoctoral Fellowship
- 2017 – 2019 Madlen Nash
MSc (epidemiology)
Primary supervisor
Thesis: *Deep learning, computer-aided radiography reading for tuberculosis*
Funding: CIHR Master's Scholarship
- 2017 – 2019 Vaidehi Nafade
MSc (epidemiology)
Primary supervisor
Thesis: *Over-the-counter antibiotic dispensing in South India: a standardised patient study*
Funding: Bill & Melinda Gates Foundation QuTUB grant
- 2015 – 2020 Sophie Huddart
PhD (epidemiology)
Primary supervisor
Thesis: *Tuberculosis Case Fatality in the Indian Private Healthcare Sector*
Funding: FRQS Doctoral Scholarship & CIHR Doctoral Scholarship
- 2019 – 2020 Pierrick Adam

- Postdoctoral Fellow
Primary supervisor
Funding: Foundation for Innovative New Diagnostics
- 2018 – 2020 Jody Boffa
Postdoctoral Fellow
Co-supervisor
Funding: MUHC-RI fellowship
- 2018 – 2020 Mikashmi Kohli
Postdoctoral Fellow
Primary supervisor
Funding: Foundation for Innovative New Diagnostics
- 2017 – 2021 Giorgia Sulis
PhD (epidemiology)
Primary supervisor
Thesis: *Antibiotic abuse in low- and middle-income countries*
Funding: Tomlinson Doctoral Award, McGill University
- 2019 – 2021 Paulami Sen
MSc (epidemiology)
Primary supervisor
Thesis: *Associations between client experience and technical care quality: A standardized patient study for TB in urban India*
Funding: CIHR Master's Scholarship
- 2016 – 2022 Emily MacLean
PhD (epidemiology)
Primary supervisor
Thesis: *Expanding the use cases of molecular testing for tuberculosis*
Funding: FRQS Doctoral Scholarship & CIHR Doctoral Scholarship
- 2020 – 2022 Charity Omenka
Postdoctoral Fellow
Primary supervisor
Funding: Bill & Melinda Gates Foundation COVET grant
- 2017 – 2022 Anita Svadzian
PhD (epidemiology)
Primary supervisor
Thesis: *Underdiagnosis and overtreatment: provider practices for tuberculosis care in India*
Funding: FRQS Scholarship
- 2020 – 2022 Lavanya Huria
MSc (epidemiology)
Primary supervisor
Thesis: *Delays and number of encounters before diagnosis for individuals with TB in an urban setting in Indonesia*
Funding: Bill & Melinda Gates Foundation COVET grant

- 2020 – 2022 Angelina Sassi
MSc (epidemiology)
Primary supervisor
Thesis: *Impact of the COVID-19 pandemic on quality of TB screening in private facilities in Bandung, Indonesia*
Funding: Bill & Melinda Gates Foundation COVET grant
- 2020 – 2023 Mikashmi Kohli
MSc (epidemiology)
Primary supervisor
Thesis: *Diagnostic accuracy of low and moderate complexity assays for pulmonary and extrapulmonary tuberculosis detection: systematic review and meta-analyses*
Funding: Dr Margaret Becklake Fellowship in Respiratory Research
- 2018 – 2023 Lena Faust
PhD (epidemiology)
Primary supervisor
Thesis: *The drug-resistant tuberculosis care cascade in Lima, Peru, prior to and during the COVID-19 pandemic*
Funding: CIHR Doctoral Scholarship
- Current**
- 2020 – Present Alexandra Zimmer
PhD (epidemiology)
Primary supervisor
Thesis: *Artificial intelligence-based analysis of cough for tuberculosis and COVID-19 screening*
Funding: CIHR Doctoral Scholarship
- 2023 – Present Luz Villa
MSc (epidemiology)
Funding: Foundation for Innovative New Diagnostics
- 2023 – Present Poshan Thapa
Postdoctoral Fellow
Funding: FRQS Postdoctoral Fellowship
- 2024 – Present Jeyashree Kathiresan
MSc (epidemiology)
Funding: Foundation for Innovative New Diagnostics
- 2024 – Present Shashika Bandara
Postdoctoral Fellow
Funding: The O’Neill-Lancet Commission on Racism, Structural Discrimination and Global Health – Structural change for health equity

Contributions on Thesis Committees, McGill University

- 2007 – 2009 Caroline Gallant
PhD Thesis Committee
Thesis: *Genetic determinants that control anti-mycobacterial immune reactivity*
Supervisor: Erwin Schurr
- 2009 – 2011 Patricia Fontela
PhD Thesis Committee
Thesis: *Surveillance of Catheter-Related Bloodstream Infections in Quebec Intensive Care Units*
Supervisors: Robert Platt & Caroline Quach
- 2007 – 2010 Olivia Oxlade
PhD Thesis Committee
Thesis: *Development and application of a comprehensive tuberculosis transmission model to evaluate approaches to tuberculosis control*
Supervisor: Dick Menzies
- 2008 – 2010 Erika Leung
MSc Thesis Committee
Thesis: *MODS for tuberculosis diagnosis*
Supervisor: Dick Menzies
- 2011 – 2015 Lena Shah
PhD Thesis Committee
Thesis: *Active case finding for TB cases in high burden, low HIV settings, Peru*
Supervisors: Timothy Brewer & Jay Kaufman
- 2011 – 2012 Amr Albanna
MSc Thesis Committee
Thesis: *Does Fixed Dose Combination Anti-tuberculous Therapy Improve Treatment Outcomes? A Systematic Review and Meta-Analysis*
Supervisor: Dick Menzies

Contributions on Thesis Committees, External

- 2011 – 2013 Peter Daley
MSc Thesis Supervision Committee
Thesis: *A Randomized Trial of Efficacy and Safety of Adjunctive Vitamin D in the Treatment of Active Tuberculosis in India*
MSc Clinical Epidemiology Program, Memorial University of Newfoundland

E3. Invited Lectures, Talks, Seminars, Presentations (2007 – Present)

Named lectures:

1. Pai M. Improving TB diagnosis: knowing the path is not the same as walking the path. Scott J. Thaler Lecture, AERAS Global TB Vaccine Foundation, Rockville, USA, 30 March 2011.
2. Pai M. The freakonomics of TB control in India. Inaugural Chanchlani Global Health Research Award, McMaster University, Hamilton, Canada, 27 November 2012.

3. Pai M. The freakonomics of TB diagnosis in India. Inaugural Ellen Jo Baron Lecture at the Department of Pathology, Stanford University, California, USA, 10 January 2013.
4. Pai M. "India: the epicentre of global TB control", in Raviglione, M. and Nunn, P. (eds), *Tuberculosis. The Biomedical & Life Sciences Collection*, Henry Stewart Talks Ltd, London (online at <http://hstalks.com/?t=BL1533302-Pai>)
5. Pai M. New diagnostics for tuberculosis: converting technologies into health impact. Jubilee Lecture Series. De La Salle Health Sciences Institute, Manila, Philippines, 3 July 2013.
6. Pai M. The Doctor Charles Scriver Keynote Lecture: "Why should you care about global health?" Canadian Medical Hall of Fame Discovery Days, McGill University, Montreal, Canada, 7 December 2016.
7. Pai M. George W. Comstock Lecture: Putting quality on the tuberculosis agenda. 21st Annual Conference of The Union - North America Region, Vancouver, Canada, 23 February 2017.
8. Pai M. 10th Annual George W. Comstock Lecture: Time for a quality revolution in tuberculosis care. Johns Hopkins University, Baltimore, USA, 5 April 2017.
9. Pai M. 12th Annual Reynard J. McDonald World TB Day lecture. Department of Medicine, Rutgers University Medical School, New Jersey, USA, 26 March 2019.
10. Pai M. Steve Lawn Memorial Lecture. London School of Hygiene and Tropical Medicine, London, UK, 23 March 2023.
11. Pai M. Steve Gloyd Lecture. University of Washington School of Public Health, Seattle, USA, 16 May 2023.
12. Pai M. PRJ Gangadharam Endowment Award and Oration, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India, 18 August 2023.
13. Pai M. REACH 25th Anniversary Oration. Bridging the know-do gap in tuberculosis care. REACH, Chennai, India, 31 January 2024.

Invited lectures and seminar presentations:

14. Pai M. Serial testing with IFN-g assays: how should we define conversions, reversions and thresholds? Invited presentation at the First Global Symposium on Interferon-g Assays – Rethinking the epidemiology of tuberculosis infection, Vancouver, Canada, 21-22 February 2007.
15. Pai M. IFN-g assays in contact and outbreak investigations: intriguing differences across exposure-gradient studies Invited presentation at the First Global Symposium on Interferon-g Assays – Rethinking the epidemiology of TB infection, Vancouver, Canada, 21-22 February 2007.
16. Pai M. Tuberculosis infection among household contacts in rural India: comparison of a whole-blood interferon-gamma assay with the tuberculin skin test. Oral presentation at the First Global Symposium on Interferon-g Assays – Rethinking the epidemiology of tuberculosis infection, Vancouver, Canada, 21-22 February 2007.
17. Pai M. Applications of IGRAs in the developing world: what is their potential? Invited presentation at the American Thoracic Society International Conference, San Francisco, USA, 20 May 2007.
18. Pai M. What is known about interferon-gamma assays and what are the areas of controversy? Invited presentation at the 4th European Regional Congress of the International Union Against

- Tuberculosis and Lung Disease, Riga, Latvia, 28 June 2007.
19. Pai M. Confounding in health research: how many ways to skin this cat? Research Master Class, Stellenbosch University, Cape Town, South Africa, 6 August 2007.
 20. Pai M. Screening healthcare workers for TB infection: should T cell assays replace the tuberculin skin test? Invited seminar presentation at the University of Cape Town, South Africa, 13 August 2007.
 21. Pai M. New tests for TB infection: what can they contribute to childhood TB diagnosis in high-burden regions? Invited symposium presentation at the 38th World Conference on Lung Health, Cape Town, South Africa, 9-12 November 2007.
 22. Pai M, Dheda K. Challenges in the diagnosis of TB among individuals with HIV infection. Invited symposium presentation at the 38th World Conference on Lung Health, Cape Town, South Africa, 9-12 November 2007.
 23. Pai M. Role of new T-cell based diagnostic tests to evaluate children and adults exposed to active TB. Invited symposium presentation at the 38th World Conference on Lung Health, Cape Town, South Africa, 9-12 November 2007.
 24. Pai M. Introduction of what is known about IGRA tests. Invited presentation at the meeting on Interferon-gamma release assays, KNCV Tuberculosis Foundation, Cape Town, South Africa, 13 November 2007.
 25. Pai M. IGRA reproducibility, conversions and reversions: longitudinal studies from India. Invited presentation at the meeting on Interferon-gamma release assays, KNCV Tuberculosis Foundation, Cape Town, South Africa, 13 November 2007.
 26. Pai M. T-cell assay conversions and reversions among contacts of TB patients in rural India. Oral symposium presentation at the American Thoracic Society International Conference, Toronto, Canada, 19 May 2008.
 27. Pai M. New tools and emerging technologies for the diagnosis of active tuberculosis and drug resistance. Invited symposium presentation at the Canadian Respiratory Conference, Montreal, Canada, 20 June 2008.
 28. Pai M. Evidence-based TB diagnosis. Invited seminar presentation at the Institute of Infectious Diseases and Molecular Medicine (IIDMM), University of Cape Town, South Africa, 30 July 2008.
 29. Pai M. Introduction to systematic reviews and meta-analysis. Invited guest lecture in the Clinical Research Methods course, Department of Medicine, University of Cape Town, South Africa, 30 July 2008.
 30. Pai M. How close are we in differentiating infected from diseased in tuberculosis? Invited symposium presentation at the 39th World Conference on Lung Health, Paris, France, 16-20 October 2008.
 31. Pai M. Evidence for active and passive smoke exposure and increased risk of TB infection, TB disease, and TB mortality. Invited symposium presentation at the 39th World Conference on Lung Health, Paris, France, 16-20 October 2008.
 32. Pai M. Comparison of gamma interferon in human and animal tuberculosis: human. Invited symposium presentation at the 39th World Conference on Lung Health, Paris, France, 16-20

- October 2008.
33. Pai M. Tobacco, TB and mortality in India and China. Invited symposium presentation at the 39th World Conference on Lung Health, Paris, France, 16-20 October 2008.
 34. Pai M. LTBI diagnosis: advances and prospects. Annual Meeting of the Stop TB Partnership New Diagnostics Working Group, 39th World Conference on Lung Health, Paris, France, 16 October 2008.
 35. Pai M. Evidence-based TB Diagnosis: How evidence informs practice and policy. Annual Meeting of the Stop TB Partnership New Diagnostics Working Group, 39th World Conference on Lung Health, Paris, France, 16 October 2008.
 36. Pai M. IGRAs for the diagnosis of LTBI: are they relevant in TB endemic settings? FIND Scientific Forum on Recent Advances in TB Diagnostics, 39th World Conference on Lung Health, Paris, France, 17 October 2008.
 37. Pai M, Scano F. What is the evidence available to support TB infection control interventions? Invited symposium presentation at the 39th World Conference on Lung Health, Paris, France, 16-20 October 2008.
 38. Pai M. Serial Testing for Tuberculosis: Can We Make Sense of T-Cell Assay Conversions and Reversions? BCCDC Public Health Grand Rounds, BC CDC, Vancouver, Canada, 30 October 2008.
 39. Pai M. Tuberculosis among healthcare workers in the era of HIV and XDR-TB. Invited seminar presentation at Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, 31 October 2008.
 40. Pai M. Closing Plenary- New Technologies for TB Diagnosis: What's in the Cards? Ontario Lung Association TB Conference, Toronto, Canada, 25 November 2008.
 41. Pai M. Protecting healthcare workers from TB in the era of HIV and XDR-TB. Invited seminar presentation at the Hinduja Hospital, Mumbai, India, 18 December 2008.
 42. Pai M. Introduction to diagnostic meta-analysis. Workshop presentation at the South Asian Cochrane Centre, Christian Medical College, Vellore, India, 12 January 2009.
 43. Pai M. New diagnostics for tuberculosis: what's in the pipeline. Invited seminar presentation at St. John's Research Institute (SJRI), Bangalore, India, 17 January 2009.
 44. Pai M. Diagnosis of tuberculosis: stepping out of Robert Koch's shadow. Invited Winter Symposium presentation at Christian Medical College, Vellore, India, 22 January 2009.
 45. Pai M. New technologies for TB diagnosis: what's in the pipeline. Invited symposium presentation organized by VM Medical College & Safdarjung Hospital, India International Centre, New Delhi, India, 20 January 2009.
 46. Pai M. Effective Use of PubMed and EndNote for Searching and Managing Medical Literature. Workshop presentation at the University of Cape Town, Lung Infection and Immunity Unit, Department of Medicine and the School of Child Health, University of Cape Town, Cape Town, South Africa, 9 March 2009.
 47. Pai M. New technologies for TB diagnosis: what's hot and what's not? Invited seminar at the Department of Pediatrics, Chris Hani Baragwanath Hospital, Johannesburg, South Africa, 10 March 2009.

48. Pai M. Evidence-based TB diagnosis: incorporating evidence into new policies. Invited symposium talk at the 5th Union Conference European Region, Dubrovnik, Croatia, 30 May 2009.
49. Pai M, Joshi R, Gajalakshmi D, Reddy MVR, Kalantri SP. Unstable IGRA conversions and revisions in a high-incidence setting. Oral symposium presentation at the 2nd Global Symposium on IGRAs, Dubrovnik, Croatia, 30 May 2009.
50. Pai M. Guidelines on IGRAs: concordant or discordant? Invited symposium talk at the 2nd Global Symposium on IGRAs, Dubrovnik, Croatia, 1 June 2009.
51. Pai M. New diagnostics for TB: Current Status. Invited seminar presentation at the Research Institute of Tuberculosis, Tokyo, Japan, 30 June 2009.
52. Pai M. Serial Testing for TB Infection: How do We Interpret IGRA Conversions and Reversions? 6th Meeting of Research Unit for TB Infection Diagnostics, Sapporo, Hokkaido, Japan, 1 July 2009.
53. Pai M. Diagnosis of LTBI in BCG recipients. Invited symposium presentation at the 49th InterScience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting, San Francisco, USA, 12 September 2009.
54. Pai M, Minion J. Optimism bias, inflated accuracy estimates, and contradicted findings in TB diagnostic research. Invited seminar presentation, Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada, 5 October 2009.
55. Pai M. New tests and biomarkers for LTBI. Invited seminar presentation at the Public Health Laboratory - Toronto, Ontario Agency for Health Protection and Promotion, Toronto, Canada, 8 October 2009.
56. Pai M. Interpreting Interferon Gamma Release Assays – “Show me the data”. Invited symposium presentation at the IDSA 47th Annual Meeting, Philadelphia, USA, 31 October 2009.
57. Pai M. Diagnosis of TB infection in HIV-infected persons. Invited symposium presentation at the IDSA 47th Annual Meeting, Philadelphia, USA, 31 October 2009.
58. Pai M. Mapping the landscape and quality of TB diagnostic research. Invited symposium presentation at the Annual Meeting of the Stop TB Partnership's New Diagnostics Working Group, 40th Union World Conference on Lung Health, Cancun, Mexico, 3 December 2009.
59. Pai M. TB Diagnostics: Translating Evidence to Policy and Practice. Invited symposium presentation at the Annual Meeting of the Global Laboratory Initiative, 40th Union World Conference on Lung Health, Cancun, Mexico, 3 December 2009.
60. Pai M. Do IGRAs have a role in developing countries? Invited symposium presentation at the 40th Union World Conference on Lung Health, Cancun, Mexico, 5 December 2009.
61. Pai M. Understanding the epidemiology of smoking and TB. Invited symposium presentation at the 40th Union World Conference on Lung Health, Cancun, Mexico, 5 December 2009.
62. Pai M. Optimism bias, inflated accuracy estimates, and contradicted findings in TB diagnostic research. Beer Seminar, Meakins-Christie Laboratories, Montreal, Canada, 1 February 2010.
63. Pai M. Are IGRAs adequate for LTBI diagnosis and disease prediction? Invited symposium presentation at the 41st Union World Conference on Lung Health, Berlin, Germany, 13 November 2010.

64. Pai M. Interferon-gamma release assays and serological tests for tuberculosis: the evidence is reviewed. Stop TB Partnership's New Diagnostics Working Group Annual Meeting. 41st Union World Conference on Lung Health, Berlin, Germany, 11 November 2010.
65. Pai M. Landscape of TB diagnostics in India. ICGEB International Symposium on TB Diagnostics: Innovating to Make an Impact, New Delhi, India, 16 December 2010.
66. Pai M. TB Diagnosis in 2011: The Good, the Bad and the Ugly. Keystone Symposium on *Tuberculosis: Immunology, Cell Biology and Novel Vaccination Strategies*, Vancouver, Canada, 15-20 January 2011.
67. Pai M. Squeezing predictive value out of IGRAs. Special Grand Rounds, BC CDC, Vancouver, Canada, 18 January 2011.
68. Pai M. TB elimination: a realistic goal? World TB Day presentation, McGill AIDS Coalition, McGill University, Montreal, Canada, 24 March 2011.
69. Pai M. Improving TB diagnosis: difference between knowing the path and walking the path. IFMSA-Québec's Global Health Colloquium, Montreal, Canada, 27 March 2011.
70. Pai M. Diagnostic research: getting it right and going beyond test accuracy. Invited talk at the Association of Medical Microbiology and Infectious Disease Canada (AMMI) Annual Conference, Montreal, Canada, 7 April 2011.
71. Pai M. Assessing the impact of novel tuberculosis diagnostics. Invited symposium talk at the 3rd North American Congress of Epidemiology, Montreal, Canada, 23 June 2011.
72. Pai M. The medical, public health and economic consequences of bad diagnostics: the case of TB serology. Invited presentation. Diagnostics track. Grand Challenges Meeting, Bill & Melinda Gates Foundation, New Delhi, India, 7 November 2011.
73. Pai M. Quality of healthcare in India: the case study of tuberculosis. Invited seminar presentation, Indian Institute of Management, Bangalore, India, 26 December 2011.
74. Pai M. Advances in TB Diagnosis. Invited seminar presentation. Singapore Thoracic Society and Infectious Disease Society, Tan Tock Seng Hospital, Singapore, 5 January 2012.
75. Pai M. Point of care testing for HIV and TB: bridging the divide. Invited seminar presentation. Red Cross War Memorial Hospital, University of Cape Town, South Africa, 7 March 2012.
76. Pai M. Assessing the impact of new diagnostics. Invited presentation. Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa, 7 March 2012.
77. Pai M. India shining: TB control must not be left in the dark. Invited seminar presentation for World TB Day, Department of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India, 24 March 2012.
78. Pai M. The freakonomics of TB diagnostics in India. Invited presentation at the Kellogg School of Management, Northwestern University, Chicago, USA, 2 May 2012.
79. Pai M. The freakonomics of TB diagnostics in India. Invited presentation at Global Health Strategies, New York, USA, 7 June 2012.
80. Denkinger C, Pai M. TB: diversity of target product profiles. Invited presentation at Global Health Strategies, New York, USA, 7 June 2012.

81. Pai M. Meta-analysis: are you a lumper or a splitter? Invited presentation at the LRS Institute of Tuberculosis and Respiratory Diseases, New Delhi, India, 5 September 2012.
82. Pai M. Moving forward in the diagnosis of infectious diseases in resource limited settings. Fondation Merieux, Veyrier du Lac, France, 8 September 2012.
83. Pai M. TB diagnostics: global market analysis and potential. Invited presentation at Diagnostics innovation in China: bringing TB and HIV molecular diagnostics to market. Bill & Melinda Gates Foundation & Chinese Center for Disease Control and Prevention, Shanghai, China, 25 September 2012.
84. Pai M. India on the Rise: Can Tuberculosis be Controlled? Invited seminar presentation at the Geospectives Seminar Series 2012-2013, Department of Geography, McGill University, Montreal, Canada, 19 October 2012.
85. Pai M. Innovations in TB diagnostics: Progress and Challenges. Symposium presentation at the 19th Canadian Conference on Global Health, Ottawa, Canada, 22 October 2012.
86. Pai M. The changing face of TB diagnosis. Invited presentation at the symposium on New Therapeutic Avenues for Tuberculosis. Department of Biochemistry, McGill University, Montreal, Canada, 30 October 2012.
87. Pai M. TB diagnostics: top 10 FAQs by test developers. Invited presentation at the Stop TB Partnership's New Diagnostics Working Group Annual Meeting, Kuala Lumpur, Malaysia, 13 November 2012.
88. Pai M. Toward point-of-care: diagnostics pipeline and target product profiles. Invited presentation at: From Data to Scale-Up: Building on the Evidence Base for New TB Diagnostics. Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 13 November 2012.
89. Pai M. New TB diagnostics: pathway from concept to delivery, GRADE and beyond. Invited presentation at the Post-graduate course - Tuberculosis diagnostic research: providing the evidence for scale-up and sustainability at Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 14 November 2012.
90. Pai M. POC testing: diversity, complexity and barriers. Invited presentation. Diagnostics track. Grand Challenges Meeting, Bill & Melinda Gates Foundation & Grand Challenges Canada, Ottawa, Canada, 11 December 2012.
91. Pai M. TB diagnostics: top 10 FAQs by test developers. Invited presentation. Biomarkers for diagnostics of TB program meeting. Grand Challenges Meeting, Bill & Melinda Gates Foundation & Grand Challenges Canada, Ottawa, Canada, 13 December 2012.
92. Pai M. Diversity of TPPs. Invited presentation. Biomarkers for diagnostics of TB program meeting. Grand Challenges Meeting, Bill & Melinda Gates Foundation & Grand Challenges Canada, Ottawa, Canada, 13 December 2012.
93. Pai M. The changing face of TB diagnosis. Invited presentation at the Department of Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, India, 28 December 2012.
94. Pai M. Point-of-care testing: rethinking the old paradigm. Invited Lecture at Cepheid Inc, Sunnyvale, USA, 9 January 2013.
95. Pai M, Banaei N. Serial Testing for TB Infection with IGRAs: What-a-Mess! Grand Rounds at the

- Department of Infectious Diseases, Stanford University, California, USA, 10 January 2013.
96. Pai M. POC testing for infectious diseases: Diversity, complexity, and barriers in developing countries. Invited symposium presentation, 5th Annual Symposium on Neglected Diseases, Henry Wheeler Center for Emerging and Neglected Diseases, University of California, Berkeley, USA, 11 January 2013.
 97. Pai M. TB control in India: challenges for universal access. Invited presentation at the Division of Communicable Disease Control, California Department of Public Health, Richmond, USA, 11 January 2013.
 98. Kik S, Pai M. Update on IGRA predictive value. Invited presentation at the 3rd Semiannual TBESC-II Meeting, Tuberculosis Epidemiologic Studies Consortium, Centers for Disease Control and Prevention, Atlanta, USA, 6 February 2013.
 99. Pai M. Point-of-care TB testing: rethinking the old paradigm. Invited presentation at the 3rd Semiannual TBESC-II Meeting, Tuberculosis Epidemiologic Studies Consortium, Centers for Disease Control and Prevention, Atlanta, USA, 6 February 2013.
 100. Pai M. Testing for latent TB infection: a long way from perfection. Invited presentation at AERAS Global TB Vaccine Foundation, Rockville, USA, 25 February 2012.
 101. Pai M. Point-of-care TB testing: thinking beyond the dipstick paradigm. Invited presentation at PATH, Washington DC, USA, 25 February 2012.
 102. Pai M. Diagnosis: the weakest link in tuberculosis control? Invited presentation at the Department of Medicine, All India Institute of Medical Sciences, New Delhi, India, 20 March 2013.
 103. Pai M. The point behind point-of-care TB testing. Invited presentation at the Centre for Biodesign Translational Health Science and Technology Institute (THSTI), New Delhi, India, 21 March 2013.
 104. Pai M. New Diagnostic Tools for Active and Latent TB: What You Need to Know. Invited symposium presentation at the Canadian Respiratory Conference, Quebec City, Canada, 13 April 2013.
 105. Pai M. Target product profiles: which attributes will increase impact? Invited presentation at the TB Modelling and Analysis Consortium meeting on "Impact and cost-effectiveness of current and future diagnostics for TB," Bill & Melinda Gates Foundation, Amsterdam, Netherlands, 24-25 April 2013.
 106. Pai M. Improving access to better diagnostics in the Indian private sector. 2013 Tuberculosis Market Forum. UNITAID and USAID. Washington DC, USA, 24 July 2013.
 107. Pai M. Point-of-care tuberculosis testing: opportunities and challenges. Keynote lecture at the 8th National Conference on Laboratory Aspects of Tuberculosis. Association of Public Health Laboratories, San Diego, USA, 19 August 2013.
 108. Pai M. IGRAs: update on serial testing and predictive value. Invited lecture at the 8th National Conference on Laboratory Aspects of Tuberculosis. Association of Public Health Laboratories, San Diego, USA, 20 August 2013.
 109. Pai M. Tips for getting published and transitioning from a postdoc fellowship to an independent position. Invited seminar presentation: GHP/CAP seminar, L'Université du Québec à Montréal (UQAM), Montreal, Canada, 20 September 2013.

110. Pai M. Broken markets and broken patients: tuberculosis in India. Invited seminar at William Davidson Institute, Ross School of Business, University of Michigan, Ann Arbor, USA, 25 September 2013.
111. Pai M. Priorities for TB diagnostics and TPPs of relevance. Invited presentation. Biomarkers for diagnostics of TB program meeting. Grand Challenges Meeting, Bill & Melinda Gates Foundation, Rio de Janeiro, Brazil, 28 October 2013.
112. Pai M. Market landscape for innovative TB diagnostics. Invited presentation at the annual meeting of the New Diagnostics Working Group of the Stop TB Partnership. 44th Union World Conference on Lung Health, Paris, France, 31 October 2013.
113. Pai M. TB diagnostics pipeline: beyond Xpert. Invited presentation at the Sponsored Satellite Symposium by UNITAID. 44th Union World Conference on Lung Health, Paris, France, 2 November 2013.
114. Pai M. Overcoming barriers to the uptake of WHO-endorsed TB tests in high burden countries. Invited presentation at the Sponsored Satellite Symposium New and classical TB diagnostics: together enhancing the management of challenging TB cases. 44th Union World Conference on Lung Health, Paris, France, 1 November 2013.
115. Pai M. TB diagnosis: market shortcomings in the private sector. Invited presentation at the 44th Union World Conference on Lung Health, Paris, France, 3 November 2013.
116. Pai M. Transforming the landscape of TB in India: Microbiologists can make a big difference. Invited presentation at the MICROCON conference of Indian Association of Medical Microbiology, Hyderabad, India, 23 November 2013.
117. Pai M. Open access publishing: the good, the bad, and the ugly. Invited seminar at the Department of Pharmacology, Faculty of Medicine, McGill University, Montreal, Canada, 2 December 2013.
118. Pai M. The value chain for diagnostics: from concept to product to impact. Invited lecture at the Diagnostics by Design: A Workshop on the Design, Development and Implementation of Global Health Technologies, University of California, Berkeley, USA, 9 January 2014.
119. Pai M. Initiative to promote affordable and quality TB tests in India. Guest lecture at the Ross School of Business, University of Michigan, Ann Arbor, USA, 12 February 2014.
120. Pai M. Quality of TB Care in India. Invited lecture at the All India Institute of Medical Sciences, New Delhi, India, 24 March 2014.
121. Pai M. Advances in TB Diagnosis. Invited lecture at Kasturba Medical College, Mangalore, Manipal University, India, 29 March 2014.
122. Pai M. Improving Quality of TB Care in India. Invited lecture at Kasturba Medical College, Manipal, Manipal University, India, 29 March 2014.
123. Pai M. Priorities for TB diagnostics and target product profiles of relevance. Invited lecture at Consensus Meeting on Target Product Profiles for new TB tests, World Health Organization, Geneva, Switzerland, 28-29 April 2014.
124. Pai M. Point-of-care testing: what is the point? Invited talk at the American Society for Microbiology Annual Conference, Boston, USA, 20 May 2014.

125. [Pai M](#). Promoting affordable and quality TB tests in India: can the broken market be fixed? Invited seminar presentation at the Division of Infectious Diseases, Boston Medical Centre, Boston University, Boston, USA, 21 May 2014.
126. [Pai M](#). Improving the quality of tuberculosis care: a critical challenge for India. Invited Medical Grand Rounds, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, USA, 22 May 2014.
127. [Pai M](#). Open access publishing: the good, the bad, and the predators. Keynote lecture. GSAN Research Symposium, Graduate Student Association for Neuroscience, McGill University, Montreal Neurological Institute, Montreal, Canada, 23 May 2014.
128. [Pai M](#). Quality of TB care in the Indian private sector: the challenge ahead. Invited presentation at the conference on "Public Private Mix (PPM) Models for the Sustainability of Successful TB Control Initiatives", co-sponsored by the World Bank and USAID, in collaboration with the Stop TB Partnership's PPM subgroup, and organized with PATH. Washington DC, USA, 28 May 2014.
129. [Pai M](#). IGRAs: what have we learnt from longitudinal studies? Invited symposium presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 7 September 2014.
130. [Pai M](#). Improving quality of tuberculosis care in India: can mystery patients help? Seminar presentation, Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada, 15 September 2014.
131. [Pai M](#). Assessing quality of care using standardized patients: the case study of tuberculosis. Inter-hospital Infectious Diseases Rounds, McGill University Health Centre, Royal Victoria Hospital, Montreal, Canada, 23 October 2014.
132. [Pai M](#). Advances in TB diagnosis. Invited plenary lecture at the 16th Joint National Conference of the National College of Chest Physicians (NCCP) & Indian Chest Society (NAPCON – 2014), Agra, India, 23 November 2014.
133. [Pai NP](#), [Pai M](#). Diagnostics at work: from the clinic to the community. McGill Mini-Med Lectures, Faculty of Medicine, McGill University, Montreal, Canada, 25 November 2014.
134. [Pai M](#). Quality of care and its importance in global health delivery. Grand Rounds, Department of Obstetrics and Gynecology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Canada, 22 January 2015.
135. [Pai M](#). Importance of private sector in tuberculosis control: the case study of India. Brown Bag Seminar, Institute for the Study of International Development (ISID), McGill University, Montreal, Canada, 22 January 2015.
136. [Pai M](#). Open access publishing: the good, the bad, and the predators. Invited seminar talk, Center for Clinical Epidemiology, Jewish General Hospital and Lady Davis Institute, Montreal, Canada, 3 February 2015.
137. [Pai M](#). TB or Not TB: first use of the standardized patient methodology to assess quality of tuberculosis care in India. Medicine Grand Rounds, McGill University Health Centre, Montreal, Canada, 14 April 2015.
138. [Pai M](#). TB diagnostics in 2015. Invited seminar presentation at Lady Hardinge Medical College, New

Delhi, India, 24 April 2015.

139. Pai M. Tuberculosis: India's persistent health challenge. Invited presentation at the Canada India Healthcare Summit, Toronto, Canada, 19 May 2015.
140. Pai M. Quality of tuberculosis care in India and implications for new drug introduction. Invited presentation at the Global Alliance for TB Drug Development, New York, USA, 20 May 2015.
141. Pai M. Global health technologies: what drives impact? Invited presentation at the Canadian Society for Epidemiology & Biostatistics (CSEB) conference, Toronto, Canada, 3 June 2015.
142. Pai M. Measuring and improving quality of TB care in India. Invited seminar presentation at the Department of Medicine, St. Michael's Hospital, Toronto, 3 June 2015.
143. Pai M. Bridging the gap between discovery and delivery in global health. Keynote lecture at the 6th Annual Lady Davis Institute Scientific Retreat, Montreal, Canada, 5 June 2015.
144. Pai M. Quality of TB care in India: why should we care? Invited lecture at the 2015 National TB Conference, Atlanta, USA, 9 June 2015.
145. Pai M. Use of standardized patients to assess quality of TB care. Invited lecture at the Workshop on Quality of Healthcare: Measurement and efforts to improve quality. Bill & Melinda Gates Foundation and Sanford School of Public Policy, Duke University. Neemrana, India, 30 June to 1 July 2015.
146. Pai M. A novel approach to assess and improve quality of tuberculosis care. Invited seminar at Infection and Immunity Research Club, Mayo Clinic, Rochester, USA, 1 September 2015.
147. Pai M. Bridging the gap between discovery and delivery in global health. Seminar presentation, MD-PhD Program Faculty of Medicine, McGill University, Montreal, Canada, 24 September 2015.
148. Pai M. Can we save open access publishing? Seminar presentation, Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada, 28 September 2015.
149. Pai M. Open access publishing: the good, the bad, and the ugly. Seminar presentation, Quebec Network on Nursing Intervention Research (RRISIQ), Montreal, Canada, 5 October 2015.
150. Pai M. Bridging the gap between discovery and delivery in global health. Seminar presentation, Infectious Diseases and Immunity in Global Health Program, McGill University Health Centre, Montreal, Canada, 7 October 2015.
151. Pai M. Making tuberculosis diagnostics more affordable. Invited symposium presentation at the 22nd Canadian Conference on Global Health, Montreal, Canada, 6 November 2015.
152. Pai M. Importance of private sector in tuberculosis control: the case study of India. Invited lecture at the International Masters for Health Leadership program, Desautels Faculty of Management, McGill University, Montreal, Canada, 17 November 2015.
153. Pai M. Tuberculosis diagnostics in 2016. Invited talk at Harvard School of Public Health, Boston, USA, 25 February 2016.
154. Pai M. India's private health sector: challenges and opportunities for TB control. Invited seminar at Harvard Global Health Institute, Boston, USA, 25 February 2016.
155. Pai M. TB or not TB: improving access to novel tuberculosis technologies in India. MDIIM Health Management Seminar, Desautels Faculty of Management, McGill University, Montreal, Canada, 18

March 2016.

156. Pai M. TB diagnostics landscape – translational challenges. Invited talk at Critical Path to TB Drug Regimens (CPTR) conference, Washington DC, USA, 6 April 2016.
157. Pai M. OTC antibiotic use by pharmacists in urban India. Invited talk at Access Advisory Committee, Global Alliance for TB Drug Development, New York, USA, 10 June 2016.
158. Pai M. Scale-up of new diagnostics. Invited talk at the 28th Coordinating Board Meeting of the Stop TB Partnership, New York, USA, 20 September 2016.
159. Pai M. From tools to patient-centric solutions. Invited talk at the Global TB Symposium, 47th Union World Conference on Lung Health, Liverpool, United Kingdom, 25 October 2016.
160. Pai M. Engaging Private Sector and Road to a Successful Implementation. Invited talk at a Symposium entitled “New tools to support the End TB Strategy”, 47th Union World Conference on Lung Health, Liverpool, United Kingdom, 27 October 2016.
161. Pai M. Diagnosis of latent TB infection: incremental, not transformative progress. Invited seminar at Memorial Sloan-Kettering Hospital, New York, USA, 11 November 2016.
162. Pai M. Suboptimal quality of care: a major impediment to TB control. Invited keynote lecture at the 2nd Annual Tuberculosis Symposium, Department of Global Health & School of Medicine, University of Washington, Seattle, USA, 2 December 2016.
163. Pai M. TB management in the era of new diagnostics. Keynote plenary talk at 71st National Conference on Tuberculosis and Chest Diseases (NATCON 2016), Chandigarh, India, 17 December 2016.
164. Pai M. Tuberculosis diagnostics: state of the art and future directions. Invited lecture at KingMed Center for Clinical Laboratory Co., Ltd, Guangzhou, China, 7 January 2017.
165. Pai M. Poor Quality of Care: A Key Driver of India's Tuberculosis Epidemic. Medicine Grand Rounds, Department of Medicine, St Michael's Hospital, Toronto, Canada, 1 March 2017.
166. Pai M. Poor quality of care: a major threat to global tuberculosis control. Medicine Grand Rounds, Boston Medical Center & Boston University School of Medicine, Boston, USA, 17 March 2017.
167. Pai M. Quality of TB care. 8th Annual CUGH Conference, Washington DC, USA, 6 April 2017.
168. Pai M. Urgent need to improve quality of TB care. Invited plenary talk at Canadian Respiratory Conference, Montreal, Canada, 28 April 2017.
169. Pai M. A global systematic review of pharmacy-based TB interventions. Invited symposium talk at the 48th Union World Conference on Lung Health, Guadalajara, Mexico, 13 October 2017.
170. Pai M. What we have learned from all the IGRA (Interferon-Gamma Release Assays) studies among healthcare workers in high-incidence countries. Invited symposium talk at the 48th Union World Conference on Lung Health, Guadalajara, Mexico, 13 October 2017.
171. Pai M. Time for a quality revolution in tuberculosis care. Invited plenary talk at the 48th Union World Conference on Lung Health, Guadalajara, Mexico, 14 October 2017.
172. Pai M. The challenge of predicting tuberculosis. Invited seminar talk at Tsinghua University, Beijing, China, 12 December 2017.

173. [Pai M.](#) Novel use of simulated patients to assess quality of TB care: lessons from large-scale studies in 3 countries. Invited talk at the IHI Africa Forum on Quality and Safety in Health Care, Durban, South Africa, 21 February 2018.
174. [Pai M.](#) Primary care: the weakest link in TB control. Invited talk at CAPRISA, University of Kwa-Zulu Natal, Durban, South Africa, 23 February 2018.
175. [Pai M.](#) Private health sector engagement: changing mindsets to achieve progress. Invited talk at the 30th Coordinating Board Meeting of the Stop TB Partnership, New Delhi, India, 15 March 2018.
176. [Pai M.](#) Primary care – the weakest link in tuberculosis control? Invited Global Health Network seminar at the University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada, 29 March 2018.
177. [Pai M.](#) Invited speaker in a Panel on Innovation to End TB, at the United Nations (UN) Civil Society Hearing on Tuberculosis, United Nations, New York, USA, 4 June 2018.
178. [Pai M.](#) Global health technologies: are we still searching for silver bullets and killer apps? Keynote speech at the 2018 annual TB Modelling and Analysis Consortium (TB MAC) scientific meeting, Washington DC, USA, 14 September 2018.
179. [Pai M.](#) Bridging the gap between innovation and impact. Seminar speaker at Rice 360 Global Health Institute, Rice University, Houston, Texas, USA, 10 October 2018.
180. [Pai M.](#) Latent TB: advances in diagnosis and treatment. Invited speaker at the Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, China, 10 December 2018.
181. [Pai M.](#) Global health technologies: can we bridge the gap between innovation and access. Invited speaker at the Schwarzman College, Tsinghua University, Beijing, China, 11 December 2018.
182. [Pai M.](#) Tuberculosis: advances in diagnosis and treatment. Invited speaker at the Xi'an Chest Hospital, Xi'an, China, 15 December 2018.
183. [Pai M.](#) Re-imagining TB Care. 2nd Annual Hinduja Hospital TB Oration. Mumbai, India, 31 March 2019.
184. [Pai M.](#) Re-imagining TB Care. Invited seminar at University College, London, UK, 9 April 2019.
185. [Pai M.](#) Pill pushers or trusted providers? Challenges and opportunities for engaging India's private health sector in tuberculosis care. Invited seminar at London School of Hygiene and Tropical Medicine, London, UK, 9 April 2019.
186. [Pai M.](#) Global health research: who leads, who gains? Invited presentation at the Duke Decolonizing Global Health Conference, Duke University, Durham, USA, 31 January 2020.
187. [Pai M.](#) Global health research needs more than a makeover. Grand Rounds at Global Health Sciences, University of California, San Francisco, USA, 20 February 2020.
188. [Pai M.](#) Reimagining Global Health In The Post-Pandemic World. Keynote lecture at the NIH Global Doctoral Partnerships Research Workshop 2020, NIH, Bethesda, USA, 15 June 2020.
189. [Pai M.](#) Global health research needs a makeover. Invited lecture at Georgetown University "Decolonization of Global Health" seminar series, Washington DC, USA, 27 August 2020.
190. [Pai M.](#) Can We Reimagine Global Health In The Post-Pandemic World? Medicine Grand Rounds, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA, 9 October 2020.

191. [Pai M](#). The art of leaning out. Women Leaders in Global Health Conference, 15 October 2020.
192. [Pai M](#). Impact of COVID pandemic on health care priorities and programmes. Plenary talk, 51st Union World Conference on Lung Health, 22 October 2020.
193. [Pai M](#). Examining power & privilege in global health and international development. Results Canada National Conference, 15 November 2020.
194. [Pai M](#). Power asymmetry in global health. Bold Conversations in DEI series, Bill & Melinda Gates Foundation, 16 November 2020.
195. [Pai M](#). Power, Privilege & Coloniality in Global Health. Department of Population Health Science and Policy Grand Rounds. Icahn School of Medicine at Mount Sinai, 9 February 2021.
196. [Pai M](#). Impact of COVID-19 on tuberculosis care and research. Keynote lecture at the Union North American Regional Conference (virtual), 25 February 2021.
197. [Pai M](#). Decolonizing Global Health. Invited plenary talk at CUGH 2022, Consortium of Universities in Global Health (virtual), 29 March 2022.
198. [Pai M](#). Allyship in global health. Grand Rounds, Institute of Global Health Sciences, University of California, San Francisco (virtual), 23 April 2022.
199. [Pai M](#). Anti-racism & decolonizing the AIDS response: Moving from rhetoric to reformation. AIDS 2022, Montreal, Canada, 1 August 2022.
200. [Pai M](#). Scientific strategies from recent outbreaks to help us prepare for Pathogen X (virtual). World Health Organization, 29 August 2022.
201. [Pai M](#). Overcoming our socialization for scarcity in TB. Talk during opening ceremony of the Union World Conference on Lung Health (virtual), 9 November 2022.
202. [Pai M](#). Allyship in global health. Invited plenary talk at the Canadian Conference on Global Health, Toronto, Canada, 21 November 2022.
203. [Pai M](#). Allyship in global health. Invited keynote talk at the Atlantic Fellows Conference, George Washington University, Washington DC, USA, 23 January 2023.
204. [Pai M](#). Allyship in global health. Invited keynote talk at the Global Health Fair, University of Alberta, Edmonton, Canada, 9 February 2023.
205. [Pai M](#). Allyship in global health. Invited global health seminar talk at Tufts University, Boston, USA, 14 March 2023.
206. [Pai M](#). Social Medicine Rounds– Global Health Transformation: From Decolonization to Collective Liberation, Montefiore & Albert Einstein College of Medicine, NY, USA, 28 March 2023.
207. [Pai M](#). A global health conversation with Dr Madhu Pai. Stanford University, USA, 26 April 2023.
208. [Pai M](#). Walking the talk: allyship in global health. Invited lecture at Berkeley School of Public Health, University of California at Berkeley, USA, 27 April 2023.
209. [Pai M](#). Global Health must Evolve from Saviorism to Solidarity. Medical Grand Rounds, Dartmouth Medical School, Hanover, USA, 4 August 2023.

E4. Clinical Teaching

1. Diagnosis of latent TB infection. Inter-hospital Infectious Diseases Grand Rounds, Montreal General Hospital, 9 November 2006.
2. Introduction to systematic reviews & meta-analysis. Guest lecture in EPIB-679, Clinical Epidemiology, 22 June 2007. Instructors: Kevin Schwartzman & Dick Menzies.
3. IFN-gamma release assays for TB infection: time to abandon the tuberculin skin test? Inter-hospital Infectious Diseases Grand Rounds, Jewish General Hospital, 1 May 2008.
4. The diagnosis and misdiagnosis of tuberculosis. Invited presentation at Tropical Diseases: A Clinical and Laboratory Update. McGill Centre for Tropical Diseases, Montreal, 3 June 2008.
5. Evidence-based TB diagnosis. Grand Rounds presentation at the MUHC Medical Grand Rounds, Department of Medicine, McGill University, Montreal, Canada. 23 September 2008.
6. Diagnosis of tuberculosis: stepping out of Robert Koch's shadow. Respiratory Rounds, Ottawa General Hospital, University of Ottawa, Ottawa, 2 February 2009.
7. Diagnosis of latent TB infection: advances and challenges. Pneumo Club, University of Ottawa, Ottawa, 2 February 2009.
8. Interpreting diagnostic evidence. Invited teaching seminar at the Division of Gynecological Oncology, Department of Obstetrics & Gynecology, Royal Victoria Hospital, McGill University Health Centre, Montreal, 2 April 2009.
9. Tuberculosis - new tests, new guidelines. Invited lecture at conference on "Tropical diseases: a review of clinical and laboratory medicine", McGill Centre for Tropical Diseases, Montreal, 10 May 2010.
10. Introduction to systematic reviews & meta-analysis. Guest lecture in EPIB-679, Clinical Epidemiology, 21 June 2010. Instructors: Kevin Schwartzman & Sasha Bernatsky.
11. Guest lecturer for Module 5 on TB and Pneumonia. Course MDX-7001: Clinical aspects of research in respiratory diseases. Lead instructor: Kevin Schwartzman. Respiratory Health Network of the FRQS (RHN). Faculté de médecine - Université Laval. Winter 2011.
12. Guest lecturer for Module 5 on TB and Pneumonia. Course MDX-7001: Clinical aspects of research in respiratory diseases. Lead instructor: Kevin Schwartzman. Respiratory Health Network of the FRQS (RHN). Faculté de médecine - Université Laval. Winter 2012.

E5. Guest Lectures in Other McGill Courses

1. Introduction to systematic reviews & meta-analysis (4 hours). Guest lecture in EPIB-695, Intermediate Epidemiology, Winter, 2007. Instructor: Jean-François Boivin.
2. Diagnostics for infectious diseases (2 hours). Guest lecture in EPIB-678, Introduction to Infectious Diseases Epidemiology, Winter 2007. Instructor: Ameer Manges.
3. Outbreak investigations in developing countries (2 hours). Guest lecture in EPIB-677, Global Health: Epidemiologic Research, Winter, 2008. Instructor: Theresa Gyorkos.
4. Diagnostics for infectious diseases (2 hours). Guest lecture in EPIB-678, Introduction to Infectious Diseases Epidemiology, Winter 2008. Instructor: Ameer Manges.
5. International health: tuberculosis (1.5 hours). Guest lecture in EPIB-501, Public health and epidemiology, Winter 2013. Instructor: Jean-François Boivin.

6. Global health (1.5 hours). Guest lecture in EPIB-501, Public health and epidemiology, Winter 2015. Instructor: Jean-François Boivin.
7. Introduction to global health (2 hours). Guest lecture in the Interprofessional Global Health Course, Winter 2015. Coordinated by student representatives from the Schools of Medicine, Dentistry, Nursing, and Physical and Occupational Therapy, McGill University.
8. Introduction to global health (2 hours). Guest lecture in the Interprofessional Global Health Course, Winter 2016. Coordinated by student representatives from the Schools of Medicine, Dentistry, Nursing, and Physical and Occupational Therapy, McGill University.
9. Introduction to global health (2 hours). Guest lecture in the Interprofessional Global Health Course, Winter 2017. Coordinated by student representatives from the Schools of Medicine, Dentistry, Nursing, and Physical and Occupational Therapy, McGill University.

E6. Teaching Contributions in Other Universities

1. Module on Diagnostic Research. Master's in Clinical Epidemiology, Stellenbosch University, Cape Town, South Africa. 4-day course. 4 to 7 March 2009.
2. Effective Use of PubMed and EndNote for Searching and Managing Medical Literature. Workshop, Faculty of Medicine, University of Cape Town, South Africa. 9 March 2009.

E7. Coordination of Short Courses and Workshops

1. EPIB-668: Advanced Diagnostic Research, May 6 - 9, 2008, as part of Summer Session in Epidemiology & Biostatistics, McGill University. Instructor: Professor Karel Moons, Julius Center for Health Sciences and Primary care, Utrecht, Netherlands. Course coordinator: Madhukar Pai.
2. "Systematic reviews & meta-analyses of diagnostic test accuracy". 2-day workshop (25/26 May 2009) held at the Montreal Chest Institute. Instructors: Dr Mariska Leeflang, University of Amsterdam, and Madhukar Pai. Course coordinator: Madhukar Pai.
3. "Montreal TB Course". 1-day course held on 30 October, 2009, at the Montreal Chest Institute. Instructors: Madhukar Pai, Dick Menzies, Kevin Schwartzman, Marcel Behr, Christina Greenaway, Jessica Minion and Barry Rabinovitch. Course coordinator: Madhukar Pai.
4. "GRADE approach to diagnostic tests and strategies." 1-day course held on 12 February 2010 at the Montreal Chest Institute. Instructors: Professor Holger Schünemann & Dr Jan Brozek, McMaster University, Hamilton. Course coordinator: Madhukar Pai.
5. "Montreal TB Course". 1-day course held on 26th November 2010, at the Montreal Chest Institute. Instructors: Madhukar Pai, Dick Menzies, Kevin Schwartzman, Marcel Behr, Erwin Schurr, Maziar Divangahi and Barry Rabinovitch. Course coordinator: Madhukar Pai.
6. "TB diagnostic research - beyond the basics". 3-day advanced course on TB diagnostic research from 12 - 15 December 2010, at the Tuberculosis Research Centre, Chennai, India. Course coordinator: Madhukar Pai.
7. "Advanced TB Diagnostics Research". 4-day advanced course on TB diagnostic research from 5 - 8 July, 2011, at McGill University, Montreal. Course coordinator: Madhukar Pai.

8. "Advanced TB Diagnostics Research". 4-day advanced course on TB diagnostic research from 6 - 9 March, 2012, at the University of Cape Town, South Africa. Course coordinator: Madhukar Pai.
9. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research from 9 - 13 July, 2012, at McGill University, Montreal. Course coordinator: Madhukar Pai.
10. "Introduction to TB Modeling". 3-day workshop at the International Union Against TB and Lung Diseases, New Delhi, from 8 - 10 November, 2012. Co-taught with David Dowdy, JHSPH, Baltimore.
11. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research, from 8 - 12 July, 2013, at McGill University, Montreal. Course coordinator: Madhukar Pai.
12. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research, from 7 - 11 July, 2014, at McGill University, Montreal. Course coordinator: Madhukar Pai.
13. "Workshop on "Evaluation of new TB diagnostics" at National Institute for Research in Tuberculosis, Chennai, India, from 8-12 December 2014. Course coordinators: Madhukar Pai & Soumya Swaminathan.
14. "Summer Institute in Infectious Diseases and Global Health". 2-week institute, from 6 - 17 July, 2015, at McGill University, Montreal. Institute director: Madhukar Pai.
15. "Global Health Diagnostics". 5-day course on global health diagnostics, from 6 - 10 July, 2015, at McGill University, Montreal. Course coordinators: Madhukar Pai, Nitika Pant Pai & Cedric Yansouni.
16. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research, from 13 - 17 July, 2015, at McGill University, Montreal. Course coordinator: Madhukar Pai.
17. "Summer Institute in Infectious Diseases and Global Health". 2-week institute, from 13 - 24 June, 2016, at McGill University, Montreal. Institute director: Madhukar Pai.
18. "Global Health Diagnostics". 5-day course on global health diagnostics, from 13 - 17 June, 2016, at McGill University, Montreal. Course coordinators: Madhukar Pai, Nitika Pant Pai & Cedric Yansouni.
19. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research from 20 - 24 June, 2016, at McGill University, Montreal. Course coordinator: Madhukar Pai.
20. "Summer Institute in Infectious Diseases and Global Health". 2-week institute, from 12 - 23 June, 2017, at McGill University, Montreal. Institute director: Madhukar Pai.
21. "Global Health Diagnostics". 5-day course on global health diagnostics, from 12 - 16 June, 2017, at McGill University, Montreal. Course coordinators: Madhukar Pai, Nitika Pant Pai & Cedric Yansouni.
22. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research from 19 - 23 June, 2017, at McGill University, Montreal. Course coordinator: Madhukar Pai.
23. "Summer Institute in Infectious Diseases and Global Health". 2-week institute, from 11 - 22 June, 2018, at McGill University, Montreal. Institute director: Madhukar Pai.
24. "Global Health Diagnostics". 5-day course on global health diagnostics, from 11 - 15 June, 2018, at McGill University, Montreal. Course coordinators: Madhukar Pai, Nitika Pant Pai & Cedric Yansouni.
25. "Advanced TB Diagnostics Research". 5-day advanced course on TB diagnostic research from 18 - 22 June, 2018, at McGill University, Montreal. Course coordinator: Madhukar Pai.

26. "Summer Institute in Infectious Diseases and Global Health". 2-week institute, from 10 - 21 June, 2019, at McGill University, Montreal. Institute director: Madhukar Pai.
27. "Advanced TB Diagnostics Research". 3-day advanced course on TB diagnostic research from 17 - 19 June, 2019, at McGill University, Montreal. Course coordinator: Madhukar Pai.
28. "Quality of TB Care". 3-day course on quality of tuberculosis care from 19 to 21 June, 2019, at McGill University, Montreal. Course coordinators: Madhukar Pai & Zelalem Temesgen.
29. "Advanced TB Diagnostics". 5-half-day advanced course on TB diagnostic research from 7 - 11 June, 2021, at McGill University, Montreal (virtual). Course coordinator: Madhukar Pai.
30. "Quality of TB Care". 5-half-day course on quality of tuberculosis care from 31 May to 4 June, 2021, at McGill University, Montreal (virtual). Course coordinators: Jishnu Das & Madhukar Pai & Zelalem Temesgen.
31. "Advanced TB Diagnostics". 5-half-day advanced course on TB diagnostic research from 6 - 10 June, 2022, at McGill University, Montreal (virtual). Course coordinator: Madhukar Pai.
32. "Quality of TB Care". 5-half-day course on quality of tuberculosis care from 30 May to 3 June, 2022, at McGill University, Montreal (virtual). Course coordinators: Madhukar Pai & Zelalem Temesgen.
33. "Advanced TB Diagnostics". 5-half-day advanced course on TB diagnostic research from 29 May to 2 June, 2023, at McGill University, Montreal (on campus and hybrid). Course coordinator: Madhukar Pai.
34. "Engaging all health providers to End TB: Public-Private Mix (PPM)". 5-half-day course from 12 - 16 June, 2023, at McGill University, Montreal (virtual). Course coordinators: Madhukar Pai & Vijayashree Yellappa.
35. "Summer Institutes in Global Health". 4-week institute, from 21 May - 14 June, 2024, at McGill University, Montreal. Summer Institutes director: Madhukar Pai.
36. "Reimagining Global Health". 4-half-day course from 21 - 24 May, 2024, at McGill University, Montreal (virtual). Course coordinator: Madhukar Pai.
37. "Advanced TB Diagnostics". 5-half-day advanced course on TB diagnostic research from 27 - 31 May, 2024, at McGill University, Montreal (virtual). Course coordinator: Madhukar Pai.
38. "Engaging all health providers to End TB: Public-Private Mix (PPM)". 5-half-day course from 3 - 7 June, 2024, at McGill University, Montreal (virtual). Course coordinators: Petra Heitkamp & Vijayashree Yellappa & Madhukar Pai.

F. Other Contributions

F1. Journals

Editorial Boards

2007 – 2019	Associate Editor, <i>Int Journal of Tuberculosis & Lung Disease</i>
2007 – 2019	Section Editor, <i>PLoS One</i>
2008 – 2011	Editor, Cochrane Infectious Diseases Review Group
2009 – Present	Academic Editor & Editorial Board Member, <i>PLoS Medicine</i>

2011 – 2013	Associate Editor, <i>Canadian TB Standards</i>
2012 – Present	International Editorial Board, <i>Lancet Infectious Diseases</i>
2013 – Present	Editorial Board Member, <i>Journal of Epidemiology & Global Health</i>
2013 – Present	Editorial Board Member, <i>Expert Review of Molecular Diagnostics</i>
2014 – Present	Editorial Board Member, <i>Indian Journal of Tuberculosis</i>
2014 – 2020	Editorial Board Member, <i>EBioMedicine</i> (Elsevier)
2015 – 2017	Editorial Board Member, <i>Scientific Reports</i> (Nature)
2015 – Present	Editorial Board Member, <i>Indian Journal of Medical Research</i>
2015 – Present	Associate Editor, <i>Journal of Clinical Tuberculosis & Mycobact Dis</i>
2016 – 2018	Reviewing Editor, <i>eLife</i>
2018 – Present	Editorial Board Member, <i>BMJ Global Health</i>
2021 – Present	Editorial Board Member, <i>Chinese Journal of Anti-tuberculosis</i>
2021 – Present	Editor-In-Chief, <i>PLoS Global Public Health</i>

Ad hoc Reviews

1. American Journal of Respiratory & Critical Care Medicine
2. Annals of the American Thoracic Society
3. Annals of Internal Medicine
4. Archives of Medical Research
5. BioMed Research International
6. BMC Infectious Diseases
7. BMC Medicine
8. BMJ
9. BMJ Global Health
10. Canadian Journal of Infectious Diseases & Medical Microbiology
11. Canadian Medical Association Journal (CMAJ)
12. Canadian Respiratory Journal
13. Chest
14. Clinical and Investigative Medicine
15. Clinical Infectious Diseases
16. Clinical Microbiology and Infection
17. Clinical and Vaccine Immunology
18. Cochrane Library
19. Drug Discovery Today
20. eLife
21. Emerging Infect Diseases
22. Epidemiology
23. Epidemiology and Infection
24. European Respiratory Disease
25. European Respiratory Journal
26. Expert Review of Anti-Infective Therapy
27. Expert Review of Molecular Diagnostics

28. Health Affairs
29. International J of Tuberculosis & Lung Disease
30. International Journal of Infectious Diseases
31. Journal of Clinical Epidemiology
32. Journal of Clinical Investigation
33. Journal of Clinical Microbiology
34. Journal of Epidemiology & Global Health
35. Journal of Infection
36. Journal of Infectious Diseases
37. Journal of the American Medical Association (JAMA)
38. Lancet
39. Lancet Global Health
40. Lancet Infectious Diseases
41. Lancet Regional Health South East Asia
42. Lancet Respiratory Medicine
43. Medical Letter
44. Microbes and Infection
45. Nephrology Dialysis Transplantation
46. New England Journal of Medicine
47. Pediatric Infectious Disease Journal
48. PLoS Global Public Health
49. PLoS Medicine
50. PLoS One
51. Pulmonary Medicine
52. Respiratory Medicine
53. Scandinavian Journal of Infectious Diseases
54. Science
55. Thorax
56. Trends in Biotechnology
57. Trends in Microbiology
58. Tuberculosis
59. Tuberculosis Research and Treatment
60. Vaccine

F2. Grant Reviews

Ad hoc Reviews

- | | |
|------|--|
| 2004 | Young Epidemiology Scholars Competition, College Board, USA |
| 2005 | Medical Research Council (MRC), South Africa |
| 2006 | UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization (WHO) |
| 2007 | McGill University Health Centre Research Institute Pilot Project Awards |
| 2007 | Research Council of Norway |
| 2008 | Natural Sciences and Engineering Research Council of Canada (NSERC) |
| 2008 | National Research Foundation (NRF), South Africa |

- 2008 Canadian Institutes of Health Research (CIHR), Canada
- 2009 National Research Foundation (NRF), South Africa
- 2009 Ontario Ministry of Health, Canada
- 2009 Canadian Institutes of Health Research (CIHR), Canada
- 2009 McGill University Health Centre Research Institute Studentship Awards
- 2010 The Wellcome Trust, UK
- 2010 McGill University Health Centre Research Institute Studentship Awards
- 2011 McGill University Health Centre Research Institute Studentship Awards
- 2011 National Institute of Allergy and Infectious Diseases (NIAID), AIDS Research Review Committee (AIDSRRRC)
- 2012 International Science and Technology Partnerships Canada Inc. (ISTPCanada)
- 2012 Simple and Affordable Molecular Testing for Tuberculosis Proposal review panel, Bill & Melinda Gates Foundation, Seattle
- 2012 Peer Reviewed Medical Research Program (PRMRP), US Army Medical Research and Materiel Command (USAMRMC)
- 2012 Grand Challenges Explorations, Phase II Proposal Review Committee, Bill & Melinda Gates Foundation, Seattle
- 2012 IIB Prog Grants, Infections and Immunity Board, Medical Research Council (MRC), UK
- 2012 DFID health research competition for the development of new technologies to impact on diseases of poverty. Department for International Development, UK
- 2012 U.S. – Indo Vaccine Action Program (VAP) Initiative on Tuberculosis, CRDF Global, U.S. National Institutes of Health’s (NIH), Government of India’s Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR)
- 2012 Member, Peer review committee for the Stars in Global Health program by the Grand Challenges Canada (GCC) and the Canadian Institutes of Health Research (CIHR)
- 2013 Leaders Opportunity Fund (LOF) review panel, Canada Foundation for Innovation (CFI).
- 2013 Simple and Affordable Molecular Testing for Tuberculosis Program for China, Bill & Melinda Gates Foundation, Seattle
- 2013 External reviewer, Stars in Global Health Canada Direct Entry to Phase II – Round 2 Investment Committee, Grand Challenges Canada (GCC) and the Canadian Institutes of Health Research (CIHR)
- 2013 External reviewer, “Clinical trials (and systematic reviews) with a high relevance for patient care”, Federal Ministry of Education and Research, Germany
- 2014 Internal peer reviewer, CIHR March 2014 open grant competition, Research Institute of the McGill University Health Centre
- 2014 External reviewer, R&D Pump-Priming & Small Initiatives Fund (PPSIF), Public Health England, UK
- 2014 External grant reviewer, UBS Optimus Foundation, Zurich, Switzerland
- 2014 McGill University Health Centre Research Institute Studentship Awards
- 2015 External reviewer for Tier 1 CRC nomination, Canada Research Chairs Program, CIHR

- 2015 Reviewer, McGill Faculty of Medicine, Internal Grant Review
- 2015 External reviewer, Stars in Global Health Canada Direct Entry to Phase II – Round 2 Investment Committee, Grand Challenges Canada (GCC) and the Canadian Institutes of Health Research (CIHR)
- 2015 Reviewer, Wellcome Trust Innovations, Affordable Healthcare in India Awards Program
- 2016 Reviewer, IC-IMPACTS Centres of Excellence, Canada

Review Committees

- 2011 – 2013 Canadian Institutes of Health Research (CIHR), Public, Community and Population Health (PH1/2) Peer Review Committee
- 2012 – 2016 Canadian Institutes of Health Research (CIHR) & Grand Challenges Canada. Stars in Global Health Program Peer Review Committee
- 2013 – Present Canadian Institutes of Health Research (CIHR). Fellowships (post-PhD) Peer Review Committee
- 2016 – 2017 Fonds de recherche du Québec - Santé. Salary Awards Peer Review Committee

F3. Administrative Responsibilities, McGill University

- 2006 – 2007 Coordinator, Weekly Departmental Seminar Series, Department of Epidemiology, Biostatistics and Occupational Health, McGill University
- 2009 – 2010 PhD Program Advisor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University
- 2013 – 2014 PhD Program Director, Department of Epidemiology, Biostatistics and Occupational Health, McGill University
- 2014 – 2020 Director, McGill Global Health Programs, McGill University
- 2018 – 2020 Director, McGill International TB Centre, McGill University
- 2020 – Present Associate Director, McGill International TB Centre, McGill University
- 2024 – Present Director, McGill Global Health Programs, McGill University

F4. Committees

McGill University

- 2006 – Present Member, PhD Admissions Committee, Department of Epidemiology, Biostatistics and Occupational Health
- 2006 – 2008 Member, PhD Committee, Department of Epidemiology, Biostatistics and Occupational Health
- 2009 – 2010 Member, Epidemiology Programs Committee, Department of Epidemiology, Biostatistics and Occupational Health
- 2010 – 2014 Member, Epidemiology Curriculum Committee, Department of Epidemiology, Biostatistics and Occupational Health
- 2011 – Present Member, Appointments/Reappointments/Promotions Committee, Department of Epidemiology, Biostatistics and Occupational Health

2011 – 2015	Member, PhD Admissions Committee, Department of Epidemiology, Biostatistics and Occupational Health
2011 – 2014	Member, MScPH (MPH) Admissions Committee, Department of Epidemiology, Biostatistics and Occupational Health
2011 – 2014	Member, Departmental Tenure Committee, Department of Epidemiology, Biostatistics and Occupational Health
2012 – Present	Member, Dean’s Task Force on Global Health, Faculty of Medicine, McGill University
2014 – Present	Member, Faculty Leadership Council, Faculty of Medicine, McGill University
2015 – 2018	Member, Departmental Tenure Committee, Department of Epidemiology, Biostatistics and Occupational Health
2015 – 2018	Member, Advisory Board, Steinberg Simulation Centre, McGill University
2020 – Present	Member, University Standing Internal Review Committee (SIRC), Office of the Provost
2021 – Present	Faculty Advisor, McCall MacBain Scholars program

External Committees, Panels & Expert Groups

2005 – 2006	Member, Steering Committee, International Standard for Tuberculosis Care, American Thoracic Society & World Health Organization (WHO)
2005 – 2006	Member, 2 nd Scientific Working Group on Tuberculosis, WHO Special Programme for Research and Training in Tropical Diseases (TDR)
2006 – Present	American Thoracic Society representative on the Stop TB Partnership's New Diagnostics Working Group
2006 – 2007	Member, Steering Committee, Tuberculosis and Smoking, International Union Against Tuberculosis & Lung Disease & WHO, Geneva
2007 – 2008	Member, Diagnostics Expert Evaluation Panel (DEEP), WHO Special Programme for Research and Training in Tropical Diseases (TDR)
2007 – 2008	Temporary Advisor, TB Infection Control Global Consultation, World Health Organization, Geneva
2006 – 2007	Expert Member, Working Group for Canadian TB Committee Advisory Committee Statement on Interferon-gamma release assays, Public Health Agency of Canada
2007 – 2008	Chair, Working Group for Updated 2008 Canadian TB Committee Advisory Committee Statement on Interferon-gamma release assays, Public Health Agency of Canada
2009 – 2010	Expert Member, Working Group for Updated 2010 Canadian TB Committee Advisory Committee Statement on Interferon-gamma release assays, Public Health Agency of Canada
2008 – Present	Member, TDR Scientific Advisory Committee for TB/HIV research, WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva
2008 – 2010	Tuberculosis X Prize Advisory Board, X Prize Foundation, USA
2008 – 2009	Member, American Thoracic Society, Assembly for Microbiology, Tuberculosis

- and Pulmonary Infections (MTPI) Program Committee
- 2008 – 2009 Member Guideline Development Group (TDG) for TB treatment guidelines, World Health Organization, Geneva
- 2008 – 2009 Core group member, TB-IC operational research project for outcome and impact indicators of TB infection control interventions, KNCV Tuberculosis Foundation, The Hague
- 2009 – 2010 Member, WHO Expert Group on Approaches to Improve Smear Microscopy for Tuberculosis Diagnosis & Non-commercial Culture Methods for MDR-TB, WHO, Geneva
- 2009 – 2010 Member, Update of Global Plan to Stop TB, Stop TB Partnership & World Health Organization, Geneva
- 2009 – 2011 Co-chair, Stop TB Partnership's New Diagnostics Working Group, WHO, Geneva
- 2009 – 2011 Member, Stop TB Partnership Coordinating Board, Stop TB Partnership & WHO, Geneva
- 2009 – 2011 Member, Disease Reference Group (DRG) on TB, leprosy and buruli ulcer, WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva
- 2009 – 2011 Chair, TB Research Movement Task Force, Stop TB Partnership & World Health Organization, Geneva
- 2007 – 2011 Member, ATS/CDC/IDSA Committee, Diagnostic Standards and Classification of Tuberculosis in Adults and Children, American Thoracic Society
- 2010 – 2011 Member, World Bank TB India Joint Monitoring Mission, World Bank, India
- 2010 – 2011 Member, WHO Expert Group on interferon-gamma release assays and commercial serodiagnostics for TB, WHO, Geneva
- 2010 – Present Member, Canadian Thoracic Society Tuberculosis Committee
- 2011 – 2014 Member, Scientific Advisory Committee, Workshop on TB and HIV Diagnostics in Adult and Pediatric Populations, Molecular Diagnostics Working Group of the US Federal TB Taskforce, NIH, USA
- 2011 – 2013 Associate Editor, Canadian TB Standards, 7th Edition, Canadian Thoracic Society
- 2012 – Present Member, Government of India & World Health Organization Joint Monitoring Mission
- 2013 – 2014 Member, Board of Advisors, Tuberculosis Epidemiologic Studies Consortium II (TBESC), US Centers for Disease Control and Prevention, Atlanta, USA
- 2013 – 2014 Member, Steering Committee, International Standards of Tuberculosis Care, 3rd Edition. American Thoracic Society & World Health Organization, USA
- 2013 – Present Chair, Scientific Advisory Group, Center for Biodesign and Diagnostics, Translational Health Science and Technology Institute, Ministry of Science & Technology, Government of India
- 2017 – Present Chair, Working Group on Public-Private Mix for TB Care and Control of the Stop TB Partnership
- 2014 – 2023 Member, Scientific Advisory Committee, Foundation for Innovative New Diagnostics, Geneva, Switzerland

2014 – Present	Member, Expert Group on Tuberculosis Prevention and Control, Global Coalition Against Tuberculosis (GCAT)
2015 – 2021	Member, Access Advisory Committee, Global Alliance for TB Drug Development, New York, USA
2015 – 2019	Member, WHO Strategic and Technical Advisory Group for Tuberculosis (STAG-TB), World Health Organization, Geneva
2016 – Present	Member, Program Steering Group, TB REACH, Stop TB Partnership, Geneva
2016 – Present	Member, International Scientific Advisory Group (ISAG), India TB Research Consortium, ICMR, New Delhi, India
2017 – 2019	Member, WHO Strategic Advisory Committee on in Vitro Diagnostics (SAGE IVD), World Health Organization, Geneva
2017 – Present	Chair, Working Group on Public Private Mix, Stop TB Partnership, Geneva
2017 – 2019	Commissioner, The Lancet Commission on Tuberculosis
2019 – 2021	Commissioner, The Lancet Commission on Diagnostics
2019 – 2023	Member, WHO Expert Advisory Group on the Governance of the Private Sector
2020 – Present	Member, Governing Body, Delhi School of Public Health
2021 – Present	Member, WHO Advisory Group on TB Diagnostics and Laboratory Strengthening
2021 – Present	Member, WHO Strategic and Technical Advisory Group (STAG) for TB, SEA region
2022 – Present	Member, WHO AMR Expert Group
2023 – Present	Adviser, WHO AMR Expert Group

F5. Contributions as Examiner

Internal – McGill University

2006	Olivia Oxlade, Examiner for PhD Protocol Defence
2007	Maala Bhatt, Internal Examiner for MSc thesis
2009	Mathieu Giroux, Internal Examiner for MSc thesis
2009	Ann Burchell, Internal Member, PhD Oral Defense Committee
2011	Data Teltsch, Internal Member, PhD Oral Defense Committee
2011	Brian Hutton, Internal Member, PhD Oral Defense Committee
2011	Hiroshi Mamiya, Internal Examiner for MSc thesis
2012	Michelle Roseman, External Examiner for MSc thesis
2015	Emilio Dirlikov, External Member, PhD thesis defense, Anthropology
2016	Deshayne Fell, Internal Examiner, PhD thesis defense, Epidemiology

External

2011	External examiner, PhD thesis, National School of Public Health at the University of Antioquia, Colombia
2014	External examiner, PhD thesis in Health Research Methodology, McMaster University, Hamilton, Canada

F6. Professional and/or Learned Societies

2004 – Present	Member, American College of Epidemiology, USA
2004 – Present	Member, Society for Epidemiologic Research, USA
2005 – Present	Member, American Thoracic Society, USA
2005 – Present	Member, International Union Against Tuberculosis & Lung Disease
2007 – Present	Member, Canadian Thoracic Society, Canada
2014 – Present	Member, Royal Society of Canada
2017 – Present	Fellow, Canadian Academy of Health Sciences
2023 – Present	Fellow, Royal Society of Canada

F7. Other Professional and Scientific Contributions

Consulting

2006 – 2010	Consultant, Foundation for Innovative New Diagnostics (FIND), Geneva
2010 – Present	Consultant, Bill & Melinda Gates Foundation, Seattle, USA

Tenure/Promotion Reviews at Other Universities

2012	Evaluation of a candidate for appointment to Associate Professor of Medicine with Tenure at the School of Medicine, Duke University, NC.
2013	Evaluation of a candidate for appointment to Professor at the London School of Hygiene and Tropical Medicine, London, UK.
2013	Evaluation of a candidate for Merit Award and Promotion at the University of Cape Town, South Africa.
2014	Evaluation of a candidate for promotion to the rank of Professor at the Keck Graduate Institute of Applied Life Sciences, Claremont, California, USA.
2014	Evaluation of a candidate for promotion to the rank of Associate Professor in Residence at the University of California, San Francisco, California, USA.
2014	Evaluation of a candidate for re-appointment at the Lady Davis Institute, Jewish General Hospital, Montreal.
2014	Evaluation of a candidate for promotion to the rank of Associate Professor at McMaster University, Hamilton, Canada.
2014	Evaluation of a candidate for promotion to the rank of Assistant Professor at the Department of Global Health and Social Medicine, Harvard Medical School, Boston
2015	Evaluation of a candidate for promotion to the rank of Associate Professor at the Department of Epidemiology of Microbial Diseases, Yale University School of Medicine & Yale School of Public Health, New Haven, USA
2015	Evaluation of a candidate for appointment to the rank of Professor with Tenure at the Department of Medicine, Stony Brook University, New York, USA
2016	Evaluation of a candidate for appointment to the rank of Associate Professor at the Department of Medicine, Johns Hopkins University, Baltimore, USA

- 2016 Evaluation of a candidate for appointment to the rank of Associate Professor at the Department of Medicine, University of Cape Town, South Africa
- 2017 Evaluation of a candidate for tenure at International Studies Department at Macalester College, St Paul, Minnesota, USA
- 2018 Evaluation of a candidate for promotion to the rank of Professor of Medicine in the Mayo Clinic College of Medicine and Science, Rochester, USA
- 2018 Evaluation of a candidate for promotion to the rank of Associate Adjunct Professor, University of California School of Public Health, Berkeley, USA
- 2018 Evaluation of a candidate for promotion to the rank of Full Professor in Residence, Step 1, University of California San Francisco, San Francisco, USA
- 2018 Evaluation of a candidate for promotion to the rank of Assistant Professor of Medicine at Harvard Medical School, Boston, USA
- 2020 Evaluation of a candidate for promotion to the rank of Associate Professor of Global Health and Social Medicine, at Harvard Medical School, Boston, USA
- 2020 Evaluation of a candidate for promotion to the rank of Associate Clinical Professor, University of Michigan School of Public Health, Michigan, USA
- 2020 Evaluation of a candidate for promotion to the rank of Associate Clinical Professor, University of Washington School of Medicine, St Louis, USA
- 2020 Evaluation of a candidate for appointment to the rank of Associate Clinical Professor, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, USA
- 2020 Evaluation of a candidate for promotion to the rank of Associate Professor, Department of Biostatistics, Boston University School of Public Health, Boston, USA
- 2020 Evaluation of a candidate for promotion to the rank of Professor, Department of Physical Therapy, University of Toronto, Canada
- 2021 Evaluation of a candidate for promotion to the rank of Professor, Department of Infectious Diseases, Mayo Clinic, Rochester
- 2021 Evaluation of a candidate for promotion to the rank of Professor, Weill Cornell Medical College, Cornell University, USA
- 2021 Evaluation of a candidate for promotion to the rank of Associate Professor, Department of Medicine, Johns Hopkins University, Baltimore, USA
- 2021 Evaluation of a candidate for tenure, Departments of Population Health and Medicine, NYU School of Medicine, NYC, USA
- 2022 Evaluation of a candidate for promotion to the rank of Associate Professor, University of Sydney, Australia
- 2022 Evaluation of a candidate for promotion to the rank of Associate Professor, Columbia University School of Public Health, NYC, USA
- 2022 Evaluation of a candidate for promotion to the rank of Associate Professor, Yale University, Connecticut, USA
- 2022 Evaluation of a candidate for promotion to the rank of Associate Professor, Rutgers New Jersey Medical School, New Jersey, USA
- 2023 Evaluation of a candidate for appointment to the rank of Assistant Professor, Boston University School of Public Health, Boston, USA

- 2023 Evaluation of a candidate for appointment to the rank of Professor, University College London, UK
- 2023 Evaluation of a candidate for appointment to the rank of Professor Adjunct in the Department of Epidemiology of Microbial Diseases, Yale School of Public Health
- 2023 Evaluation of a candidate for appointment to the rank of Associate Professor, Stanford University School of Medicine, California, USA
- 2023 Evaluation of a candidate for appointment to the rank of Associate Professor with tenure, Department of Civil and Environmental Engineering at the University of California, Berkeley
- 2023 Evaluation of a candidate for promotion to the rank of Associate Professor in the tenure track at North Carolina State University, NC, USA
- 2023 Evaluation of a candidate for appointment as Associate Professor, tenure track, in the Department of Epidemiology, School of Public and Population Health (SPPH) at The University of Texas Medical Branch (UTMB)
- 2024 Evaluated of a candidate for promotion to the rank of Associate Professor at the Ben-Gurion University of the Negev
- 2024 Evaluation of a candidate for promotion to the rank of Full Professor at the McMaster University, Hamilton, Ontario
- 2024 Evaluation of a candidate for promotion to the rank of Full Professor at the School of Medicine, Faculty of Medicine, at the Catholic University of Chile
- 2024 Evaluation of a candidate for appointment to the rank of Full Professor at the London School of Hygiene and Tropical Medicine, London, UK
- 2024 Evaluation of a candidate for promotion to the rank of Associate Professor of Clinical Pediatrics, Step 1 at University of California, San Francisco
- 2024 Evaluation of a candidate for promotion to the rank of Professor in the Department of Pathology and Laboratory Medicine, Aga Khan University, Pakistan

G. Research

G1. Research Activities

My general interests include infectious diseases epidemiology, global health research, evidence-based medicine, diagnostic research methodology, knowledge synthesis and knowledge transfer (systematic reviews, meta-analyses, and guideline development). My specific research program is on TB, focused on:

- 1) Evaluation of novel diagnostic tools and biomarkers for TB
- 2) Nosocomial TB and TB infection control in developing countries
- 3) Knowledge Synthesis: Evidence-based TB diagnosis
- 4) Knowledge Translation: Development of evidence-based standards for TB care and control
- 5) Measurement and improvement of quality of TB care

1) Evaluation of novel diagnostic tools and biomarkers for TB

Research on LTBI diagnostics: Detection and treatment of latent TB infection (LTBI) is an important component of TB control. Currently, diagnosis of LTBI relies on the tuberculin skin test (TST), a century-old test with several limitations. A breakthrough in recent years has been the development of interferon-g release assays (IGRAs) for LTBI. From a clinical and public health perspective, it is important to determine if IGRAs should replace the TST, and to assess their role and relevance in high burden

countries. By conducting field evaluations of IGRAs, our work has generated interesting and useful information on how these tests perform in high-risk populations such as healthcare workers (Pai M et al. *JAMA* 2005; Zwerling A et al. *PLoS One* 2013), children (Dogra S et al. *J Infect* 2007; Ling D et al. *Ped Infect Dis J* 2012), and TB patients with HIV co-infection (Pai M et al. *Infection* 2007; Ling et al. *ERJ* 2011). Our data has informed evidence-based guidelines on how IGRAs should be used in clinical practice – they have been used as the evidence-base in the 7th Edition of the Canadian TB Standards (2013).

Research on active TB diagnostics: We have evaluated novel diagnostics for TB various settings - Montreal, India and S Africa. In these projects, we are evaluating tests such as MODS (Sarojini JM et al. *IJTL D* 2010), optimized sputum microscopy (Daley P et al. *PLoS One* 2009), urinary antigen detection [LAM] (Daley P et al. *IJTL D* 2009; Dheda K et al. *PLoS One* 2010), LED microscopy (Shenai S et al. *IJTL D* 2010; Minion J et al. *J Clin Micro* 2011; Minion J et al. *PLoS One* 2011), and Xpert MTB/RIF (Sohn H et al. *CID* 2014; Alvarez GG et al. *Chest* 2015). We have also published mathematical models on the impact of new diagnostics (Sun A et al. *Am J Epid* 2013; Salje H et al. *PLoS Med* 2014; Moses et al. *Sci Reports* 2016; Murray et al. *BMJ Global Health* 2016).

2) Nosocomial TB and TB infection control in resource-limited settings

TB is a significant but neglected occupational problem among healthcare workers (HCWs) in poor countries. With the emergence of extensively drug-resistant TB (XDR-TB), there is growing concern about a real need to protect HCWs and HIV infected patients from TB. To inform policies and guidelines on TB infection control in developing countries, it is important to conduct research on dynamics of nosocomial transmission in high burden settings, and determine the effectiveness and feasibility of simple and low-cost interventions that may work in resource limited settings.

Our research in India and South Africa has shown that TB is an important problem among HCWs (Pai et al. *Emerg Infect Dis* 2006; Joshi R et al. *PLoS Med* 2006; Joshi et al. *PLoS One* 2007; Christopher et al. *PLoS One* 2010), and the annual risk of TB infection is high, even among young medical and nursing trainees (Christopher et al. *PLoS One* 2011) who are frequently exposed to TB (Pai M et al. *J Occup Med* 2006). Our work in India, for the first time, showed that interpretation of serial testing with novel T-cell based assays is complicated because of non-specific variations, conversions and reversions (Pai et al. *AJRCCM* 2006; 174 349-355). This led to our work on evaluating the reproducibility of T-cell-based assays in HCWs in India and S Africa (Veerapathran et al. *PLoS One* 2008 & van-Zyl Smit. *AJRCCM* 2009). Using data from India, we used Bayesian latent class analysis and mixture models to improve our estimates of TB prevalence in HCWs (Pai M et al. *IJTL D* 2008).

3) Knowledge Synthesis: Evidence-based TB diagnostics

Knowledge synthesis and knowledge translation are increasingly important for evidence-based clinical practice and evidence-based public health. High quality diagnostic studies are critical to evaluate new tools, to develop evidence-based policies on TB diagnostics, and, ultimately, for effective control of the global TB epidemic. Systematic reviews and meta-analyses provide the best synthesis of current evidence and have the potential to impact policy. I have conducted and supervised over 50 meta-analyses on various TB diagnostics. In addition to informing the field of evidence-based TB diagnosis (Pai M et al. *PLoS Med* 2008), and the development of the International Standards for TB Care (Hopewell et al. *Lancet Infect Dis* 2006), these reviews have been helpful in making policy decisions and in identifying key knowledge

gaps and unresolved questions. For example, our review on yield of serial sputum smear examination (*IJTL* 2007;11(5):484-95) influenced WHO's policy decision to reduce the number of sputum smears from three to two. Our meta-analyses on line-probe assays (Ling D et al. *ERJ* 2008), serological assays (Steingart KR et al. *PLoS Med* 2011), Xpert MTB/RIF (Steingart K et al. *Cochrane Library* 2014; Denkinger CM et al. *ERJ* 2014) and IGRAs (Pai M et al. *Annals Int Med* 2008; Cattamanchi A et al. *JAIDS* 2011; Rangaka M et al. *Lancet Infect Dis* 2012) have all been used by WHO for policy recommendations on TB diagnostics. Our systematic reviews on IGRAs have also informed policy recommendations in Canada (Canadian TB Standards) and US Centers for Disease Control (MMWR 2010).

4) Knowledge translation: Development of evidence-based standards for TB care and control

In order to control the TB epidemic, we need to ensure that our standards of TB care are based on rigorous scientific evidence, are clear and well understood, and are accessible to and applied by all types of health care providers -- public, private, certified, and non-traditional -- in all corners of the world. I participated in the development of the "*International Standards for Tuberculosis Care (ISTC)*," an initiative to develop evidence-based standard of care guidelines for TB, aimed primarily at the private healthcare sector. My role was to compile evidence-based guidelines on TB care, and co-author the standards. The ISTC report was published in 2006 (*Lancet Infect Dis* 2006;6:710-25). The ISTC is now an integral part of the new Global Stop TB Strategy. Also, I participated in developing the Canadian TB Committee's Advisory Committee Statements on Interferon-g assays for TB infection (*Can Commun Dis Rep* 2007; *CCDR* 2008; *CCDR* 2010). I served as the Associate Editor for the 7th Edition of the Canadian TB Standards (2013). I have also contributed to WHO guidelines on TB treatment (WHO, 2010), TB infection control (WHO 2009), and several WHO policies on TB diagnostics (previous section).

I am internationally recognized for my work which led to a historic negative WHO policy against inaccurate TB antibody blood tests (published in 2011), which was then taken up by the Government of India, which banned the use, sale and import of these blood tests in the year 2012. Subsequently, I partnered with the Clinton Foundation to create the "Initiative for Promoting Affordable and Quality TB Tests" (IPAQT) to make WHO-approved TB tests more affordable, so they could replace the banned, inaccurate tests. This unique market-shaping initiative has been featured in the *Wall Street Journal*, *British Medical Journal*, and WHO Global TB Report, among others.

5) Measurement and improvement of quality of TB care

Poor quality TB care can result in patient morbidity and mortality, and can also generate drug-resistance. India accounts for 25% of the global TB burden, and quality of care in the private sector is known to be highly variable and often suboptimal. We developed a new method for measuring quality of TB care using standardized patients [SP] ("mystery clients") who present typical TB case scenarios to health care providers. In a pilot study in Delhi, we demonstrated the feasibility and validity of this approach (Das J et al. *Lancet Infect Dis* 2015). The pilot study showed poor quality of TB care and a big gap between what providers knew about TB and what they actually did in practice. Subsequently, we rolled out this methodology across 3 cities in India, with over 7000 simulated patient interactions (Kwan et al. *PLOS Med* 2018). To provide some examples, insights from this work helped uncover that private providers underutilize TB tests, even when simulated patients present with typical TB symptoms; and pharmacists do not dispense any TB drugs over the counter (Satyanarayana S et al. *Lancet Infect Dis* 2016), but rarely refer persons with TB symptoms. This simulated patient method for TB has now been used in Kenya, China, South Africa, Indonesia and Nigeria, inspired by our work in India.

G2. Personal Salary Awards

2022 – 2029	Canada Research Chair (Tier 1), renewal Canada Research Chairs Program & CIHR	\$1,400,000
2015 – 2022	Canada Research Chair (Tier 1) Canada Research Chairs Program & CIHR	\$1,400,000
2014 – 2017	FRQS Chercheur Boursier – Senior Fonds de recherche du Québec – Santé (FRQS) Rating (score): 93/100 Rank within the committee: 1	\$211,962
2012 – 2014	FRQS Chercheur Boursier – Junior 2 Fonds de recherche du Québec – Santé (FRQS) Rating (score): 95/100 Rank within the committee: 2	\$128,472
2007 – 2012	CIHR New Investigator Award Canadian Institutes of Health Research (CIHR) Rating (score): 4.36/5.00 Rank within the committee: 4	\$300,000
2007 – 2011	FRSQ Chercheur Boursier – Junior 1 Fonds de la recherche en santé du Québec (FRSQ) Rating (score): 96/100 Rank within the committee: 1	Declined
2007 – 2010	Établissement de jeunes chercheurs Fonds de la recherche en santé du Québec (FRSQ) Rating (score): 96/100 Rank within the committee: 1	\$45,000

G3. Research Grants

Current Grants

As Principal Investigator (PI):

202409PJT	Pai, M (PI)	1 April 2025 – 31 March 2030
Canadian Institutes of Health Research (CIHR)		
<i>Why are women at greater risk for multi-drug resistant tuberculosis?</i>		
Role: PI		
Amount: \$1,147,500		
INV-065185	Pai, M (PI)	19 July 2024 – 30 Nov. 2025
Bill & Melinda Gates Foundation (BMGF)		
<i>Critical path analysis & TA for new TB diagnostics in priority countries</i>		
Role: PI		

Amount: \$493,281 US
Rating and rank: Not provided

PJT-191882 Pai, M (PI) 1 April 2024 – 31 March 2028
Canadian Institutes of Health Research (CIHR)
Empowering informal healthcare providers to detect tuberculosis using tongue swabs: a field-based, open-label, cluster randomized trial in India
Role: PI
Amount: \$569,926
Rating and rank: rank #8

INV-069540 Pai, M (PI) 18 Jan. 2024 – 30 June 2025
Bill & Melinda Gates Foundation (BMGF)
Systematic reviews on sputum expectoration proportion
Role: PI
Amount: \$188,600 US
Rating and rank: Not provided

N/A Pai, M (PI) 1 Jan. 2024 – 31 Dec. 2025
Georgetown University
The O'Neill-Lancet Commission on Racism, Structural Discrimination and Global Health – Structural change for health equity
Role: PI
Amount: \$264,737 US
Rating and rank: Not provided

INV-066261 Pai, M (PI) 30 Oct. 2023 – 21 Oct. 2026
Bill & Melinda Gates Foundation (BMGF)
Capacity building for Advanced TB diagnostics in SEAR countries
Role: PI
Amount: \$187,550 US
Rating and rank: Not provided

SFG5-01 Pai, M (Co-PI) 1 May 2023 – 30 April 2025
McGill Interdisciplinary Initiative in Infection and Immunity (MI4) Seed Grant
Reducing antibiotic abuse at the primary care level using locally adapted, digitally delivered, clinical decision support tool: a pilot, intervention study in India
Role: Co-PI [with Rahimi SA]
Amount: \$150,000
Rank within the committee: Not provided

N/A Pai, M (PI) 1 Jan. 2023 – 31 Dec. 2025
Foundation for Innovative New Diagnostics (FIND)
Tuberculosis diagnostics, supporting work for essential diagnostics list and digital health: medical and impact
Role: PI

Amount: \$195,672.50 US

Rating and rank: Not provided

N/A Pai, M (PI)

1 Jan. 2023 – 31 Dec. 2025

Foundation for Innovative New Diagnostics (FIND)

Tuberculosis diagnostics, supporting work for essential diagnostics list and digital health: access

Role: PI

Amount: \$194,470.75 US

Rating and rank: Not provided

INV-042531 Pai, M (PI)

9 July 2022 – 30 June 2025

Bill & Melinda Gates Foundation (BMGF)

Sustaining the TB PPM Learning Network

This project will maintain a learning network (community of practice) around private provider engagement and tuberculosis

Role: PI

Amount: \$993,778 US

Rating and rank: Not provided

EGA-179418 Pai, M (Nominated PI)

1 Dec. 2021 – 31 March 2025

Canadian Institutes of Health Research (CIHR)

Artificial intelligence-based analysis of cough for COVID-19 screening in Montreal

Role: NPI [with Grandjean Lapierre S]

Amount: \$449,926

Rating and rank: rank #2

Completed Grants

As Principal Investigator (PI):

INV-022420 Pai, M (PI)

22 Sept. 2020 – 31 Dec. 2023

Bill & Melinda Gates Foundation (BMGF)

Covid-19 impact on private health markets

This project will assess the impact of the Covid-19 pandemic on private health markets in 3 countries and its impact on tuberculosis care

Role: PI

Amount: \$1,323,642 US

Rating and rank: Not provided

109554-001 Pai, M (Nominated PI)

1 Aug. 2020 – 31 March 2023

Canadian Institutes of Health Research (CIHR) & International Development Research Centre (IDRC)

Validation of rapid, molecular testing for COVID-19 and integration with TB diagnostics

Role: PI

Amount: \$421,479

Rating and rank: 4.45, rank #4

OPP1172634 Daftary, A (Nominated PI) 9 Aug. 2017 – 31 Dec. 2020
Bill & Melinda Gates Foundation (BMGF)

Standardized patients: An approach to understanding the realities of South Africa's TB care cascade

This project will use standardized patients to evaluate quality of TB and TB-HIV care in the private sector in two provinces of South Africa.

Role: Co-PI [with Daftary A]

Amount: \$652,488 US

Rating and rank: Not provided

PCS164943 Pai, M (PI) 1 May 2019 – 31 March 2020

Canadian Institutes of Health Research (CIHR) – Planning and Dissemination Grant

Engaging global leaders and champions for ending TB

This is a one-year planning and dissemination grant to support NTP managers and TB advocates to attend the 2019 Summer Institute in Infectious Diseases and Global Health.

Role: PI

Amount: \$10,000

Rating and rank: 4.73, 1

R-ST-POC-1706-03538 Pai, M (PI) 31 March 2017 – 30 Sept. 2018

Grand Challenges Canada (GCC)

Stars in Global Health grants

Improving the diagnosis of childhood tuberculosis in high burden settings

Role: PI

Amount: \$100,000

Rating and rank: Not provided

Pai, M (Nominated PI) 1 June 2015 – 31 March 2018

IC-IMPACTS Centres of Excellence

Engaging Community Pharmacists in India to Enhance Early Detection of Tuberculosis

This project is focused on improving tuberculosis detection in India, by engaging community-based pharmacists and use mobile technologies to facilitate referral and linkages.

Role: Co-PI [with Jha N]

Amount: \$252,500

Rank within the committee: Not provided

MOP-325986 Dendukuri, N (Nominated PI) 1 Oct. 2014 – 30 Sept. 2017

Canadian Institutes of Health Research (CIHR)

Statistical methods to support diagnosis of pediatric tuberculosis in the absence of a gold standard reference.

Role: Co-PI [with Dendukuri N]

Amount: \$256,932

Rating (score): 4.65/5.00

Rank within the committee: 1

Pai, M (PI) 1 Sept. 2016 – 31 Aug. 2017

Merck, Sharpe & Dohme Corporation Funds – Translational Research
Improving the Diagnosis of Childhood Tuberculosis in High Burden Settings

Role: PI

Amount: \$44,000

Rating and rank: Not provided

Pai, M (PI)

1 Feb. 2014 – 31 Dec. 2016

Capital for Good (CfG) Advocacy Initiative

Innovative approaches to TB diagnostics: engaging policy makers from low-income countries

Role: PI

Amount: \$195,500 US

Rating and rank: Not provided

MOP-130330 Pai, M (PI)

1 Oct. 2013 – 30 Sept. 2015

Canadian Institutes of Health Research (CIHR)

Modeling the reproducibility of blood assays for TB infection

This study will model the reproducibility of interferon-gamma release assays for latent TB infection.

Role: PI

Amount: \$235,157

Rating (score): 4.23/5.00

Rank within the committee: 7

MOP-123291 Pai, M (Nominated PI)

1 Oct. 2012 – 30 Sept. 2015

Canadian Institutes of Health Research (CIHR)

Modeling the public health impact of TB and HIV diagnostics

This study will model the public health impact and cost-effectiveness of rapid diagnostics for TB and HIV in Canada and India.

Role: Co-PI [with Dowdy D]

Amount: \$274,351

Rating (score): 4.50/5.00

Rank within the committee: 2

OPP1061487 Pai, M (Nominated PI)

1 Aug. 2012 – 31 July 2015

Bill & Melinda Gates Foundation (BMGF)

Target product profiles for point-of-care TB testing

This project will develop target product profiles (TPPs) for point-of-care (POC) TB testing, to accelerate further development and validation work in this area.

Role: Co-PI [with Pai NP]

Amount: \$1,190,749 US

Rating and rank: Not provided

Pai, M (PI)

1 Oct. 2013 – 31 March 2015

Grand Challenges Canada (GCC)

Stars in Global Health grants

Mystery clients to assess and improve quality of TB care in India

Role: PI

Amount: \$113,000

Rating and rank: Not provided

MOP-89857 Dendukuri, N (Nominated PI) 1 Oct. 2011 – 30 Sept. 2014

Canadian Institutes of Health Research (CIHR)

Development of statistical methods for meta-analysis of tuberculosis diagnostic studies.

This project is focused on the development of new tools to improve meta-analyses of tuberculosis diagnostic studies.

Role: Co-PI [with Dendukuri N]

Amount: \$282,798

Rating (score): 4.24/5.00

Rank within the committee: 1

MOP-89918 Pai, M (Nominated PI) 1 Oct. 2011 – 30 Sept. 2014

Canadian Institutes of Health Research (CIHR)

Improving tuberculosis diagnosis in vulnerable populations: impact and cost-effectiveness of a novel, rapid molecular assay.

This study evaluates a new rapid point-of-care molecular assay for the diagnosis of TB in Montreal and Iqaluit.

Role: Co-PI [with Alvarez G]

Amount: \$355,730

Rating (score): 4.13/5.00

Rank within the committee: 4

Pai, M (PI) 1 July 2011 – 30 June 2013

Grand Challenges Canada (GCC)

Canadian Rising Stars in Global Health grants

A low-cost, multiplexed, point-of-care test for extra-pulmonary tuberculosis.

Role: PI

Amount: \$113,000

Rating and rank: Not provided

MOP-81362 Pai, M (PI) 1 Oct. 2009 – 30 Sept. 2012

Canadian Institutes of Health Research (CIHR)

Tuberculosis screening of health care workers: do novel blood tests have a role?

This study is continuation of a cohort study of new in-vitro tests for the diagnosis of latent TB infection among healthcare workers in Montreal and India.

Role: PI

Amount: \$336,725

Rating (score): 4.26/5.00

Rank within the committee: 1

MOP-89918 Pai, M (PI) 1 Oct. 2008 – 30 Sept. 2011

Canadian Institutes of Health Research (CIHR)

Innovative approaches for diagnosing tuberculosis in the era of HIV.

This study is a 3-year study of new tests for the diagnosis of TB in Canada, India and S Africa.

Role: PI

Amount: \$319,198

Rating (score): 4.18/5.00

Rank within the committee: 2

MOP-89857 Dendukuri, N (Nominated PI) 1 Oct. 2008 – 30 Sept. 2011

Canadian Institutes of Health Research (CIHR)

Novel statistical methods for tuberculosis diagnostic studies.

This is a 3-year study of new statistical approaches for evaluating tests for the diagnosis of TB.

Role: Co-PI [with Dendukuri N]

Amount: \$182,976

Rating (score): 4.13/5.00

Rank within the committee: 3

MOP-81362 Pai, M (PI) 1 Oct. 2006 – 30 Sept. 2009

Canadian Institutes of Health Research (CIHR)

Validation of interferon-gamma assay for the diagnosis of tuberculosis infection in health care workers.

This study was a 3-year cohort study of new in-vitro tests for the diagnosis of latent TB infection among healthcare workers in Montreal and India.

Role: PI

Amount: \$249,285

Rating (score): 4.23/5.00

Rank within the committee: 4

MUHC-RI Pai, M (PI) 15 May 2007 – 14 May 2009

McGill University Health Centre - Research Institute

Tuberculosis contact investigation in Montreal: comparison of T cell based interferon-g assays with the tuberculin test.

This was a pilot project for evaluation of a new diagnostic test for TB.

Role: PI

Amount: \$20,000

Rating and rank: Not provided

MISRI Pai, M (PI) 1 July 2007 – 30 June 2008

McGill University: McGill-India Strategic Research Initiative

Improving the Diagnosis of Tuberculosis Among HIV Infected and Non-Infected Individuals in India.

This was a pilot project for evaluation of new diagnostic tests for TB in HIV patients in India.

Role: PI

Amount: \$15,000

Rating and rank: Not provided

As Co-Investigator:

N/A Banerjee, AT & Chirgwin, JCL (PIs) 1 Oct. 2021 – 30 Sept. 2023

Canadian Institutes of Health Research (CIHR)

Best practices for community-led strategies to boost vaccine confidence: A case study in Parc-Extension, Québec

Role: Co-Investigator

Amount: \$143,885

Rating and rank: Not provided

N/A Menzies, R (PI) 1 July 2015 – 30 June 2022

Canadian Institutes of Health Research (CIHR) – Foundation Scheme

Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease

This is a seven-year research program focusing on treatment of latent TB infection and drug resistance.

Role: Named program expert

Amount: \$7,899,734

Consolidated ranking (score, stage 2): 62.9%

Rank (stage 2): 145/445

N/A Horton, S (PI) 1 Jan. 2020 – 31 Dec. 2020

Canadian Institutes of Health Research (CIHR) – Planning and Dissemination Grant

Advancing equitable access to diagnostics

This is a one-year planning and dissemination grant focused on access to diagnostics.

Role: Co-investigator

Amount: \$18,500

Rating and rank: N/A

N/A Ahmad Khan, F (PI) 1 July 2016 – 30 June 2019

Canadian Institutes of Health Research (CIHR) – Project Scheme

Computer-aided detection of pulmonary tuberculosis on digital chest x-rays: its role in the detection of active tuberculosis in a high burden setting of low HIV prevalence

Role: Co-investigator

Amount: \$283,183

N/A Benedetti, A (PI) 1 April 2014 – 31 March 2017

Canadian Institutes of Health Research (CIHR)

Statistical challenges in individual patient data meta analysis

Role: Co-investigator

Amount: \$189,279

Rating (score): 4.41/5.00

Rank within the committee: 3

MCT-94831 Menzies, R (PI) 1 Jan. 2009 – 31 March 2016

Canadian Institutes of Health Research (CIHR)

A Randomized Trial of 4 Months Rifampin vs. 9 Months Isoniazid for Latent Tuberculosis Infection.

This is a randomized controlled trial of a short drug regimen for treatment of latent TB infection.

Role: Co-investigator

Amount: \$4,877,968

Rating (score): 4.42/5.00

Rating and rank: Not provided

RRD-153877 Menzies, R (PI) 1 April 2006 – 31 March 2011
Canadian Institutes of Health Research (CIHR) - Team Grant (Research Resource Grant)
Understanding the keys to TB: exposure to infection, and infection to disease.
This study is a cohort study of TB transmission among household contacts of TB cases in Montreal.
Role: Co-investigator
Amount: \$ 919,550
Rating (score): 4.6/5.00
Rank within the committee: Not provided

KRS-102067 Pai, NP (PI) 1 Jan. 2010 – 31 March 2011
Canadian Institutes of Health Research (CIHR)
Diagnostic performance of rapid tests for HIV and related coinfections in vulnerable populations.
This is a knowledge synthesis grant.
Role: Co-investigator
Amount: \$55,395
Rating and rank: Not provided

TBSusgent Dheda, K (PI) 1 Feb. 2009 – 31 Jan. 2011
European Commission (EU-FP7)
Sustaining research momentum over the coming decades: mentoring the next generation of researchers for tuberculosis.
This is a multi-country training grant for mentoring new researchers in TB.
Role: Co-investigator
Amount: € 60,600
Rating and rank: Not provided

GGH-84625 Vissandjee, B (PI) 1 July 2007 – 30 June 2009
Canadian Institutes of Health Research (CIHR)
Integrating gender sensitivity in TB programs in India: Building international partnerships and models for equitable access.
This was a CIHR seed grant for gender and health research.
Role: Co-investigator
Amount: \$74,984
Rating (score): 4.13/5.00
Rank within the committee: 4

MELS-MRI-MDEIE Vissandjee, B (PI) 1 April 2007 – 31 March 2009
Gouvernement du Québec, Initiative Inde 2007
Préoccupations liées aux rapports sociaux de genre dans les programmes de prévention et de traitement contre la tuberculose en Inde: Vers une construction de partenariats internationaux et approches pour un accès équitable.
This was a seed grant for collaborative research in India.
Role: Co-investigator
Amount: \$20,000

Rating and rank: Not provided

G4. Publications

G4a. Peer Reviewed Articles: Original Research Contributions

1. Rao S, Pai M, Iyanar A, Joseph A. Sanitation for rural communities: first win the people's support. *World Health Forum* 1997, Vol 18:262-265.
2. Pai M, Zachariah A, Rose W, Satyajit S, Verghese S, Joseph A. Malaria and migrant labourers: socio-epidemiological inquiry. *Economic and Political Weekly*, Vol XXXII, No 16, 1997.
3. Pai M, Kang G, Ramakrishna BS, Venkataraman A, Muliylil JP. An epidemic of diarrhoea in south India caused by enteroaggregative *Escherichia coli*. *Indian J Med Res* 1997;106:7-12.
4. Abraham M, Pai M, Kang G, Asokan GV, Magesh SR, Bhattacharji S, Ramakrishna BS. An outbreak of food poisoning in Tamil Nadu associated with *Yersinia enterocolitica*. *Indian J Med Res* 1997;106:465-468.
5. Pai M, Sundaram P, Radhakrishnan KK, Thomas K, Muliylil JP. Hepatitis B immunization coverage and awareness in middle and upper class population in Chennai City. *Indian Pediatrics* 1998; 35:922-23.
6. Alaganantham TP, Pai M, Vaidehi T, Thomas J. Seroepidemiology of *Helicobacter pylori* infection in an urban, upper-class population in Chennai City. *Indian J Gastroenterology* 1999;18(2):66-68.
7. Pai M, Sundaram P, Radhakrishnan K K, Thomas K, Muliylil JP. A high rate of caesarean sections in an affluent section of Chennai City: Is it cause for concern? *Natl Med J India* 1999;12(4)156-158.
8. Rajaram R, Rajagopalan RE, Pai M, Mahendran S. Survival after cardiopulmonary resuscitation in an urban Indian hospital. *Natl Med J India* 1999;12(2):51-55.
9. Rajagopalan RE, Chandrasekaran S, Pai M, Rajaram R, Mahendran S. Pre-hospital delay in acute myocardial infarction in an urban Indian hospital: a prospective study. *Natl Med J India* 2001;14(1):8-12.
10. Santhanam I, Pai M, Kasturi K, Radhamani MP. Mortality after admission in the pediatric emergency department: a prospective study from a referral, children's hospital in south India. *Ped Crit Care Med* 2002;3:358-363.
11. Badam P, Solao V, Pai M, Kalantri SP. Poor accuracy of the Siriraj and Guy's hospital stroke scores in distinguishing haemorrhagic from ischaemic stroke in a rural, tertiary care hospital. *Natl Med J India* 2003;16(1):8-12.
12. Singh M, Pai M, Kalantri SP. Accuracy of perception and touch for detecting fever in adults: a hospital-based study from a rural, tertiary hospital in Central India. *Trop Med & Int Health* 2003;8:408-14.
13. †Indra R, Patil SS, Joshi R, Pai M, Kalantri SP. Accuracy of physical examination in the diagnosis of hypothyroidism: a cross-sectional, double-blind study. *J Postgrad Med* 2004;50(1):7-11.
14. †Joshi R, Singh A, Jajoo N, Pai M, Kalantri SP. Accuracy and reliability of palpation and percussion for detecting hepatomegaly: a rural hospital-based study. *Indian J Gastroenterol* 2004;23:171-74.

15. †Patil SS, Joshi R, Gupta G, Reddy MVR, Pai M, Kalantri SP. Risk factors for acute myocardial infarction in a rural population in central India: a hospital-based case-control study. *Natl Med J India* 2004;17:189-94.
16. Pai M, Gokhale K, Joshi RJ, Dogra S, Kalantri SP, Mendiratta DK, Narang P, Daley CL, Granich RM, Mazurek GH, Reingold AL, Riley LW, Colford, JM. *Mycobacterium tuberculosis* infection in health care workers in rural India: comparison of a whole-blood, interferon-g assay with tuberculin skin testing. *JAMA* 2005;293:2746-55.
17. †Geetadevi Y, Joshi R, Pai M, Kalantri SP. Simple clinical predictors of brain lesions in patients with impaired consciousness: a cross sectional study from a rural, tertiary hospital in central India. *Clin Neurol Neurosurg* 2005 Dec;108(1):25-31.
18. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri SP, Reingold AL, Colford, JM, Riley LW, Menzies D. Serial testing of health care workers for tuberculosis using interferon-g assay. *Am J Respir Crit Care Med* 2006; 174 349-355.
19. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, Kalantri SP. Persistently elevated T cell interferon-g responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. *J Occup Med Toxicol* 2006;1:7.
20. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? *Int J Tuberc Lung Dis* 2006;10(11):1192-1204.
21. †Dogra S, Narang P, Mendiratta DK, Chaturvedi P, Reingold AL, Colford, JM, Riley LW, Pai M. Comparison of a whole-blood, interferon-g assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. *J Infect* 2007;54:267-76. [Corresponding author]
22. Kalantri SP, Joshi R, Lokhande T, Singh A, Morgan M, Colford JM, Pai M. Accuracy and reliability of physical signs in the diagnosis of pleural effusion. *Resp Med* 2007;101:431-38. [Corresponding author]
23. Pai M, Joshi R, Bandopadhyay M, Narang P, Dogra S, Taksande B, Kalantri S. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T cell responses during anti-tuberculosis treatment. *Infection* 2007;35:98-103.
24. Pai NP, Joshi R, Dogra S, Taksande B, Kalantri SP, Pai M, Narang P, Tulsy JP, Reingold AL. Evaluation of Diagnostic Accuracy, Feasibility and Client Preference for Rapid Oral Fluid-Based Diagnosis of HIV Infection in Rural India. *PLoS One* 2007;2(4):e367.
25. Dheda K, Pooran A, Pai M, Miller RF, Lesley K, Booth H, Scott GE, Akbar A, Zumla A, Rook GA. Interpretation of *M. tuberculosis* antigen-specific IFN- γ release assays (T-SPOT.TB) and factors that may modulate test results. *J Infect* 2007;55:169-73.
26. Birkner MD, Kalantri SP, Solao V, Badam P, Joshi R, Goel A, Pai M, Hubbard AE. Creating Diagnostic Scores using Data-Adaptive Regression: An application to prediction of 30-day Mortality among Stroke Victims in a Rural Hospital in India. *Therapeutics and Clinical Risk Management* 2007;3(3):475-84.
27. †Joshi R, Patil S, Kalantri SP, Schwartzman K, Menzies D, Pai M. Prevalence of abnormal radiological findings in health care workers with latent tuberculosis infection and correlations with T cell immune response. *PLoS One* 2007;2(8):e805. [Corresponding author]

28. †Anandharaman V, Joshi R, Goswami K, Dogra S, Moodie EM, Reddy MVR, Kalantri SP, Schwartzman K, Behr M, Menzies D, Pai M. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. *PLoS One* 2008;3(3):e1850. [Corresponding author]
29. Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M. Thinking in three dimensions: A web-based algorithm to aid the interpretation of the tuberculin skin test results. *Int J Tuberc Lung Dis* 2008;12(5):498-505.
30. Pai NP, Barick R, Tulsy JP, Shivkumar PV, Cohan D, Kalantri S, Pai M, Klein MB, Chhabra S. Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. *PLoS Med* 2008;5(5):e92.
31. **Pai M, **Dendukuri N, Wang L, Joshi R, Kalantri S, Rieder HL. Improving the estimation of TB infection prevalence using T-cell-based assay and mixture models. *Int J Tuberc Lung Dis* 2008;12(8):895-902. [**joint first authors]
32. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, Reddy MVR, Kalantri S, Hill PC, Menzies D, Hopewell PC. T-cell assay conversions and reversions among household contacts of TB patients in rural India. *Int J Tuberc Lung Dis* 2009;13(1):84-92.
33. Pai NP, Joshi R, Moodie EM, Taksande B, Kalantri S, Pai M, Tulsy JP, Reingold A. Profile of adults seeking voluntary HIV testing and counseling in rural Central India: results from a hospital-based study. *AIDS Care* 2009;21:294-300.
34. †van Zyl Smit R, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Bateman E, Dheda K. Within-subject variability and boosting of T cell IFN- γ responses following tuberculin skin testing. *Am J Resp Crit Care Med* 2009;180:49-58.
35. Daley P, Michael JS, Kalaiselvan S, Latha A, Mathai D, John KR, Pai M. A Pilot Study of Short-duration Sputum Pretreatment Procedures for Optimizing Smear Microscopy for Tuberculosis. *PLoS One* 2009;4(5): e5626. [Corresponding author]
36. Daley P, Michael JS, Hmar P, Latha A, Chordia P, Mathai D, John KR, Pai M. Blinded Evaluation of Commercial Urinary Lipo-Arabinomannan for Active Tuberculosis: A pilot study. *Int J Tuberc Lung Dis* 2009;13(8):989-995. [Corresponding author]
37. Oxlade O, Schwartzman K, Behr MA, Benedetti A, Pai M, Heymann J, Menzies D. Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? *Int J Tuberc Lung Dis* 2009 13(10):1238-46.
38. †Fontela PS, Pai NP, Schiller I, Dendukuri N, Ramsay A, Pai M. Quality and Reporting of Diagnostic Accuracy Studies in TB, HIV and Malaria: Evaluation Using QUADAS and STARD Standards. *PLoS One* 2009;4(11): e7753. [Corresponding author]
39. Sarojini JM, Daley P, Kalaiselvan S, Latha A, Mathai D, John KR, Pai M. Diagnostic Accuracy of Microscopic Observation Drug Susceptibility assay (MODS): A Pilot Study from India. *Int J Tuberc Lung Dis* 2010;14(4):482-88. [Senior author]
40. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van-zyl Smit R, Peter J, Green C, Badri M, Sechi L, Sharma S, Hoelscher M, Dawson R, Whitelaw A, Blackburn J, Pai M, Zumla A. Clinical Utility of a Commercial LAM-ELISA Assay for TB Diagnosis in HIV-Infected Patients Using Urine and Sputum Samples. *PLoS One* 2010;5(3): e9848.

41. Oxlade O, Schwartzman K, Pai M, Heymann J, Benedetti A, Royce S, Menzies D. Predicting outcomes and drug resistance with standardized treatment of active tuberculosis. *Eur Resp Journal* 2010;36: 870-877.
42. Christopher DJ, Daley P, Armstrong L, James P, Gupta R, Premkumar B, Michael JS, Radha V, Zwerling A, Schiller I, Dendukuri N, Pai M. Tuberculosis infection among young nursing trainees in South India. *PLoS One* 2010;5(4): e10408. [Corresponding author]
43. O'Donnell MR, Jarand J, Loveday M, Padayatch N, Zelnick J, Werner L, Naidoo N, Master I, Osburn G, Kvasnovsky C, Shean K, Pai M, Van der Walt M, Horsburgh CR, Dheda K. High Incidence of Hospital Admissions with Multidrug Resistant and Extensively Drug Resistant Tuberculosis among South African Health Care Workers. *Annals Int Med* 2010;153:516-522.
44. Shenai S, Minion J, Vadwai V, Tipnis T, Shetty S, Salvi A, Udhwadia Z, Pai M, Rodrigues C. Evaluation of LED based fluorescence microscopy for the detection of mycobacteria in a TB endemic region. *Int J Tuberc Lung Dis* 2010;15(4):483-8.
45. Oxlade O, Schwartzman K, Benedetti A, Pai M, Heymann J, Menzies D. Developing a tuberculosis transmission model that accounts for changes in population health. *Med Decis Making* 2011; 31:53-68.
46. Fontela PS, Platt RW, Rocher I, Frenette C, Moore D, Fortin É, Buckeridge D, Pai M, Quach C. Surveillance Provinciale des Infections Nosocomiales (SPIN) Program: implementation of a mandatory surveillance program for central line-associated bloodstream infections. *Am J Infect Control*. 2011;39(4):329-35.
47. *Brunet L, Pai M, Davids V, Ling D, Paradis G, Lenders L, Meldau R, van-zyl Smit RV, Calligaro G, Allwood B, Dawson R, Zumla A, Dheda K. High prevalence of smoking among patients with suspected tuberculosis in South Africa. *Eur Respir J* 2011; 38: 139–146.
48. *Zwerling A, Behr M, Varma A, Brewer T, Menzies D, Pai M. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. *PLoS Med* 2011;8(3): e1001012.
49. *Ling D, Pai M, V. Davids, L. Brunet, L. Lenders, R. Meldau, G. Calligaro, B. Allwood, R. van Zyl-Smit, J. Peter, E. Bateman, R. Dawson, and K. Dheda. Are interferon- γ release assays useful for active tuberculosis in a high-burden setting? *Eur Respir J* 2011; 38: 649–656.
50. Moyo S, Isaacs F, Gelderbloem S, Verver S, Hawkrigde A, Hatherill M, Tameris M, Workman L, Pai M, Hussey G, Hanekom W, Mahomed H. Tuberculin skin test and QuantiFERON assay in young children investigated for tuberculosis in South Africa. *Int J Tuberc Lung Dis* 2011;15(9):1176-1181.
51. Joshi R, Narang U, Zwerling A, Jain D, Jain V, Kalantri SP, Pai M. Predictive value of latent tuberculosis tests in Indian health-care workers: a cohort study. *Eur Respir J* 2011;38(6):1475-77.
52. *Minion J, Shenai S, Vadwai V, Tipnis T, Greenaway C, Menzies D, Ramsay A, Rodrigues C, Pai M. Fading of auramine-stained mycobacterial smears and implications for external quality assurance. *J Clin Micro* 2011;49(5):2024-26.
53. Theron G, Peter J, Pai M, Dheda K. Evaluation of the Xpert® MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. *Am J Resp Crit Care Med* 2011; 184(1):132-40.

54. Whitelaw A, Peter J, Sohn H, Viljoen D, Theron G, Badri M, Davids V, Pai M, Dheda K. Comparative cost and performance of light-emitting diode microscopy in HIV–tuberculosis-co-infected patients. *Eur Respir J* 2011;38 1393-1397.
55. Dowdy D, Cattamanchi A, Steingart KR, Pai M. Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. *PLoS Med* 2011; 8(7): e1001063.
56. Dowdy D, Steingart KR, Pai M. Serological Testing versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis. *PLoS Med* 2011;8(8): e1001074.
57. *Minion J, Pai M, Menzies D, Ramsay A, Greenaway C. Comparison of LED and conventional fluorescence microscopy for detection of acid fast bacilli in a low-incidence setting. *PLoS One* 2011; 6(7): e22495.
58. Christopher DJ, James P, Daley P, Armstrong L, Isaac BT, Balmugesh T, Premkumar B, Zwerling A, Pai M. High annual risk of tuberculosis infection among nursing students in South India: a cohort study. *PLoS One* 2011; 6(10): e26199.
59. Fontela P, Platt RW, Rocher I, Frenette C, Moore D, Fortin E, Buckeridge D, Pai M, Quach C. Epidemiology of Central Line-Associated Bloodstream Infections in Quebec Intensive Care Units: A 6-year Review. *Am J Infect Control*. 2012 Apr;40(3):221-6.
60. *Grenier J, Pinto L, Nair D, Steingart KR, Dowdy D, Ramsay A, Pai M. Widespread use of serological tests for tuberculosis: data from 22 high-burden countries. *Eur Respir J* 2012;39(2):502-505.
61. Rangaka MX, Gideon H, Wilkinson K, Pai M, Mwansa-Kambafilwe J, Maartens G, Glynn JR, Boulle A, Fielding K, Goliath R, Titus R. Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms. *Eur Respir J* 2012; 39: 163–171.
62. Jaroslawski S, Pai M. Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. *J Epi Global Health* 2012;2:39-50.
63. Dendukuri N, Schiller I, Joseph L, Pai M. Bayesian meta-analysis of the accuracy of a test for tuberculous pleuritis in the absence of a gold-standard reference. *Biometrics* 2012;68(4):1285-93.
64. *Denkinger CM, Grenier J, Minion J, Pai M. Promise versus reality: optimism bias in package inserts of tuberculosis diagnostics. *J Clin Micro* 2012;50(7):2455-61.
65. Fontela PS, Quach C, Buckeridge D, Pai M, Platt RW. Surveillance Length and Validity of Benchmarks for Central Line-Associated Bloodstream Infection Incidence Rates in Intensive Care Units. *PLoS One* 2012;7(5): e36582.
66. Pai NP, Vadnais C, Denkinger CM, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in resource-limited settings. *PLoS Medicine* 2012;9(9)e1001306.
67. †Bhargava A, Pai M, Bhargava M, Marais B, Menzies D. Can social interventions prevent tuberculosis? The Papworth experiment (1918-1943) revisited. *Am J Resp Crit Care Med* 2012;186:442-449.
68. *Ling D, Crepeau C, Dufresne M, Khan S, Quach C, Dendukuri N, Schwartzman K, Menzies D, Lands L, Pai M. Evaluation of the Impact of Interferon-Gamma Release Assays on Management of Childhood Tuberculosis. *Ped Infect Dis J* 2012;31:1258-62.

69. *Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Research questions and priorities for tuberculosis: A survey of published systematic reviews and meta-analyses. *PLoS One* 2012;7(7):e42479.
70. *Zwerling A, Cojocariu M, McIntosh F, Pietrangelo F, Behr M, Schwartzman K, Benedetti A, Dendukuri N, Menzies D, Pai M. TB screening in Canadian Health Care Workers using Interferon-gamma release assays. *PLoS One* 2012;7(8):e43014.
71. *Nicolau I, Tian L, Menzies D, Ostiguy G, Pai M. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. *PLoS One* 2012;7(9):e45913.
72. Fontela P, Rocher I, Platt RW, Pai M, Buckeridge DL, Frenette C, Dionne M, Quach C. Evaluation of the reporting validity of central line-associated bloodstream infection data to a provincial surveillance program. *Infection Control and Hospital Epidemiology* 2013;34(2):217-220.
73. *Denkinger CM, Pai M, Patel M, Menzies D. Interferon-gamma release assay for treatment monitoring of active tuberculosis - An explosion in the spaghetti factory. *J Clin Micro* 2013; 51:607-610.
74. *Pinto LM, Dheda K, Theron G, Allwood B, Calligaro G, van-zyl Smit R, Peter J, Schwartzman K, Menzies D, Bateman E, Pai M, Dawson R. Development of a simple reliable radiographic scoring system to aid the diagnosis of pulmonary tuberculosis. *PLoS One* 2013; 8(1): e54235.
75. *Zwerling A, Benedetti A, Cojocariu M, McIntosh F, Pietrangelo F, Behr M, Schwartzman K, Menzies D, Pai M. Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability? *PLoS One* 2013;8(1): e54748.
76. Wells W, Boehme C, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuns J, Kim P, Kimerling M, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins M, Peter T, Zignol M, Zumla A, Schito M. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. *Lancet Infect Dis* 2013;13(5):449-58.
77. *Zwerling A, Joshi R, Kalantri SP, Gajalakshmi D, Reddy MVR, Benedetti A, Schwartzman K, Menzies D, Pai M. Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. *J Epi Global Health* 2013;3:105-117.
78. *Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Methodological and reporting quality of tuberculosis systematic reviews. *Int J Tuberc Lung Dis* 2013;17: 1160-1169.
79. *Ling D, Nicol M, Pai M, Pienaar S, Dendukuri N, Zar HJ. Incremental value of T-SPOT.TB for diagnosis of active pulmonary tuberculosis in children in a high-burden setting: a multivariable analysis. *Thorax* 2013;68:860-866.
80. Sun A, Pai M, Deo S, Srinath S, Dowdy D. Modeling the Impact of Alternative Strategies for Rapid Molecular Diagnosis of Tuberculosis in Southeast Asia. *Am J Epidemiol* 2013; 178:1740-1749.
81. *Denkinger C, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular TB diagnostics? *Eur Respir J* 2013;42:544-547.
82. Christopher DJ, Schumacher S, Michael JS, Luo R, Balamugesh T, Pollock N, Pai M, Denkinger CM. Performance of Xpert® MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. *Eur Respir J* 2013;42:1427-29.
83. Gaur R, Pai M, Banaei N. Impact of blood volume, tube shaking, and incubation time on the reproducibility of QuantiFERON-TB Gold In-Tube assay. *J Clin Micro* 2013;51(11):3521-3526.

84. Slater M, Welland G, [Pai M](#), Parsonnet J, Banaei N. Challenges with QuantiFERON-TB assay for large-scale, routine screening of US healthcare workers. *Am J Resp Crit Care Med* 2013;188(8):1005-1010.
85. †Bhargava A, Chatterjee M, Jain Y, Chatterjee B, Kataria A, Bhargava M, Kataria R, D'Souza R, Jain R, Benedetti A, [Pai M](#), Menzies D. Nutritional Status of Adult Patients with Pulmonary Tuberculosis in Rural Central India and Its Association with Mortality. *PLoS One* 2013;8(10): e77979.
86. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, [Pai M](#), Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K. Feasibility, accuracy and clinical impact of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised controlled trial. *Lancet* 2014;383:424-35.
87. *Denkinger CM, [Pai M](#), Dowdy D. Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis? *PLoS One* 2014;9(1): e84197.
88. *Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, Dan A, McIntosh F, [Pai M](#), Denkinger CM. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. *Clin Infect Dis* 2014; 58(7):970-6.
89. *Denkinger CM, Kalantri Y, Schumacher SG, Michael JS, Shankar D, Saxena A, Sriram N, Balamugesh T, Luo R, Pollock N, [Pai M](#), Christopher DJ. Challenges in the Development of an Immunochromatographic Interferon-Gamma Test for Diagnosis of Pleural Tuberculosis. *PLoS One* 2013;8(12): e85447.
90. *Kik S, Denkinger CM, Chedore P, [Pai M](#). Replacing smear microscopy for the diagnosis of tuberculosis: What is the market potential? *Eur Respir J* 2014; 43:1793-1796.
91. *Ling D, [Pai M](#), Schiller I, Dendukuri N. A Bayesian framework for estimating the incremental value of a diagnostic test in the absence of a gold standard. *BMC Medical Research Methodology* 2014, 14:67.
92. *Zwerling A, [Pai M](#), Michael JS, Christopher DJ. Serial testing using interferon-gamma release assays in nursing students in India. *Eur Respir J* 44(1):257-60.
93. *Kik S, Denkinger CM, Casenghi M, Vadnais C, [Pai M](#). Tuberculosis diagnostics: which target product profiles should be prioritised. *Eur Respir J* 2014 44:537-540.
94. †Bhargava A, Benedetti A, Oxlade O, [Pai M](#), Menzies D. Undernutrition and the incidence of tuberculosis in India: National and sub-national estimates of the population attributable fraction related to undernutrition. *Natl Med J India* 2014;27:128-33.
95. Salje H, Andrews JR, Deo S, Satyanarayana S, Sun AY, [Pai M](#), Dowdy DW. The importance of implementation strategy in scaling up of Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. *PLoS Med* 2014;11(7):e1001674.
96. TB Diagnostics Market Analysis Consortium. Market Assessment of Tuberculosis Diagnostics in Brazil in 2012. *PLoS One* 2014; 9(8): e104105. [role: Consortium leader]
97. *Satyanarayana S, Sagili K, Chadha S, [Pai M](#). Use of rapid, point-of-care tests by primary health care providers in India: findings from a community-based survey. *Public Health Action* 2014;4(4):1-3.
98. Christopher DJ, Shankar D, Datey A, Zwerling A, [Pai M](#). Safety of the two-step tuberculin skin test in Indian health care workers. *Int J Mycobact* 2014;3(4):247-51.

99. *Qin ZZ, [Pai M](#), van Gemert W, Sahu S, Ghiasi M, Creswell J. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? *Eur Respir J* 2015; 45:549-54.
100. Engel N, Davids M, Blankvoort, Pai NP, Dheda K, [Pai M](#). Compounding diagnostic delays: a qualitative study of point-of-care testing in South Africa. *Trop Med Int Health* 2015;20(4):493–500.
101. TB Diagnostics Market Analysis Consortium. Market Assessment of Tuberculosis Diagnostics in South Africa in 2012-2013. *Int J Tuberc Lung Dis* 2015;19(2):216-22. [role: Consortium leader]
102. *Kik SV, Denkinger CM, Jefferson C, Ginnard J, [Pai M](#). Potential market for novel TB diagnostics: worth the investment? *J Infect Dis* 2015;211(S2):S58-S66.
103. Little K, [Pai M](#), Dowdy D. Costs and Consequences of Using Interferon- γ Release Assays for the Diagnosis of Active Tuberculosis in India. *PLoS One* 2015; 10(4): e0124525.
104. Alvarez GG, Van Dyk D, Desjardins M, Yasseen A, Aaron SD, Cameron W, Obed N, Baikie M, Pakhale S, Denkinger CM, Sohn H, [Pai M](#). The feasibility, accuracy and impact of Xpert[®] MTB/RIF testing in a remote Aboriginal community in Canada. *Chest* 2015;148(3):767-73.
105. Theron G, Peter J, Zijenah L, Chanda D, Mangu C, Clowes P, Rachow A, Lesosky M, Hoelscher M, Pym A, Mwaba P, Mason P, Naidoo P, Pooran A, Sohn H, [Pai M](#), Stein DJ, Dheda K. Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. *BMC Infect Dis* 2015;15:253.
106. *Schumacher S, Thangakunam B, Denkinger CM, Oliver AA, Shakti KB, Qin ZZ, Michael JS, Luo R, [Pai M](#), Christopher DJ. Impact of point-of-care implementation of Xpert MTB/RIF: product versus process innovation. *Int J Tuberc Lung Dis* 2015;7:1084-1090.
107. Das J, Kwan A, Daniels B, Satyanarayana S, Subbaraman R, Bergkvist S, Das RK, Das V, [Pai M](#). Use of standardized patients to assess quality of tuberculosis care: a pilot, cross-sectional study. *Lancet Infect Dis* 2015; 15(11):1305-13.
108. Engel N, Ganesh G, Patil M, Yellappa V, Pant Pai N, Vadnais C, [Pai M](#). Barriers to point-of-care testing in India: Results from qualitative research across different settings, users and major diseases. *PLoS One* 2015; 10(8): e0135112.
109. *Pande T, [Pai M](#), Khan F, Denkinger CM. Use of Chest X-rays in the 22 Highest Tuberculosis Burden Countries. *Eur Resp J* 2015;46(6):1816-19.
110. Davids M, Dheda K, Pai NP, Cogill D, [Pai M](#), Engel N. A survey on use of rapid tests and tuberculosis diagnostic practices by primary health care providers in South Africa: Implications for the development of new point-of-care tests. *PLoS One* 2015; 10(10): e0141453.
111. *McDowell A, [Pai M](#). Treatment as Diagnosis and Diagnosis as Treatment: Empirical Management of Presumptive TB in the Indian Private Sector. *Int J Tuberc Lung Dis* 2016; 20(4):536–543.
112. TB Diagnostics Market Analysis Consortium. Market Assessment of Tuberculosis Diagnostics in India in 2013. *Int J Tuberc Lung Dis* 2016;20(3):304-313. [role: Consortium leader]
113. TB Diagnostics Market Analysis Consortium. Market Assessment of Tuberculosis Diagnostics in China in 2012. *Int J Tuberc Lung Dis* 2016;20(3): 295-303. [role: Consortium leader]
114. *Puri L, Oghor C, Denkinger CM, [Pai M](#). Xpert MTB/RIF for tuberculosis: access and price in highly privatized health markets. *Lancet Global Health* 2016;4:e94-95.

115. Murrison LB, Ananthkrishnan R, Ananthkrishnan S, Auguesteen S, Krishnan N, Pai M, Dowdy D. How do patients access the private sector in Chennai, India? An evaluation of delays in tuberculosis diagnosis. *Int J Tuberc Lung Dis* 2016; 20(4):544–551.
116. Murrison LB, Ananthkrishnan R, Krishnan N, Pai M, Dowdy D. How do urban Indian private practitioners diagnose and treat tuberculosis? A cross-sectional study in Chennai. *PLoS One* 2016; 11(2): e0149862.
117. *McDowell A, Pai M. Alternative medicine: an ethnographic study of how practitioners of Indian medical systems manage TB in Mumbai. *Trans of the Roy Soc Trop Med Hyg* 2016 110 (3): 192-198.
118. Oxlade O, Sugarman J, Alvarez G, Pai M, Schwartzman K. Xpert®MTB/RIF for the diagnosis of tuberculosis in a remote Arctic setting: Impact on cost and time to treatment initiation. *PLoS One* 2016;11(3): e0150119.
119. Fox G, Benedetti A, Mitnick C, Pai M, Menzies D. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. *PLoS One* 2016;11(3): e0151724.
120. Bronner Murrison L, Ananthkrishnan R, Sukumar S, Augustine S, Krishnan N, Pai M, Dowdy D. Use of Rapid, Point-of-Care Assays by Private Practitioners in Chennai, India: Priorities for Tuberculosis Diagnostic Testing. *PLoS One* 2016;11(6): e0155775.
121. *Schumacher SG, van Smeden M, Dendukuri N, Joseph L, Moons KGM, Nicol M, Pai M, Zar H. Diagnostic test accuracy in childhood pulmonary tuberculosis: a Bayesian latent class analysis. *Am J Epidemiol* 2016; 184 (9): 690-700.
122. *Satyanarayana S, Kwan A, Daniels B, Subbaraman R, McDowell A, Bergkvist S, Ras R, Das V, Das J, Pai M. Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: a cross-sectional study. *Lancet Infect Dis* 2016; 16: 1261–68.
123. Moses M, Zwerling A, Cattamanchi A, Denkinger CM, Banaei N, Kik SV, Metcalfe JZ, Pai M, Dowdy D. Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. *Sci Reports* 2016; 6:30781.
124. Murray M, Cattamanchi A, Denkinger CM, van't Hoog A, Pai M, Dowdy D. Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. *BMJ Global Health* 2016;1:e000064.
125. *Huddart S, MacLean E, Pai M. Location, location, location: tuberculosis services in highest burden countries. *Lancet Global Health* 2016;4:e907-e908.
126. Engel N, Wachter K, Pai M, Gallarda J, Boehme C, Celentano I, Weintraub R. Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform. *BMJ Global Health* 2016;1: e000132.
127. Moon H, Gaur R, Tien S, Spangler M, Pai M, Banaei N. Evaluation of QuantiFERON®-TB Gold-Plus in Healthcare Workers in a Low-Incidence Setting. *J Clin Micro* 2017; 55:1650 –1657.
128. †Puri L, Das J, Pai M, Agrawal P, Fitzgerald JE, Kelley E, Kesler S, Mate K, Mohanan M, Okrainec A, Aggarwal R. Enhancing quality of medical care in low income and middle income countries through simulation-based initiatives: recommendations of the Simnovate Global Health Domain Group. *BMJ Sim Tech Enhanced Learning* 2017;3:S15-S22.

129. *Cazabon D, Suresh A, Oghor C, Qin ZZ, Kik S, Denkinger CM, Pai M. Implementation of Xpert MTB/RIF in 22 High Burden Countries: are we making progress? *Eur Respir J* 2017; 50: 1700918.
130. *Nash M, Ramapuram J, Huddart S, Pai M, Baliga S. Use of the GeneXpert tuberculosis system for HIV viral load testing in India. *Lancet Global Health* 2017; 5: e754-e755.
131. Engel N, Davids M, Blankvoort N, Dheda K, Pant Pai N, Pai M. Making HIV testing work at the point of care in South Africa: A qualitative study of diagnostic practices. *BMC Health Services Research* 2017; 17:408.
132. Wang Z, Dendukuri N, Pai M, Joseph L. Taking Costs and Diagnostic Test Accuracy into Account when Designing Prevalence Studies: An Application to Childhood Tuberculosis Prevalence. *Med Decision Making* 2017; 37(8):922-929.
133. Yellapa V, Devadasan N, Krumeich A, Pai NP, Vadnais C, Pai M, Engel N. How Patients Navigate Diagnostic Ecosystem in a Fragmented Health System: A Qualitative Study from India. *Global Health Action* 2017;10: 1350452.
134. Rendell N, Bekhbat S, Ganbataar G, Dorjravdan M, Pai M, Dobler C. Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers. *PeerJ* 2017;5:e3567; DOI 10.7717/peerj.3567.
135. †Pande T, Saravu K, Temesgen Z, Seyoum A, Rai S, Rao R, Mahadev D, Pai M, Gagnon MP. Evaluating clinicians' user experience and acceptability of LearnTB, a smartphone application for tuberculosis in India. *mHealth* 2017;3:30.
136. Sylvia S, Xue H, Zhou C, Shi Y, Yi H, Zhou H, Pai M, Das J. Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study. *PLoS Med* 2017;14(10): e1002405.
137. Sharma SK, Mohan A, Singh AD, Mishra H, Pandey RM, Singh BK, Sharma R, Babu P, Pai M, Dheda K. Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. *Sci Reports* 2018;8: 8828.
138. *Nafade V, Nash M, Huddart S, Pande T, Gebreselassie N, Lienhardt C, Pai M. A bibliometric analysis of tuberculosis research, 2007–2016. *PLoS One* 2018; 13(6): e0199706.
139. *Pande T, Huddart S, Xavier W, Kulavalli S, Chen T, Pai M, Saravu K. Prevalence of diabetes mellitus amongst hospitalized tuberculosis patients at an Indian tertiary care center: A descriptive analysis. *PLoS One* 2018;13(7): e0200838.
140. *Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C, Qin ZZ, Waning B, Pai M. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016 [version 2; referees: 4 approved] *Gates Open Research* 2018, 2:35 (doi: 10.12688/gatesopenres.12842.2).
141. *Kohli M, Walia K, Mazumdar S, Boehme CC, Katz Z, Pai M. Availability of essential diagnostics at the primary care in India. *Lancet Infect Dis* 2018;18:1064-65.
142. Kwan A, Daniels B, Saria V, Satyanarayana S, Subbaraman R, McDowell A, Bergkvist S, Das R, Das V, Das J, Pai M. Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities. *PLoS Med* 2018; 15(9):e1002653.

143. Hogan C, Tien S, [Pai M](#), Banaei N. Higher positivity rate with 4th generation QuantiFERON-TB Gold Plus assay in low-risk U.S. healthcare workers. *J Clin Micro* 2019; 57:e01688-18.
144. *Huddart S, Bossuroy T, Pons V, Baral S, [Pai M](#), Delavallade C. Knowledge about tuberculosis and infection prevention behavior: A nine city longitudinal study from India. *PLoS One* 2018; 13(10): e0206245.
145. *Ponnudurai N, Denkinger C, Van Gemert W, [Pai M](#). New TB tools need to be affordable in the private sector: The case study of Xpert MTB/RIF. *J Epidemiol Global Health* 2018; 8(3-4); 103–105.
146. *Sen P, Kohli M, [Pai M](#). Industry Perspectives on the WHO Essential Diagnostics List. *J Clin Micro* 2019; 57:e01637-18.
147. Daniels B, Kwan A, Satyanarayana S, Subbaraman R, Das RK, Das V, Das J, [Pai M](#). Use of standardised patients to assess gender differences in quality of tuberculosis care in urban India: a two-city, cross-sectional study. *Lancet Global Health* 2019;7:e633-43.
148. Mazumdar S, Satyanarayana S, [Pai M](#). Self-reported tuberculosis in India – Evidence from NFHS-4. *BMJ Global Health* 2019;4:e001371.
149. Daftary A, Satyanarayana S, Jha N, Singh M, Mondal S, Vadnais C, [Pai M](#). Can community pharmacists improve TB case finding? A mixed methods intervention study in India. *BMJ Glob Health* 2019;4:e001417.
150. Daniels B, Kwan A, [Pai M](#), Das J. Lessons on the quality of tuberculosis diagnosis from standardized patients in China, India, Kenya, and South Africa. *J Clin Tuberc Other Mycobact Dis* 2019;16: 100109.
151. Sohn H, Kasaie P, Kendall E, Gomez GB, Vassall A, [Pai M](#), Dowdy D. Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. *BMC Med* 2019 Aug 6;17(1):155.
152. Kwan A, Daniels B, Bergkvist S, Das V, [Pai M](#), Das J. Use of standardised patients for healthcare quality research in low- and middle-income countries. *BMJ Global Health* 2019;4:e001669.
153. *Nafade V, Sen P, [Pai M](#). Global health journals need to address equity, diversity and inclusion. *BMJ Global Health* 2019;4:e002018.
154. *Nafade V, Huddart SK, Sulis G, Daftary A, Miraj S, Saravu K, [Pai M](#). Over-the-counter antibiotic dispensing by pharmacies: a standardised patient study in Udupi district, India. *BMJ Global Health* 2019;4:e001869.
155. Denkinger CM, Schumacher SG, Gilpin C, Korobitsyn A, Wells WA, [Pai M](#), Leeflang M, Steingart KR, Bulterys M, Schünemann H, Glaziou P. Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles. *Journal of Infectious Diseases* 2019;220, Supplement 3: S91–S98.
156. Schumacher SG, Wells WA, Nicol M, Steingart K, Theron G, Dorman SE, [Pai M](#). Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. *Journal of Infectious Diseases* 2019;220, Supplement 3:S98-107.
157. Dabas H, Deo S, Sabharwal M, Pal A, Salim S, Nair L, Chauhan K, Maheshwari P, Parulkar A, Singh R, Chitalia M, Kaur M, Oghor C, Ponnudurai N, Kumta S, Small P, Dewan P, [Pai M](#). Initiative for

- Promoting Affordable and Quality Tuberculosis Tests (IPAQT): a market-shaping intervention in India. *BMJ Global Health* 2019;4:e001539.
158. *Nash M Rajagopal K, Andarde J, Sukumar C, Chawla K, Shenoy V, Pande T, Huddart SK, Pai M, Saravu K. Deep learning, computer-aided radiography reading for tuberculosis: a diagnostic accuracy study from a tertiary hospital in India. *Scientific Reports* 2020;10:210.
159. *Huddart SK, Svadzian A, Nafade V, Satyanarayana S, Pai M. Tuberculosis case fatality in India: a systematic review and meta-analysis. *BMJ Global Health* 2020;5:e002080.
160. *Singhroy DN, MacLean E, Kohli M, Lessem E, Branigan D, England K, Suleiman K, Drain PK, Ruhwald M, Schumacher S, Denkinge CM, Waning B, Van Gemert W, Pai M. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. *Gates Open Research* 2020, 4:24 (<https://doi.org/10.12688/gatesopenres.13112.1>)
161. *Faust L, Ruhwald M, Schumacher S, Pai M. How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers. *Health Sci Rep*; 2020;3:e158.
162. †Togun T, Hoggart CJ, Agbla SC, Gomez MP, Egere U, Sillah AK, Saïdy B, Mendy F, Pai M, Kampmann B. A three-marker protein biosignature distinguishes tuberculosis from other respiratory diseases in Gambian children. *EBioMedicine* 2020; 58 (2020) 102909.
163. *Svadzian A, Vasquez N, Abimbola S, Pai M. Global health degrees: at what cost? *BMJ Global Health* 2020;5:e003310.
164. *Sulis G, Daniels B, Kwan A, Gandra S, Daftary A, Das J, Pai M. Antibiotic overuse in the primary health care setting: a secondary data analysis of standardised patient studies from India, China and Kenya. *BMJ Global Health* 2020;5:e003393.
165. Sánchez-Sánchez J, Alarcón-Loayza J, Villa-Castillo L, Kohli M, Boehme CC, Carmona S, Garcia PJ, Pai M, Ugarte-Gil C. Availability of essential diagnostics at primary care public clinics in Peru. *Microbes and Infection* 2020; <https://doi.org/10.1016/j.micinf.2020.09.007>.
166. *Faust L, Zimmer AJ, Kohli M, Saha S, Boffa J, Bayot ML, Nsofor I, Campos L, Mashamba-Thompson T, Herrera R, Emeka E, Shrestha S, Ugarte-Gil C, Katamba A, Pambudi I, Bichara D, Calderon RI, Ahmadzada N, Safdar MA, Nikam C, Lázari CdS, Hussain H, Win MM, Than KZ, Ahumibe A, Waning B, Pai M. SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector. *Microbes and Infection* 2020; 22:511-14.
167. Pande T, Vasquez NA, Cazabon D, Creswell J, Brouwer M, Ramis O, Stevens RH, Ananthkrishnan R, Qayyum S, Alphonsus C, Oga-Omenka C, Nafade V, Sen P, Pai M. Finding the missing millions: lessons from 10 active case finding interventions in high tuberculosis burden countries. *BMJ Global Health* 2020;5:e003835.
168. *MacLean E, Bigio J, Singh U, Klinton JS, Pai M. Global tuberculosis awards must do better with equity, diversity and inclusion. *Lancet* 2021; 397:192-3.
169. *Huddart S, Singh M, Jha N, Benedetti A, Pai M. Case fatality and recurrent tuberculosis among patients managed in the private sector: A cohort study in Patna, India. *PLoS One* 2021; 16(3): e0249225.

170. Boffa J, Moyo S, Chikovore J, Salomon A, Daniels B, Kwan AT, [Pai M](#), Daftary A. Quality of care for tuberculosis and HIV in the private health sector: a cross-sectional, standardised patient study in South Africa. *BMJ Global Health* 2021;6:e005250.
171. Kamchedzera W, Maheswaran H, Squire SB, Joekes E, [Pai M](#), Nliwasa M, Lalloo DG, Webb EL, Corbett EL, MacPherson P. Economic costs of accessing tuberculosis (TB) diagnostic services in Malawi: an analysis of patient costs from a randomised controlled trial of computer-aided chest x-ray interpretation. *Wellcome Open Res* 2021;6:153.
172. *Sulis G, Batomen B, Kotwani A, [Pai M](#), Gandra S. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. *PLoS Med* 2021; 18(7): e1003682.
173. *Huddart SK, Ingawale P, Edwin J, Jondhale V, [Pai M](#), Benedetti A, Shah D, Vijayan S. TB case fatality and recurrence in a private sector cohort in Mumbai, India. *Int J Tuberc Lung Dis* 2021; 25(9):738–746.
174. MacPherson P, Webb EL, Kamchedzera W, Joekes E, Mjoli G, Lalloo DG, Divala TH, Choko AT, Burke RM, Maheswaran H, [Pai M](#). Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis. *PLoS Med* 2021; 18(9): e1003752.
175. Fleming KA, Horton S, Wilson ML, Atun R, DeStigter K, Flanigan J, Sayed S, Adam P, Aguilar B, Andronikou S, Boehme C, Cherniak W, Cheung AN, Dahn B, Donoso-Bach L, Douglas T, Garcia P, Hussain S, Iyer HS, Kohli M, Labrique AB, Looi LM, Meara JG, Nkengasong J, [Pai M](#), Pool KL, Ramaiya K, Schroeder L, Shah D, Sullivan R, Tan BS, Walia K. *The Lancet* Commission on diagnostics: transforming access to diagnostics. *Lancet* 2021; S0140-6736(21)00673-5.
176. Klinton JS, Petra Heitkamp P, Rashid A, Faleye BO, That HW, Hussain H, Syed I, Farough K, Mortera L, Lwin MM, Jha N, Ananthakrishnan R, Mahfuza R, Chadha SS, Banu S, Mannan S, Vijayan S, Ahmed S, Ali T, Oga-Omenka C, Kaur M, Singh U, Wells W, Stallworthy G, Dias HM, [Pai M](#). One year of COVID-19 and its impact on private provider engagement for TB: A rapid assessment of intermediary NGOs in seven high TB burden countries. *J Clinical Tuberculosis and Other Mycobacterial Diseases* 2021;25: 100277.
177. Tavaziva G, Harris M, Abidi SK, Geric C, Breuninger M, Dheda K, Esmail A, Muyoyeta M, Reither K, Majidulla A, Khan AJ, Campbell JR, David PM, Denkinger C, Miller C, Nathavitharana R, [Pai M](#), Benedetti A, Khan FA. Chest X-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: an individual patient data meta-analysis of diagnostic accuracy. *Clin Infect Dis* 2021 Jul 21, doi.org/10.1093/cid/ciab639.
178. Das V, Daniels B, Kwan A, Saria V, Das R, [Pai M](#), Das J. Simulated patients and their reality: an inquiry into theory and method. *Soc Sci Med* 2022 May 1;300:114571.
179. Lancione S, Alvarez JV, Alsdurf H, [Pai M](#), Zwerling AA. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. *BMJ Global Health* 2022;7:e007462.
180. Salomon A, Boffa J, Moyo S, Chikovore J, Sulis G, Daniels B, Kwan A, Mkhombo T, Wu S, [Pai M](#), Daftary A. Prescribing practices for presumptive TB among private general practitioners in South Africa: a cross-sectional, standardised patient study. *BMJ Global Health* 2022;7:e007456.
181. Bigio J, Aquilera Vasquez N, *Hurria L, Pande T, Creswell J, Ananthakrishnan R, Bimba JS, Cuevas LE,

- Vo L, Bakker MI, Rahman MT, [Pai M](#). Engaging pharmacies in tuberculosis control: operational lessons from 19 case detection interventions in high-burden countries. *BMJ Global Health* 2022;7:e008661.
182. Sayegh H, Harden C, Khan H, [Pai M](#), Eichbaum QG, Ibingira C, Goba G. Global health education in high-income countries: confronting coloniality and power asymmetry. *BMJ Global Health* 2022;7:e008501.
183. *MacLean EL, *Kohli M, Köppel L, Schiller I, Sharma SK, [Pai M](#), Denkinger CM, Dendukuri N. Bayesian latent class analysis produced diagnostic accuracy estimates that were more interpretable than composite reference standards for extrapulmonary tuberculosis tests. *Diagn Progn Res* 2022;6(1):1-10.
184. Mannan S, *Oga-Omenka C, ThekkePurakkal AS, *Huria L, Kalra A, Gandhi R, Kapoor T, Gunawardena N, Raj S, Kaur M, *Sassi A, Pande T, Shibu V, Sarin S, Chadha SS, Heitkamp P, Das J, Rao R, [Pai M](#). Adaptations to the first wave of the COVID-19 pandemic by private sector tuberculosis care providers in India. *J Clin Tuberculosis* 2022;28: 100327.
185. Daniels B, Shah D, Kwan AT, Das R, Das V, Puri V, Tipre P, Waghmare U, Gomare M, Keskar P, Das J, [Pai M](#). Tuberculosis diagnosis and management in the public versus private sector: a standardised patients study in Mumbai, India. *BMJ Global Health* 2022;0:e009657.
186. *Svadzian A, Daniels B, Sulis G, Das J, Daftary A, Kwan A, Das V, Das R, [Pai M](#). Do private providers initiate anti-tuberculosis therapy on the basis of chest radiographs? A standardised patient study in urban India. *Lancet Reg Health South East Asia* 2023;13: 100152.
187. *MacLean E, Villa-Castillo L, Espinoza-Lopez P, Caceres T, Sulis G, Kohli M, Pai M, Ugarte-Gil C. Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study. *Lancet Microbe* 2023;4: e452–60.
188. Oga-Omenka C, *Sassi A, Vasquez NA, Baruwa E, Rosapep L, Daniels B, Olusola-Faleye B, Huria L, Adamu A, Johns B, Das J, [Pai M](#). Tuberculosis service disruptions and adaptations during the first year of the COVID-19 pandemic in the private health sector of two urban settings in Nigeria—A mixed methods study. *PLOS Glob Public Health* 2023; 3(3): e0001618.
189. *Svadzian A, Daniels B, Sulis G, Das J, Daftary A, Kwan A, Das V, Das R, [Pai M](#). Use of standardised patients to assess tuberculosis case management by private pharmacies in Patna, India: A repeat cross-sectional study. *PLOS Glob Public Health* 2023;3(5): e0001898.
190. Pretorius C, Arinaminpathy N, Mandal S, Sahu S, [Pai M](#), Wong B. One Million Lives Saved Per Year: A Cost–Benefit Analysis of the Q3 Global Plan to End Tuberculosis, 2023–2030 and Beyond. *Journal of Benefit-Cost Analysis* 2023, 1–17.
191. *Bigio J, Hannay E, [Pai M](#), Alisjahbana B, Das R, Huynh HB, Khan U, Mortera L, Nguyen TA, Safdar MA, Shrestha S. The inclusion of diagnostics in national health insurance schemes in Cambodia, India, Indonesia, Nepal, Pakistan, Philippines and Viet Nam. *BMJ Global Health* 2023;8:e012512.
192. Houston A, Liu J, Habib R, Murthy S, [Pai M](#). Canada’s role in covid-19 global vaccine equity failures. *BMJ* 2023;382:e075149.
193. Bhargava A, Bhargava M, Meher A, Benedetti A, Velayutham B, Teja GS, Watson B, Barik G, Pathak RR, Prasad R, Dayal R, Madhukeshwar AK, Chadha V, [Pai M](#), Joshi R, Menzies D, Swaminathan S. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients

- with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. *Lancet* 2023 Aug 19;402(10402):627-40.
194. Reid M, Agbassi YJ, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Sari AH, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Scientific advances and the end of tuberculosis: a report from the *Lancet* Commission on Tuberculosis. *Lancet* 2023 Oct 21;402(10411):1473-98.
 195. *Bigio J, MacLean E, Das R, Sulis G, Kohli M, Berhane S, Dinnes J, Deeks J, Brumer L, Denkinger C, Pai M. Accuracy of package inserts of SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus systematic review data. *Lancet Microbe* 2023; 4(11):e875-e882.
 196. Saria V, Das V, Daniels B, Pai M, Das J. The family doctor: health, kin testing and primary care in Patna, India. *Anthropology & Medicine* 2023 Jul 3;30(3):246-61.
 197. *Huria L, Lestari BW, Saptiningrum E, Fikri AR, Oga-Omenka C, Kafi MAH, Daniels B, Vasquez NA, *Sassi A, Das J, Jani ID, Pai M, Alisjahbana B. Care pathways of individuals with tuberculosis before and during the COVID-19 pandemic in Bandung, Indonesia. *PLOS Glob Public Health* 2024;4(1): e0002251.
 198. *Sassi A, Lestari BW, El Muna K.U.N., Oga-Omenka C, Afifah N, Widarna R, *Huria L, Aguilera Vasquez N, Benedetti A, Hadisoemarto PF, Daniels B, Das J, Pai M, Alisjahbana B. Impact of the COVID-19 pandemic on quality of tuberculosis care in private facilities in Bandung, Indonesia: a repeated cross-sectional standardized patients study. *BMC Public Health* 2024; 24, 102.
 199. Oga-Omenka C, Rosapep L, Baruwa E, Huria L, Vasquez NA, Faleye BO, Kafi MA, Sassi A, Nwosu C, Johns B, Adamu A, Chijioke-Akaniro O, Anyaike C, Pai M. Individual journeys to tuberculosis care in Nigeria's private sector during the COVID-19 pandemic. *BMJ Glob Health* 2024;9:e013124.
 200. Faust L, Caceres-Cardenas G, Martinez L, Huddart S, Vidal JR, Corilloclla-Torres R, Ayllon MC, Benedetti A, Pai M, Ugarte-Gil C. Tuberculosis case notifications and outcomes in Peruvian prisons prior to and during the COVID-19 pandemic: a national-level interrupted time series analysis. *Lancet Regional Health – Americas* 2024;33: 100723.
 201. Broger T, Marx FM, Theron G, Marais BJ, Nicol MP, Kerkhoff AD, Nathavitharana R, Huerga H, Gupta-Wright A, Kohli M, Nichols BE, Muyoyeta M, Meintjes G, Ruhwald M, Peeling RW, Pai NP, Pollock NR, Pai M, Cattamanchi A, Dowdy DW, Dewan P, Denkinger CM. Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future research. *Lancet Global Health* 2024; 12: e1184–91
 202. *Faust L, Ranjan A, Jha N, Pai M, Huddart S. Case fatality among people with drug-susceptible TB enrolled in a private health sector TB treatment support program in Bihar, India during the first year of the COVID-19 pandemic. *PLOS Glob Public Health* 2024;4(9): e0003277.
 203. Widarna R, Afifah N, Djunaedy HAK, *Sassi A, Vasquez NA, Oga-Omenka C, Salindri AD, Lestari BW, Pai M, Alisjahbana B. The shifting landscape of private healthcare providers before and during the COVID-19 pandemic: Lessons to strengthen the private sectors engagement for future pandemic and tuberculosis care. *PLOS Glob Public Health* 2024; 4(10): e0003112.

204. *Sassi A, Rosapep L, Faleye BO, Baruwa E, Johns B, Kafi MA, *Huria L, Aguilera Vasquez N, Daniels B, Das J, Anyaike C, Chijioke-Akaniro O, Pai M, Oga-Omenka C. Private sector tuberculosis care quality during the COVID-19 pandemic: a repeated cross-sectional standardised patients study of adherence to national TB guidelines in urban Nigeria. *BMJ Global Health* 2024;9:e015474.
205. Vasquez NA, Oga-Omenka C, Yellappa V, Lestari BW, *Sassi A, Sheokand S, Olusola-Faleye B, *Huria L, Brubacher LJ, Baruwa E, Alisjahbana B, Pai M. COVID-19 policies and tuberculosis services in private health sectors of India, Indonesia, and Nigeria. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* 2025 Feb 1;38:100503 .
206. Brubacher LJ, Yellappa V, Lestari BW, Heitkamp P, Vasquez NA, *Sassi A, Olusola-Faleye B, Thapa P, Klinton JS, Sheokand S, Pai M. Health and tuberculosis systems resilience, the role of the private sector and pandemic preparedness: insights from a cross-country qualitative study with policy-makers in India, Indonesia and Nigeria. *BMJ Glob Health* 2025 Jan 20;10(1).

*First author was student/trainee under my supervision

†First author was student/trainee under my co-supervision

G4b. Peer Reviewed Articles: Meta-Analyses and Systematic Reviews

1. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. *Lancet Infect Dis* 2003;3:633-43.
2. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. *BMC Infect Dis* 2004;4:6.
3. Pai M, Riley LW, Colford JM. Interferon-g assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004;4:761-76.
4. Gorman JD, David-Vaudey E, Pai M, Lum RF, Criswell LA. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. *Arthritis Rheum* 2004 Nov;50(11):3476-84.
5. Gorman JD, David-Vaudey E, Pai M, Lum RF, Criswell LA. Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis. *Arthritis Rheum* 2004 Mar;50(3):753-62.
6. Pai M, Kalantri SP, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based assays for the rapid detection of rifampicin resistance in *Mycobacterium tuberculosis*: a meta-analysis. *J Infect* 2005;51:175-187.
7. *Kalantri SP, Pai M, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based tests for the detection of *Mycobacterium tuberculosis* in clinical specimens: a systematic review and meta-analysis. *BMC Infect Dis* 2005;5:59.
8. *Morgan M, Kalantri SP, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in *Mycobacterium tuberculosis*: a systematic review and meta-analysis. *BMC Infect Dis* 2005;5:62. [Corresponding author]
9. †Flores LL, Pai M, Colford JM, Riley LW. In-house nucleic acid amplification tests for the detection of *Mycobacterium tuberculosis* in sputum specimens: a meta-analysis. *BMC Microbiology*

- 2005;5:55.
10. Hwang J, Bitarakwate E, Pai M, Reingold A, Rosenthal PJ, Dorsey D. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. *Trop Med Int Health* 2006; 11(6):789-799.
 11. Steingart KR, Henry M, Ng N, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. *Lancet Infect Dis* 2006;6:568-79. [Corresponding author]
 12. Steingart KR, Ng N, Henry M, Hopewell PC, Ramsay A, Cunningham C, Urbanczik R, Perkins M, Aziz MA, Pai M. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. *Lancet Infect Dis* 2006;7:664-74. [Corresponding author]
 13. *Joshi R, Reingold A, Menzies D, Pai M. Tuberculosis among health care workers in low and middle income countries: a systematic review. *PLoS Medicine* 2006;3(12):e494. [Corresponding author]
 14. Menzies D, Pai M, Comstock G. New tests for diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Ann Intern Med* 2007;146:340-354.
 15. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. The risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. *Arch Intern Med* 2007;167:335-342.
 16. Mase S, Ramsay A, Ng N, Henry M, Hopewell PC, Cunningham C, Urbanczik R, Perkins M, Aziz MA, Pai M. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. *Int J Tuberc Lung Dis* 2007;11(5):484-95.
 17. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, Menzies D, Cunningham C, Weldingh K, Pai M. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. *PLoS Medicine* 2007;4(6):e202. [Corresponding author]
 18. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, Menzies D, Cunningham C, Weldingh K, Pai M. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. *Thorax* 2007; 62:911-918. [Corresponding author]
 19. Daley P, Thomas S, Pai M. Nucleic acid amplification tests for the diagnosis of tuberculous lymphadenitis: a meta-analysis. *Int J Tuberc Lung Dis* 2007;11(11): 1166-1176.
 20. *Ling D, Flores L, Riley L, Pai M. Commercial Nucleic-Acid Amplification Tests for Diagnosis of Pulmonary Tuberculosis in Respiratory Specimens: Meta-Analysis and Meta-Regression. *PLoS One* 2008;3(2):e1536.
 21. †Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. *Lancet Infect Dis* 2008;8(6):359-68.
 22. Pai M, Zwerling A, Menzies D. Systematic Review: T-cell Based Assays for the Diagnosis of Latent Tuberculosis Infection-An Update. *Ann Intern Med* 2008;149:177-184.
 23. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis *Ann Intern Med* 2008;149:123-134.
 24. *Ling D, Zwerling A, Pai M. GenoType MTBDR assays for diagnosis of multidrug-resistant tuberculosis: a meta-analysis. *Eur Resp Journal* 2008;32:1165-74.

25. Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, Ramsay A, Pai M, Laal S. Performance of Purified Antigens for Serodiagnosis of Pulmonary Tuberculosis: a Meta-analysis. *Clin Vacc Immunol* 2009;16(2):260-76.
26. Menzies D, Benedetti A, Paydar A, Royce S, Pai M, Burman W, Vernon A, Liendarth C. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. *PLoS Med* 2009;6(9):e1000150.
27. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Liendarth C, Burman W. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. *PLoS Med* 2009;6(9):e1000146.
28. †van Zyl Smit R, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. *PLoS One* 2009;4(12):e8517. [Corresponding author]
29. †Khan F, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV co-infected patients: a systematic review and meta-analysis. *Clin Infect Dis* 2010;50(9):1288-99.
30. Cattamanchi A, Davis JL, Pai M, Huang L, Hopewell P C, Steingart KR. Does bleach processing increase the accuracy of sputum smear microscopy for diagnosing pulmonary tuberculosis? An updated systematic review and meta-analysis. *J Clin Micro* 2010; 48:2433-2439.
31. *Minion J, Pai M. Bacteriophage assays for rifampin resistance detection in Mycobacterium tuberculosis: updated meta-analysis. *Int J Tuberc Lung Dis* 2010; 14(8):941-51. [Corresponding author]
32. *Minion J, Leung E, Menzies D, Pai M. Microscopic-Observation Drug Susceptibility and Thin Layer Agar assays for the detection of drug resistant tuberculosis: a Systematic Review and Meta-Analysis. *Lancet Infect Dis* 2010;10(10):688-98. [Corresponding author]
33. Rylance J, Pai M, Lienhardt C, Garner P. Priorities for tuberculosis research: a systematic review. *Lancet Infect Dis* 2010;10:886-92.
34. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Huang L, Hopewell, PC, Pai M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals - A systematic review and meta-analysis. *JAIDS* 2011 56(3):230-238. [Corresponding author]
35. Metcalfe JZ, Everett C, Steingart KR, Cattamanchi A, Huang L, Hopewell, PC, Pai M. Interferon-g Release Assays for Active Pulmonary TB Diagnosis in Low- and Middle-Income Countries: Systematic Review and Meta-Analysis. *J Infect Dis* 2011 204: S1120-S1129. [Corresponding author]
36. *Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. *Eur Respir J* 2011; 38:1398-1405.
37. Steingart KR, Flores L, Dendukuri N, Schiller I, Laal S, Ramsay A, Hopewell PC, Pai M. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: An updated systematic review and meta-analysis. *PLoS Med* 2011; 8(8): e1001062.
38. Flores L, Steingart KR, Dendukuri N, Schiller I, Minion J, Pai M, Ramsay A, Henry M, Laal S. Systematic Review and Meta-Analysis of Antigen Detection Tests for the Diagnosis of Tuberculosis. *Clin Vaccine Immunol* 2011;18:1616-1627.

39. *Zwerling A, van den Hoff S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. *Thorax* 2012; 67:62-70. [Corresponding author]
40. †Leung E, Minion J, Benedetti A, Pai M, Menzies D. Microscopic Observation Drug-Susceptibility and Thin Layer Agar for Tuberculosis Diagnosis: A Systematic Review. *Int J Tuberc Lung Dis* 2012 Jan;16(1):16-23.
41. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-gamma release assays for incident active tuberculosis: A systematic review and meta-analysis. *Lancet Infect Dis* 2012;12(1):45-55 [Corresponding author]
42. *Chartrand C, Leeflang M, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. *Ann Intern Med* 2012;156:500-511. [Corresponding author]
43. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, Deriemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. *PLoS Med* 2012;9(8): e1001300.
44. *Pinto L, Pai M, Dheda K, Schwartzman K, Menzies D, Steingart KR. Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. *Eur Respir J* 2013;42:480-494.
45. Steingart KR, Sohn H, Schiller I, Kloda L, Boehme C, Pai M, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database of Systematic Reviews*, 2013, Issue 1. Art. No.: CD009593.
46. Sreeramareddy CTS, Qin ZZ, Satyanarayana S, Subbaraman R, Pai M. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. *Int J Tuberc Lung Dis* 2014;18(3):255-66.
47. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme C, Pai M, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database of Systematic Reviews*, 2014, Issue 1. DOI: 10.1002/14651858.CD009593.pub3.
48. *Denkinger CM, Schumacher S, Boehme C, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2014 44:435-446.
49. †Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei N, Cattamanchi A, Metcalfe JZ, Dowdy D, van-zyl Smit R, Dendukuri N, Pai M, Denkinger CM. Reproducibility of Interferon Gamma Release Assays: a Systematic Review. *Ann Am Thorac Soc* 2014;11:1267-1276.

50. *Satyanarayana S, Subbaraman R, Shete P, Gore G, Das J, Cattamanchi A, Mayer K, Menzies D, Harries AD, Hopewell P, Pai M. Quality of tuberculosis care in India: a systematic review. *Int J Tuberc Lung Dis* 2015;19(7):751-763.
51. *Schumacher SG, Sohn H, Qin ZZ, Gore G, Davis JL, Denkinger CM, Pai M. Impact of molecular diagnostics for tuberculosis on patient-important outcomes: a systematic review of study methodologies. *PLoS One* 2016;11(3): e0151073.
52. *Pande T, Cohen C, Pai M, Khan F. Computer Aided Detection of Pulmonary Tuberculosis on Digital Chest Radiographs: a systematic review. *Int J Tuberc Lung Dis* 2016; 20(9):1226–1230.
53. Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, Rade K, Swaminathan S, Mayer KH. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis. *PLoS Med* 2016;13(10): e1002149.
54. Nathavitharana R, Cudahy P, Schumacher S, Steingart K, Pai M, Denkinger CM. Accuracy of Line Probe Assays for the Diagnosis of Pulmonary and Multidrug-Resistant TB: A Systematic Review and Meta-Analysis. *Eur Respir J* 2017; 49: 1601075.
55. *Hogan C, Puri L, Gore G, Pai M. Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: a systematic review and meta-analysis. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* 2017;6:1-7.
56. *Nash M, Huddart SK, Badar S, Baliga S, Saravu K, Pai M. Performance of the Xpert® HIV-1 1 Viral Load assay: A systematic review and meta-analysis. *J Clin Micro* 2018;56:e01673-17.
57. *Togun TO, MacLean E, Kampmann B, Pai M. Biomarkers for diagnosis of childhood tuberculosis: A systematic review. *PLoS One* 2018;13(9): e0204029.
58. *MacLean E, Broger T, Yerliyaka S, Fernandez-Carballo BL, Pai M, Denkinger CM. A systematic review of biomarkers to detect active tuberculosis. *Nature Microbiology* 2019; May;4(5):748-758.
59. *MacLean E, Sulis G, Denkinger CM, Johnston JC, Pai M, Khan FA. Diagnostic accuracy of stool Xpert MTB/RIF for the detection of pulmonary tuberculosis in children: a systematic review and meta-analysis. *J Clin Micro* 2019; 24;57(6): e02057-18.
60. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart KR. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database of Systematic Reviews* 2019, Issue 6. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub4.
61. Harris M, Qi A, Jeagal L, Torabi N, Menzies D, Korobitsyn A, Pai M, Nathavitharana RR, Ahmad Khan F. A systematic review of the diagnostic accuracy of artificial intelligence-based computer programs to analyze chest x-rays for pulmonary tuberculosis. *PLoS One* 2019;14(9): e0221339.
62. *Cazabon D, Pande T, Sen P, Daftary A, Arsenault C, Bhatnagar H, O'Brien K, Pai M. User experience and patient satisfaction with tuberculosis care in low- and middle-income countries: A systematic review. *J Clin Tuberc* 2020; 1001542.
63. *Sulis G, Adam P, Nafade V, Gore G, Daniels B, Daftary A, Das J, Gandra S, Pai M. Antibiotic prescription practices in primary care in low- and middle-income countries: A systematic review and meta-analysis. *PLoS Med* 2020; 17(6): e1003139.
64. *Kohli M, MacLean E, Pai M, Schumacher S, Denkinger CM. Diagnostic accuracy of centralised

- assays for TB detection and detection of resistance to rifampicin and isoniazid: A systematic review and meta-analysis. *Eur Respir J* 2020 Feb 1;57(2): 2000747.
65. *Svazian A, Sulis G, Gore G, Pai M, Denkinger CM. Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis. *BMJ Global Health* 2020;5:e003438.
 66. Zifodya JS, Kreniske JS, Schiller I, *Kohli M, Dendukuri N, Schumacher SG, Ochodo EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. *Cochrane Database of Systematic Reviews* 2021, Issue 2. Art. No.: CD009593.
 67. Bigio J, *Kohli M, Klinton JS, *MacLean E, Gore G, Small PM, Ruhwald M, Weber SF, Jha S, Pai M. Diagnostic accuracy of point-of-care ultrasound for pulmonary tuberculosis: A systematic review. *PLoS One* 2021;16(5): e0251236.
 68. Bigio J, *MacLean E, Vasquez NA, *Huria L, *Kohli M, Gore G, Hannay E, Pai M, *Adam P. Most common reasons for primary care visits in low- and middle-income countries: A systematic review. *PLoS Glob Public Health* 2022;2(5): e0000196.
 69. Lee JH, Garg T, Lee J, McGrath S, Rosman L, Schumacher SG, Benedetti A, Qin ZZ, Gore G, Pai M, Sohn H. Impact of molecular diagnostic tests on diagnostic and treatment delays in tuberculosis: a systematic review and meta-analysis. *BMC Infect Dis* 2022; 22(1): 940.
 70. Jhaveri TA, Jhaveri D, Galivanche A, Lubeck-Schricker M, Voehler D, Chung M, Thekkur P, Chadha V, Nathavitharana R, Kumar AM, Shewade HD, Powers K, Mayer KH, Haberer JE, Bain P, Pai M, Satyanarayana S, Subbaraman R. Barriers to engagement in the care cascade for tuberculosis disease in India: A systematic review of quantitative studies. *PLoS Med* 2024;21(5): e1004409.
 71. Tandan M, *Thapa P, Bhandari B, Gandra S, Timalisina D, Bohora S, Thapaliya S, Bhusal A, Gore GC, Sheokand S, Shukla P, Joshi C, Mudgal N, Pai M, Sulis G. Antibiotic dispensing practices among informal healthcare providers in low-income and middle-income countries: a scoping review protocol. *BMJ Open* 2024;14:e086164.

*First author was student/trainee under my supervision

†First author was student/trainee under my co-supervision

G4c. Peer Reviewed Articles: Narrative Reviews

1. Pai M. Unnecessary Medical Interventions: Caesarean sections as a case study. *Economic & Political Weekly*, July 29, 2000:2755-2761.
2. Miller I, Alagappan K, Pai M, van der Vlugt T, Doraisamy D, Rajagopalan A. Recognizing emergency medicine in India. *Natl Med J India* 2001;14(5):325-328.
3. Pai M, Colford JM. Clinical trials in India sponsored by the pharmaceutical industry. *Natl Med J India* 2002;15(2):93-95.
4. Pai M, McCulloch M, Enanoria W, Colford JM. Systematic reviews of diagnostic test evaluations: what's behind the scenes? *ACP Journal Club* July/August 2004;141:A-11 – A-13.
5. Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, Tharyan P, Colford, JM. Systematic reviews and meta-analyses: An illustrated, step-by-step guide. *Natl Med J India* 2004;17(2):86-95.

6. Pai M. Alternatives to the tuberculin skin test: Interferon-g assays in the diagnosis of *Mycobacterium tuberculosis* infection. *Indian J Med Microbiol* 2005;23(3):151-58.
7. **Nahid P, **Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. *Proc Am Thorac Soc* 2006;3:103-110. [**joint first authors]
8. Pai M, Kalantri SP, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. *Exp Rev Mol Diag* 2006;6(3):413-422.
9. Pai M, Kalantri SP, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance. *Exp Rev Mol Diag* 2006;6(3):423-32.
10. Pai M, Kalantri SP, Aggarwal AN, Menzies D, Blumberg HM. Nosocomial tuberculosis in India. *Emerg Infect Dis* 2006;12(9):1311-18.
11. Marais BJ, Pai M. Recent advances in the diagnosis of childhood tuberculosis. *Arch Dis Child* 2007; 92:446-452.
12. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T Cell Assays for the Diagnosis of Latent Tuberculosis Infection: Moving the Research Agenda Forward. *Lancet Infect Dis* 2007;7:428-38.
13. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis infection – can disease be predicted? *Trends Mol Med* 2007;13(5):175-182.
14. Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. *Paed Resp Rev* 2007;8:124-133.
15. Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. *Int J Tuberc Lung Dis* 2007;11(6):593-605.
16. Pai M, Mohan A, Dheda K, Leung C, Yew W, Christopher D, Sharma SK. Lethal interaction: the colliding epidemics of tobacco and tuberculosis. *Exp Rev Anti Infect Ther* 2007;5(3):385-391.
17. Fair E, Hopewell PC, Pai M. The International Standards for Tuberculosis Care: Revisiting the cornerstones of tuberculosis care. *Exp Rev Anti Infect Ther* 2007;5(1):61-65. [Corresponding author]
18. Trajman A, Pai M, Dheda K, van Zyl Smit, Zwerling AA, Joshi R, Kalantri S, Daley P, Menzies D. Novel tests for diagnosing tuberculous pleural effusion: what works and what does not? *Eur Resp Journal* 2008;31(5):1098-1106. [Corresponding author]
19. Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis of multidrug resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges. *Can J Infect Dis Med Micro* 2008;19(2):169-172. [Corresponding author]
20. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. *PLoS Med* 2008;5(7): e156.
21. Pai M, O'Brien R. New Diagnostics for Latent and Active Tuberculosis: State of the Art and Future Prospects. *Sem Resp Crit Care Med* 2008;29(5):560-68.
22. Davies PDO, Pai M. The diagnosis and misdiagnosis of tuberculosis. *Int J Tuberc Lung Dis* 2008;12(11):1226-34.
23. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-g release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. *Curr Opinion Pulm Med* 2009;15:188-200.

24. *Minion J, Zwerling A, Pai M. Diagnostics for tuberculosis: what new knowledge did we gain through *The International Journal of Tuberculosis and Lung Disease* in 2008? *Int J Tuberc Lung Dis* 2009;13(6):691-97. [Corresponding author]
25. *Sohn H, Minion J, Albert H, Dheda K, Pai M. TB diagnostic tests: how do we figure out their costs? *Exp Rev Anti-Infect Ther* 2009;7(6):723-33. [Corresponding author]
26. Parkash O, Singh BP, Pai M. Regions of Differences Encoded Antigens as Targets for Immunodiagnosis of Tuberculosis in Humans. *Scand J Immunol* 2009; 70, 345–357.
27. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and Improved Technologies for Tuberculosis Diagnosis: Progress and Challenges. *Clinics Chest Med* 2009;30:701-16.
28. †van Zyl Smit R, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, Dheda K. Global Lung Health: The Colliding Epidemics of Tuberculosis, Tobacco Smoking, HIV and COPD. *Eur Resp Journal* 2010;35:27-33.
29. Pai M, Minion J, Steingart K, Ramsay A. New and Improved Tuberculosis Diagnostics: Evidence, Policy, Practice and Impact. *Curr Op Pulm Med* 2010;16:271-84.
30. **Wallis R, **Pai M, Menzies D, Doherty T, Walzl G, Perkins MD, Zumla A. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. *Lancet* 2010;375:1920-37. [**joint first authors]
31. van-zyl Smit R, Brunet L, Pai M, Yew WW. The convergence of the global smoking, COPD, Tuberculosis, HIV, and respiratory infection epidemics. *Infect Dis Clinics North America* 2010;24(3) 693-703.
32. *Ling DI, Zwerling A, Steingart KR, Pai M. Immune-based diagnostics for TB in children: what is the evidence? *Paediatr Respir Rev* 2011;12(1):9-15. [Corresponding author]
33. Smith R, Cattamanchi A, Steingart KR, Dheda K, Denkinger C, Winthrop K, Pai M. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. *Curr Op Rheum* 2011 Jul;23(4):377-384.
34. Denkinger C, Dheda K, Pai M. Guidelines on IGRAs for tuberculosis infection: concordance, discordance or confusion? *Clin Microbiol Infect* 2011;17:806-814.
35. *Bhargava A, Pinto LM, Pai M. Mismanagement of tuberculosis in India: causes, consequences, and the way forward. *Hypothesis* 2011;9(1):e7.
36. Ramsay A, Steingart K, Cunningham J, Pai M. Translating tuberculosis research into global policies: the example of an international collaboration on diagnostics. *Int J Tuberc Lung Dis* 2011; 15(10):1283–1293.
37. Lienhardt C, Espinal M, Pai M, Maher D, Raviglione M. What research is needed to stop TB? Introducing the TB Research Movement. *PLoS Med* 2011;8(11): e1001135.
38. *Pinto L, Grenier J, Schumacher S, Denkinger C, Steingart KR, Pai M. Immunodiagnosis of tuberculosis: state-of-the-art. *Med Princ Pract* 2012;21:4-13.
39. Pai NP, Pai M. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. *Discovery Med* 2012;13(68).
40. Cobelens F, van den Hof S, Pai M, Squire B, Ramsay A, Kimerling M. Which new diagnostics for

- tuberculosis, and when? *Journal Infect Dis* 2012;205 (Suppl 2): S191-198.
41. Steingart KR, Ramsay AR, Dowdy DW, Pai M. Serological tests for the diagnosis of active tuberculosis: relevance for India. *Ind J Med Res* 2012;135:695-702.
 42. Dowdy DW, Pai M. Bridging the Gap Between Knowledge and Health: The Epidemiologist as Accountable Health Advocate ("AHA!"). *Epidemiology* 2012 Nov;23(6):914-8.
 43. Dowdy DW, Pai M. The Epidemiologist as Accountable Health Advocate ("AHA!"): A Useful Model for Promoting Health. *Epidemiology* 2012 Nov;23(6):927-8.
 44. Pai M, Palamountain K. New tuberculosis technologies: challenges for retooling and scale-up. *Int J Tuberc Lung Dis* 2012;16:1281-1290.
 45. *Denkinger CM, Grenier J, Stratis A, Akkihal A, Pai N, Pai M. Mobile-health to improve tuberculosis care and control: a call worth making. *Int J Tuberc Lung Dis* 2013;17(6):719-27.
 46. Pai M. Diagnosis of pulmonary tuberculosis: what every GP should know. *GP Clinics* 2013;3(11):22-28.
 47. Pai M, Chedore P. Diagnosis of tuberculosis: importance of appropriate specimen collection. *GP Clinics* 2013;3(12):22-29.
 48. Rabinovitch B, Pai M. Interpretation of chest x-rays in tuberculosis. *GP Clinics* 2013;4(13):21-29.
 49. Pai M. Diagnosis of pulmonary tuberculosis: recent advances. *J Ind Med Assoc* 2013;111(5):332-336.
 50. Pai M. Improving access to affordable and quality TB tests in India. *GP Clinics* 2013;4(8):10-14.
 51. Pollock N, McAdam AJ, Pai M, Nardell EA, Bernardo J, Banaei N, Mobo J. Interferon-gamma release assays for diagnosis of latent tuberculosis in healthcare workers in low incidence settings: pros and cons. *Clin Chem* 2014 May;60(5):714-8.
 52. Pai M, Denkinger CM, Kik S, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy D, Dheda K, Banaei N. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. *Clin Microbiol Rev* 2014 27:3-20.
 53. Pai M, Satyanarayanan S, Hopewell P. Improving quality of tuberculosis care in India. *Ind J Tuberc* 2014;61:12-18.
 54. Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire B, White R. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. *Int J Tuberc Lung Dis* 2014;18(9):1012-18.
 55. *Pinto LM, Pai M. Treatment of pulmonary tuberculosis: what every GP should know. *GP Clinics* 2014;5(4):16-20.
 56. Pai M. Laboratory diagnosis of tuberculosis: state-of-the-art. *World Clin Pulm Crit Care Med* 2014;3(1):66-78.
 57. Pai M, Ghiasi M, Pai N. Point-of-care diagnostic testing in global health: what is the point? *Microbe* 2015;10(3):103-107.
 58. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. *J Infect Dis* 2015;211(S2):S21-28.

59. Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M. Defining the needs for next generation assays for tuberculosis. *J Infect Dis* 2015 211(S2):S29-38.
60. Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD. Molecular drug susceptibility testing – defining assay characteristics for the use at the level of the microscopy center. *J Infect Dis* 2015 211(S2):S39-49.
61. *Ghiasi M, Pande T, Pai M. Advances in tuberculosis diagnostics. *Curr Trop Med Rep* 2015;2:54-61.
62. Wells W, Uplekar M, Pai M. Achieving systemic and scalable private sector engagement in TB care and prevention in Asia. *PLoS Med* 2015;12(6): e1001842.
63. Banaei N, Gaur R, Pai M. Interferon- γ release assays for latent tuberculosis: what are the sources of variability? *J Clin Micro* 2016 54:845-850.
64. Pai M, Daftary A, Satyanarayana S. Tuberculosis control: challenges and opportunities for India. *Trans Roy Soc Trop Med & Hyg* 2016 110 (3): 158-160.
65. Andre E, Isaacs C, Affolabi D, Alagna R, DeJong B, Cambau E, Churchyard G, Cohen T, Delmee M, Delvenne J-C, Farhat M, Habib A, Holme P, Keshavjee S, Khan AJ, Lightfoot P, Moore D, Moreno Y, Pai M, Mundade Y, Patel S, Nyaruhirira A, Rocha LE, Creswell J, Boehme C. Connectivity of diagnostic technologies: improving surveillance and accelerating TB elimination. *Int J Tuberc Lung Dis* 2016;20(8):999–1003.
66. *Huddart S, Nash M, Pai M. Tuberculosis Diagnosis: Challenges and Solutions. *J Health Specialties* 2016;4(4):230-237.
67. Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out, and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt, and how can we do better? *Eur Respir J* 2016; 48: 516–525.
68. Pai M, Behr M, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. *Nature Reviews Disease Primers* 2016;2:1-23.
69. Pai M, Behr M. 2016. Latent Mycobacterium tuberculosis infection and interferon-gamma release assays. *Microbiol Spectrum* 4(6):TBTB2-0023-2016. doi:10.1128/microbiolspec.TBTB2-0023 -2016.
70. Pai M, Nicol MP, Boehme CC. 2016. Tuberculosis diagnostics: state of the art and future directions. *Microbiol Spectrum* 4(4):TBTB2-0019-2016. doi:10.1128/microbiolspec .TBTB2-0019-2016.
71. *Cazabon D, Alsdurf H, Satyanarayana S, Nathavitharana R, Subbaraman R, Daftary A, Pai M. Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. *Int J Infect Dis* 2017; 56:111–116.
72. Yerlikaya S, Broger T, MacLean E, Pai M, Denkinger C. A Tuberculosis Biomarker Database: The Key to Novel TB Diagnostics. *Int J Infect Dis* 2017;56:253–257.
73. Lee RS, Pai M. Real-time sequencing of Mycobacterium tuberculosis: are we there yet?) *J Clin Micro* 2017;55:1249-54.
74. Pai M, Furin J. Tuberculosis innovations mean little, if they cannot save lives. *eLife* 2017;6:e25956.

75. Khan FA, Pande T, Tessema B, Song R, Benedetti A, Pai M, Lonnroth K, Denkinger CM. Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy. *Eur Respir J* 2017; 50: 1700953.
76. *Togun T, Kampmann B, Pai M. Diagnosis of childhood tuberculosis. *Reference Module in Biomedical Sciences* 2017;1-13. <http://dx.doi.org/10.1016/B978-0-12-801238-3.64157-0>
77. Miller R, Das, J, Pai M. Quality of tuberculosis care by Indian pharmacies: mystery clients offer new insights. *J Clin Tuberc Other Mycobact Dis* 2018;10:6–8.
78. *Huddart SK, Nafade V, Pai M. Tuberculosis: a persistent health challenge for India. *Current Epidemiology Reports* 2018 Mar;5:18-23.
79. *MacLean E, Pai M. Urine Lipoarabinomannan for Tuberculosis Diagnosis: Evolution and Prospects. *Clin Chem* 2018;64(8) 1133-1135.
80. Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer K, Thomas B, Haberer J. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. *BMJ Glob Health* 2018;3:e001018.
81. *MacLean E, Saravu K, Pai M. Diagnosing active tuberculosis in people living with HIV: an ongoing challenge. *Current Opinion in HIV and AIDS* 2019; 14(1), 46–54.
82. Padayatchi N, Daftary A, Naidu N, Naidoo K, Pai M. Tuberculosis: Treatment Failure, or Failure to Treat? Lessons from India and South Africa. *BMJ Glob Health* 2019;4:e001097.
83. Subbaraman R, Nathavitharana RR, Mayer KH, Satyanarayana S, Chadha VK, Arinaminpathy N, Pai M. Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care. *PLoS Med* 2019; 16(2): e1002754.
84. Cox V, Cox H, Pai M, Stillo J, Citro B, Brigden G. Health care gaps in the global burden of drug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2019; 23(2):125–135.
85. Furin J, Cox H, Pai M. Tuberculosis. *Lancet* 2019; 393(10181):1642-1656.
86. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M et al. Building a tuberculosis-free world: The *Lancet* Commission on tuberculosis. *Lancet* 2019;393(10178):1331-1384.
87. Kendall E, Sahu S, Pai M, et al. What will it take to eliminate drug-resistant tuberculosis? *Int J Tuberc Lung Dis* 2019;23(5):535–546.
88. Talbot EA, Pai M. Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations. *Int J Tuberc Lung Dis* 2019;23:774-782.
89. Agins B, Ikeda D, Reid M, Goosby E, Pai M, Cattamanchi A. Improving the cascade of global tuberculosis care: moving from the “what” to the “how” of quality improvement. *Lancet Infect Dis* 2019 Dec 1;19(12):e437-43.
90. Chikovore J, Pai M, Horton KC, Daftary A, Kumwenda MK, Hart G, Corbett EL. Missing men with tuberculosis: the need to address structural influences and implement targeted and multidimensional interventions. *BMJ Global Health* 2020;5:e002255.

91. Shafeque A, Bigio J, Hogan C, Pai M, Banaei N. Fourth generation QuantiFERON-TB Gold-Plus: What is the evidence? *J Clin Microbiol* 2020; 58:e01950-19.
92. Stallworthy G, Monica Dias H, Pai M. Quality of tuberculosis care in the private health sector. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* 2020;100171.
93. *MacLean E, Kohli M, Weber S, Suresh A, Schumacher S, Denkinge CM, Pai M. Advances in Molecular Diagnosis of Tuberculosis. *J Clin Micro* 2020; 58:e01582-19.
94. Shrinivasan R, Rane S, Pai M. India's syndemic of tuberculosis and COVID-19. *BMJ Global Health* 2020;5:e003979.
95. Abimbola S, Pai M. Will global health survive its decolonisation? *Lancet* 2020;396:1627-1628.
96. Hannay E, Boehme C, Pai M. Promoting diagnostics as a global good. *Nature Med* 2021; 7(3):367-368.
97. Saha S, Pai M. Can COVID-19 innovations and systems help low- and middle-income countries to re-imagine healthcare delivery. *Med* 2021;2:1-4.
98. Cao X-F, Li Y, Xin H-N, Zhang H-R, Pai M, Gao L. Application of artificial intelligence in digital chest radiography reading for pulmonary tuberculosis screening. *Chronic Diseases and Translational Medicine* 2021; 7(1): 35–40
99. Abimbola S, Asthana S, Montenegro C, Guinto RR, Jumbam DT, Louskieter L, Kabubei KM, Munshi S, Muraya K, Okumu F, Saha S, Saluja D, Pai M. Addressing power asymmetries in global health: Imperatives in the wake of the COVID-19 pandemic. *PLoS Med* 2021;18(4): e1003604.
100. *Zimmer A, Kinton JS, Oga-Omenka C, Heitkamp P, Nyirenda C, Furin J, Pai M. Tuberculosis in times of Covid-19. *J Epidemiol Comm Health* 2022 Mar 1;76(3):310-6.
101. Pai M, Kasaeva T, Swaminathan S. Covid-19's Devastating Effect on Tuberculosis Care — A Path to Recovery. *New England Journal of Medicine* 2022; 386;16: 1490-93.
102. *MacLean EL, Villa-Castillo L, Ruhwald M, Ugarte-Gil C, Pai M. Integrated testing for TB and COVID-19, *Med* 2022; 3(3):162-166.
103. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, Udwardia Z, Chang KC, Peter J, Pooran A, von Delft A, von Delft D, Martinson N, Loveday M, Charalambous S, Kachingwe E, Jassat W, Cohen C, Pai M. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. *Lancet Respir Med* 2022; 10:6:603-622.
104. Yamey G, Garcia P, Hassan F, Mao W, McDade KK, Pai M, Saha S, Schellekens P, Taylor A, Udayakumar K. It is not too late to achieve global covid-19 vaccine equity. *BMJ* 2022;376:e070650.
105. Charani E, Abimbola S, Pai M, Adeyi O, Mendelson M, Laxminarayan R, Rasheed MA. Funders: The missing link in equitable global health research? *PLoS Glob Public Health* 2022;2(6): e0000583.
106. *Zimmer AJ, Ugarte-Gil C, Pathri R, Dewan P, Jaganath D, Cattamanchi A, Pai M, Grandjean Lapierre S. Making cough count in tuberculosis care. *Commun Med* 2022; 2(1)1-8.
107. Khan T, Abimbola S, Kyobutungi C, Pai M. How we classify countries and people—and why it matters. *BMJ Global Health* 2022;7(6):e009704.
108. Campbell JR, Pease C, Daley P, Pai M, Menzies R. Diagnosis of tuberculosis infection. *Canadian*

Journal of Respiratory, Critical Care, and Sleep Medicine 2022; 6:sup1, 49-65.

109. *Faust L, Naidoo P, Caceres-Cardenas G, Ugarte-Gil C, Muyoyeta M, Kerkhoff AD, Nagarajan K, Satyanarayana S, Rakotosamimanana N, Lapierre SG, Adejumo OA, Kuye J, Oga-Omenka C, Pai M, Subbaraman R. Improving measurement of tuberculosis care cascades to enhance people-centered care. *Lancet Infect Dis* 2023;23(12):e547-e557.
110. Bhatia V, Rijal S, Sharma M, Islam A, Vassall A, Bhargava A, Thida A, Basri C, Onozaki I, Pai M, Rezwani MK. Ending TB in South-East Asia: flagship priority and response transformation. *The Lancet Regional Health – Southeast Asia* 2023;18:10030.
111. Bhargava A, Bhargava M, Pai M. Tuberculosis: a biosocial problem that requires biosocial solutions. *Lancet* 2024;403:1-3.
112. Farhat M, Cox H, Ghanam M, Denkinger CM, Rodrigues C, Abd El Aziz MS, Enkh-Amgalan H, Vambe D, Ugarte-Gil C, Furin J, Pai M. Drug-resistant tuberculosis: a persistent global health concern. *Nature Rev Microbiology* 2024 Mar 22:1-9.
113. Nafade V, Sen P, Arentz M, Kadam R, Bigio J, Allen LN, Blandina DM, Bosire S, Ferreira J, Jha S, John O, Kalantri SP, Mwirigi N, Faal-Omisore M, Ugarte-Gil C, Vijayan S, Wangari MC, Pai M. The value of diagnostic imaging for enhancing primary care in low- and middle-income countries. *eClinicalMedicine* 2024;77: 102899.

*First author was student/trainee under my supervision

†First author was student/trainee under my co-supervision

G4d. Editorials, Commentaries & Perspectives (Not Peer Reviewed)

1. Pai M. Accuracy and reliability of nucleic acid amplification tests in the diagnosis of tuberculosis: a summary of current evidence. *Natl Med J India* 2004;17(5):233-36.
2. Pai M, Lewinsohn D. Can immunosuppression and anergy affect interferon-g assays for tuberculosis. *Am J Respir Crit Care Med* 2005;172:519-21.
3. Pai M, Kalantri SP. Bacteriophage-based assays for tuberculosis. *Indian J Med Microbiol* 2005;23(3):149-150.
4. Pai M, Sharma S. Better reporting of studies of diagnostic accuracy. *Indian J Med Microbiol* 2005; 23(4):210-13.
5. Hopewell PC, Pai M. Tuberculosis, vulnerability, and access to quality care. *JAMA* 2005; 293:2790-93.
6. Pai M, O'Brien R. Tuberculosis diagnostics trials: do they lack methodological rigor? *Exp Rev Mol Diag* 2006;6(4):509-514.
7. Marais BJ, Pai M. Specimen collection methods in the diagnosis of childhood tuberculosis. *Indian J Med Microbiol* 2006; 24:249-251. [Corresponding author]
8. Pai M, Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? *Clin Infect Dis* 2007;44:74-77.
9. Pai M, Menzies D. The new IGRA and the old TST: making good use of disagreement. *Am J Resp Crit Care Med* 2007;175:529-31.

10. Viridi JS, Gulati P, Pai M. Genetic diversity of pathogenic microorganisms and its medical and public health significance. *Ind J Med Microbiol* 2007;25(1):2-3.
11. Pai M. Protecting healthcare workers from tuberculosis in the era of extensively drug-resistant tuberculosis. *Natl Med J India* 2007;20(1):1-3.
12. Pai M, Sharma SK. Are we providing quality care to our patients with tuberculosis? *Ind J Med Res* 2007;125:491-97.
13. Pai M, Daley P, Hopewell PC. International Standards for Tuberculosis Care: Relevance and Implications for Laboratory Professionals. *Ind J Med Micro* 2007;25(2):89-92.
14. Steingart K, Ramsay A, Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. *Exp Rev Anti Infect Ther* 2007;5(3):327-331. [Corresponding author]
15. Pai M, O'Brien R. Serial testing for tuberculosis infection: can we make sense of T-cell assay conversions and reversions? *PLoS Med* 2007;4(6):e208.
16. Vissandjee B, Pai M. The socio-cultural challenge in public health interventions: the case of tuberculosis in India. *Int J Public Health* 2007;52:199-201.
17. Steingart K, Ramsay A, Pai M. Commercial serological tests for the diagnosis of tuberculosis: do they work? *Future Microbiology* 2007;2(4):355-59. [Corresponding author]
18. Pai M, Ling D. Rapid diagnosis of extra-pulmonary tuberculosis using nucleic acid amplification tests: what is the evidence? *Future Microbiol* 2008;3(1):1-4.
19. Migliori GB, Pai M, Matteelli A, Cirillo D. Extensively drug resistant tuberculosis - a threat to tuberculosis control. *Eur Infect Dis* 2007;2:115-118.
20. Joshi R, Pai M. Can pleural tuberculosis be diagnosed using interferon-gamma release assays? *Respiration* 2008;76:128-30.
21. Ling DI, Zwerling A, Pai M. Rapid diagnosis of drug-resistant tuberculosis using line probe assays: from evidence to policy. *Exp Rev Res Med* 2008;2(5):583-588. [Corresponding author]
22. Pai M. New Diagnostics and Emerging Technologies for Tuberculosis. *Canadian Respiratory Journal* 2008;15(Supplement C):7C-8C.
23. Lange C, Pai M, Drobniewski F, Migliori GB. Interferon-g release assays for the diagnosis of active tuberculosis: sensible or silly? *Eur Resp Journal* 2009;33:1250-53.
24. Minion J, Sohn H, Pai M. Light-emitting diode technologies for TB diagnosis: what's on the market? *Exp Rev Med Devices* 2009;6(4):341-45. [Corresponding author]
25. Pai M, Ramsay A, O'Brien R. Comprehensive new resource for evidence-based TB diagnosis. *Expert Rev Mol Diagn* 2009;9(7):637-39.
26. Pai M. Guest editorial: Evidence-based TB diagnosis. *Infect Dis Journal Pakistan* 2009;18(4):98.
27. Minion J, Pai M. Evidence-based Diagnosis of Tuberculosis: Resources for the Medical Microbiologist. *Ind J Med Micro* 2010;28:2-4. [Corresponding author]
28. Pai M. Spectrum of latent tuberculosis: existing tests cannot resolve underlying phenotypes. *Nature Rev Microbiol* 2010;8(3):242-243.
29. Minion J, Pai M. Expanding the use of MODS in TB/HIV management. *Clin Infect Dis* 2010;50:997-

999. [Corresponding author]
30. Chartrand C, Minion J, Pai M. Rapid diagnostics for influenza: what are the options? *Future Microbiol* 2010;5(10):1451-55. [Corresponding author]
 31. Small PM, Pai M. Tuberculosis diagnosis - time for a game change. *N Eng J Med* 2010;363:1070-71.
 32. Ramsay A, Steingart K, Pai M. Assessing the impact of new diagnostics on tuberculosis control. *Int J Tuberc Lung Dis* 2010;14(12):1506-7. [Corresponding author]
 33. Zar HJ, Pai M. Childhood tuberculosis - a new era. *Paediatr Respir Rev* 2011; 12(1):1-2.
 34. Pai M. Improving tuberculosis diagnosis: difference between knowing the path and walking the path. *Expert Rev Mol Diag* 2011;11(3):241-44.
 35. Pai M. A process of elimination. *Pub Serv Review Int Dev* 2011. Issue 18, April 2011.
 36. Pai M. Tuberculosis Control in India: Time to get dangerously ambitious? *Natl Med J India* 2011; 24(2):65-68.
 37. Zwerling A, Pai M. The BCG world atlas: a new, open-access resource for clinicians and researchers. *Expert Rev Anti Infect Ther* 2011;9(8), 559–561.
 38. Pai M, Christopher DJ. Protecting young healthcare trainees from tuberculosis: Can we overcome apathy? *Natl Med J India* 2011; 24(4):198-200.
 39. Pai M, Dowdy D, Steingart K. Editorial: The medical, public health and economic consequences of bad diagnostics. *TropIKA.Net*, 10 August 2011.
 40. Denkinger CM, Pai M. Point-of-care tuberculosis diagnosis: are we there yet? *Lancet Infect Dis* 2012;12:169-170.
 41. Engel N, Kenneth J, Pai M. TB diagnostics in India: creating an ecosystem for innovation. *Exp Rev Mol Diagn* 2012; 12(1), 21–24.
 42. Pai M. As India grows, tuberculosis control must not be left behind. *Lancet Infect Dis* 2012;12:263-65.
 43. Pai M, Elwood K. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: Dynamic patterns and interpretational challenges. *Can Resp J* 2012;19(2):81-83.
 44. Chartrand C, Pai M. How accurate are rapid influenza diagnostic tests? *Expert Rev Anti Infect Ther* 2012;10(6):615-17.
 45. Baloch NA, Pai M. Tuberculosis control: business models for the private sector. *Lancet Infect Dis* 2012;12:579-580.
 46. Pai M. Serial testing with TB interferon-g release assays: toward a nuanced understanding. *Chest* 2012;142:1366-68.
 47. Pai M, Das J. Management of tuberculosis in India: time for a deeper drive into quality. *Natl Med J India* 2013;26(2):65-68.
 48. Pai M. Tuberculosis diagnostics: test developers' FAQs. *Int J Tuberc Lung Dis* 2013;17(5):1-2.
 49. Pai M, Memish Z. New tuberculosis tools are here: can we deliver them for maximal impact? *J Epi*

- Global Health* 2013;3:1-2.
50. Pai M. Diagnostics for tuberculosis: what test developers want to know. *Exp Rev Mol Diag* 2013; 13(4):311-14.
 51. Engel N, Pai M. Tuberculosis diagnostics: why we need more qualitative research. *J Epi Global Health* 2013;3:119-121.
 52. Pai M. Promoting Affordable and Quality Tuberculosis Testing in India. *J Lab Physicians* 2013;5(1):1-4.
 53. Qin ZZ, Pai M. Tuberculosis control in India: the critical need for reducing diagnostic and treatment delays. *J Clin Sci Res* 2013;2:123-5.
 54. Pai M. Tuberculosis control in India: Time to think beyond DOTS. *J Mahatma Gandhi Inst Med Sci* 2013;18:94-6.
 55. Pai M, Banaei N. Occupational screening of healthcare workers for tuberculosis infection: tuberculin skin testing or interferon-g release assays? *Occup Med* 2013 63: 458-460.
 56. Van Zyl-smit R, Pai M. Smoking and tuberculosis infection: Chasing associations with imperfect exposure and outcome measures. *Int J Tuberc Lung Dis* 2013;17(11):1375-76.
 57. Qin ZZ, Pai M. A new resource for tuberculosis diagnostics developers. *Future Microbiol* 2013;8(12):1507-09.
 58. Denkinger CM, Kik S, Pai M. Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. *Exp Rev Mol Diag* 2013;13(8):763-67.
 59. Pai M, Dowdy D. Tuberculosis: progress and challenges in product development and delivery. *Lancet Resp Med* 2014;2(1):25-27.
 60. Pai M, Kik S, Banaei N. Occupational screening for tuberculosis: a testing time for interferon-g release assays. *Ann Am Thorac Soc* 2014;11(3):399-401.
 61. Pai M, Yadav P, Anupindi R. Tuberculosis control needs a complete and patient-centric solution. *Lancet Global Health* 2014;2:e189-e190.
 62. Pai M. Improving the quality of tuberculosis care: we need standards, and strategies to translate them into practice. *J Epi Global Health* 2014;4(2):77-80.
 63. Pai M, Nathavitharana R. Extrapulmonary tuberculosis: new diagnostics and new policies. *Indian J Chest Dis Allied Sci* 2014;56:71-73.
 64. Ratnavelu VK, Pai M. Tuberculosis care in India: how can private practitioners make a difference? *Chest (India Edition)* 2014;5(1):4 – 6.
 65. Schumacher S, Pai M. Xpert MTB/RIF for extrapulmonary tuberculosis: time to look beyond accuracy. *Int J Tuberc Lung Dis* 2015;19(1):2.
 66. Pai M, Memish Z. Global tuberculosis control requires greater ambition and resources. *J Epi Global Health* 2015;5:1-2.
 67. Pai M, Raison C. Transforming the diagnosis of tuberculosis: an editorial board member's opinion at the 15th year of *Expert Review of Molecular Diagnostics*. *Exp Rev Mol Diag* 2015;15(3):295-298.
 68. Pai M. Innovations in Tuberculosis Diagnostics: Progress and Translational Challenges.

- EBioMedicine* 2015;2:182-183.
69. Pai M. TB control requires new tools, policies, and delivery models. *Ind J Tuberc* 2015;62:1-3.
 70. Pai M, Dewan PK. Testing and treating the missing millions with tuberculosis. *PLoS Med* 2015;12(3):e1001805.
 71. Pai M. The End TB Strategy: India Can Blaze the Trail. *Ind J Med Res* 2015;141:259-262.
 72. Pai M, Rodrigues C. Management of latent tuberculosis infection: an evidence-based approach. *Lung India* 2015;32:205-7.
 73. Subbaraman R, Pai M. A killer combination that must be stopped. *Int J Tuberc Lung Dis* 2015;19(8):877-78.
 74. Sotgiu G, Pai M. Diagnostics for latent tuberculosis infection: incremental, not transformative progress. *Eur Respir J* 2016 47:704-706.
 75. Pai M, Memish Z. Antimicrobial resistance and the growing threat of drug-resistant tuberculosis. *J Epi Global Health* 2016; 6:45-47.
 76. Pai M, Temesgen Z. Mind the Gap: time to address implementation gaps in tuberculosis diagnosis and treatment. *J Clin Tuberc* 2017;6:14-15.
 77. Daftary A, Pai M. Tuberculosis therapy in Mumbai: critical importance of drug-susceptibility testing. *Lung India* 2016;33:251-2.
 78. Daftary A, Jha N, Pai M. Enhancing the role of pharmacists in the cascade of tuberculosis care. *J Epidemiol Global Health* 2017;7:1-4.
 79. Nathavitharana R, Peters J, Lederer P, Delft A, Farley J, Pai M, Jaramillo E, Raviglione M, Nardell E. Engaging health-care workers to reduce tuberculosis transmission. *Lancet Infect Dis* 2016; 16:883-885.
 80. MacLean E, Huddart S, Pai M. Molecular diagnosis of tuberculosis: we need solutions that span the healthcare value chain. *Exp Rev Mol Diag* 2017;17:5-7.
 81. Togun T, Pai M. The uncertain science of predicting tuberculosis. *Lancet Respir Med* 2017;5(4):239-40.
 82. Pai M, Memish Z. New tuberculosis estimates must motivate countries to act. *J Epidemiol Global Health* 2017;7:97-98.
 83. Pai M, Correa N, Mistry N, Jha P. Reducing global tuberculosis deaths: time for India to step up. *Lancet* 2017; 389:1174-76.
 84. Pai M, Koul P. India's fight against tuberculosis: how can chest physicians help? *Lung India* 2017;34(2):120-121.
 85. Pai M, Bhaumik S, Bhuyan S. India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality. *BMJ Global Health* 2017;2:e000326.
 86. Sulis G, Pai M. Missing tuberculosis patients in the private sector: business as usual will not deliver results. *Pub Health Action* 2017; 7(2): 80-81.
 87. Banaei N, Pai M. Detecting New Mycobacterium Tuberculosis Infection: Time for a More Nuanced Interpretation of QuantiFERON Conversions. *Am J Respir Crit Care Med* 2017;196:546-547.

88. Svadzian A, Pai M. Countries Need to Step Up to End Tuberculosis. *J Clin Tuberc* 2017;8:33-34.
89. Pai M. Do rats pass the sniff test? *Int J Tuberc Lung Dis* 2017; 21(11):1089–1090.
90. Ahlbrand SE, Pai M. A 360-degree view of an ancient killer disease. *J Epi Global Health* 2017; 7:209–210.
91. Daftary A, Frick M, Venkatesan N, Pai M. Fighting TB stigma: we need to apply lessons learned from HIV activism. *BMJ Global Health* 2017;2:e000515.
92. Pai M, Schumacher S, Abimbola S. Surrogate endpoints in global health research: still searching for killer apps and silver bullets? *BMJ Global Health* 2018;3:e000755.
93. Pai M. Time for high-burden countries to lead the tuberculosis research agenda. *PLoS Med* 2018;15(3): e1002544.
94. Dias HM, Pai M, Raviglione MC. Ending tuberculosis in India: a political challenge and an opportunity. *Indian J Med Res* 2018;147:217-20.
95. Nathavitharana R, Pai M. New tools and strategies to improve outcomes in hospitalized, tuberculosis and HIV-infected patients. *Lancet* 2018;392(10144):256-258.
96. Schroeder L, Pai M. A list to cement the rightful place of diagnostics in healthcare. *J Clin Micro* 2018 56:e01137-18.
97. Kohli M, Sen P, Pai M. Improving access to essential tests for infectious diseases. *Microbes Infect* 2019;21:1-3.
98. Sulis G, Pai M. Tuberculosis in Pregnancy: A Treacherous Yet Neglected Issue. *J Obstet Gynaecol Can* 2018;40(8):1003–1005.
99. Moussy F, Berumen A, Pai M. The WHO list of essential in vitro diagnostics: Development and next steps. *EBioMedicine* 2018;37:1-2.
100. Pai M, Temesgen Z. Quality: the missing ingredient in TB care and control. *J Clinical Tuberc* 2019;14:12-13.
101. Saravu K, Pai M. Drug-resistant tuberculosis: Progress towards shorter and safer regimens. *Lung India* 2019;36:373-5.
102. Pai M, Walia K, Boehme C. Essential medicines and essential diagnostics: a package deal. *Lancet Public Health* 2019 Oct 1;4(10):e492 .
103. Adam P, Pai M. Implementation of Xpert® MTB/RIF in high-burden countries: voices from the field matter. *Public Health Action* 2019;9:78-79.
104. Sulis G, Pai M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. *PLoS Med* 2020; 17(1): e1003023.
105. Pai M. Tuberculosis: the story after the primer. *Nature Rev Dis Primers* 2020; 6:29.
106. Pai M. Covidization of research: what are the risks?. *Nature Medicine* 2020; 26:1159.
107. *Oga-Omenka C, Akinrin AT, Boffa J, Heitkamp P, Pai M, Zarowsky C. Lessons from the COVID-19 global health response to inform TB case finding. *Healthcare* 2021;9:100487.
108. Bigio J, Sassi A, Temesgen Z, Pai M. Improving the quality of tuberculosis care in the post-pandemic

- world. *J Clinical Tuberc* 2021;23:100212.
109. Boffa J, Mhlaba T, Sulis G, Moyo S, Sifumba Z, Pai M, A Daftary. COVID-19 and tuberculosis in South Africa: A dangerous combination. *South African Medical Journal* 2020;110(5):341-342.
 110. Ruhwald M, Carmona S, Pai M. Learning from Covid-19 to reimagine tuberculosis diagnosis. *Lancet Microbe* 2021; 2(5):e169-e170.
 111. Atkins S, Banerjee A, Bachynski K, Daftary A, Desai G, Gross A, Hedt-Gauthier B, Mendenall E, Meier BM, Nixon SA, Nolan A, Palermo T, Phelan A, Pyzik O, Roach P, Sangaramoorthy T, Standley C, Yamey G, Abimbola S, Pai M. Using the COVID-19 pandemic to reimagine global health teaching in high-income countries. *BMJ Global Health* 2021;6:e005649.
 112. Kuppalli K, Galla P, Cherabuddi K, Kalantri SP, Mohanan M, Mukherjee B, Pinto L, Prakash M, Pramesh CS, Rathi S, Pant Pai N, Yamey G, Pai M. India's COVID-19 crisis: a call for international action. *Lancet* 2021: 397(10290):2132-2135.
 113. Bigio J, van Gemert W, Kaiser B, Waning B, Pai M. Asia emerges as a hotbed of diagnostic innovations for tuberculosis. *J Clinical Tuberc* 2021; 25:100267.
 114. Chagla Z, Pai M. Covid-19 boosters in rich nations will delay vaccines for all. *Nature Med* 2021; 27(10):1659-1660.
 115. Kyobutungi C, Robinson J, Pai M. *PLoS Global Public Health*, charting a new path towards equity, diversity and inclusion in global health. *PLoS Glob Public Health* 2021;1(10): e0000038.
 116. Pai M, Alakija A. Vax the world. *Science* 2021;374:1031.
 117. Pramesh CS, Babu GR, Basu J, Bhushan I, Booth CM, Chinnaswamy G, Guleria R, Kalantri SP, Kang G, Mohan P, Mor N, Pai M, Prakash M, Rupali P, Sampathkumar P, Sengar M, Sullivan R, Ranganatha P. Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. *Nature Medicine* 2021; Aug;27(8):1324-7.
 118. Pai M, Zar HJ. Childhood tuberculosis – time for shorter and differentiated treatment. *N Eng J Med* 2022;386:988-99.
 119. Fatah, FZ, Furin J, Pai M. When it comes to stopping tuberculosis, what is actually “missing”? *PLOS Global Public Health* 2022; 2(3): e0000319.
 120. McKenna L, Frick M, Angami K, Dubula V, Furin J, Harrington M, Hausler H, Heitkamp P, Herrera R, Lynch S, Mitnick CD, Moses GK, Ndjeka N, Nyang'wa BT, Palazuelos L, Ulysse P, Pai M. The 1/4/6x24 campaign to cure tuberculosis quickly. *Nat Med* 2023;29:16-17.
 121. Hannay E, Pai M. Breaking the cycle of neglect: building on momentum from Covid-19 to drive access to diagnostic testing. *eClinicalMedicine* 2023;57: 101867.
 122. Kyobutungi C, Gitahi G, Wangari M-C, Siema P, Gitau E, Sipalla F, Pai M, Oti SO. From vaccine to visa apartheid, how anti-Blackness persists in global health. *PLOS Glob Public Health* 2023; 3(2): e0001663.
 123. Kasaeva T, Dias M, Pai M. Fast-tracking progress to End TB: high-level opportunities for investment and action. *Lancet* 2023;401:975-78.
 124. Pai M, Swaminathan S. India is well placed to scale innovations in tuberculosis diagnostics. *Indian J Med Res* 2023; 157(2&3):114-117.

125. Pai M, Dewan P, Swaminathan S. Transforming tuberculosis diagnosis. *Nature Micro* 2023; 8:756–759.
126. Titanji BK, Pai M. Leveraging the positives from the pandemic to strengthen infectious disease care in low-income and middle-income countries. *Lancet Infect Dis* 2023; 23: 890-892.
127. Miller R, Wafula F, Eman K, Rakesh PS, Faleye B, Duggan C, Pinto GS, Heitkamp P, Rana N, Klinton JS, Sulis G, Omenka C, Pai M. Pharmacy engagement in TB prevention and care: not if, but how? *BMJ Global Health* 2023;8:e013104.
128. Branigan D, Denkinger CM, Furin J, Heitkamp P, Deborggraeve S, van Gemert W, Herrera R, Kondratyuk S, McKenna L, Ndjeka N, Omar SV, Pai M. Diagnostics to support the scaling up of shorter, safer tuberculosis regimens. *Lancet Microbe* 2023 Oct 1;4(10):e758-60.
129. Banerjee A, Bandara S, Senga J, Gonzalez N, Pai M. Are we training our students to be white saviours in global health? *Lancet* 2023; 402: 520-21.
130. Anand SS, Pai M. Glocal is Global: reimagining the training of global health students in high-income countries. *Lancet Global Health* 2023 Nov 1;11(11):e1686-7.
131. Bertram K, Pai M. Single-issue advocacy in global health: Possibilities and perils. *PLOS Glob Public Health* 2023; 3(9): e0002368.
132. Robinson J, Kyobutungi C, Nyakoojo Z, Pai M. Editors as allies: Our two-year experience at *PLOS Global Public Health*. *PLOS Glob Public Health* 2023; 3(11): e0002644.
133. *Thapa P, Narasimhan P, Beek K, Hall JJ, Jayasuriya R, Mukherjee PS, Sheokand S, Heitkamp P, Shukla P, Klinton JS, Yellappa V, Mudgal N, Pai M. Unlocking the Potential of Informal Healthcare Providers in Tuberculosis Care: Insights from India. *BMJ Global Health* 2024;9:e015212.
134. Pai M, Abimbola S. Science should save all, not just some. *Science* 2024; 385:581.
135. Pai M, Gandra S, Thapa P, Carmona S. Tackling antimicrobial resistance: recognizing the proposed five blind spots can accelerate progress. *Lancet Microbe* 2024; 100968.
136. Adetifa I, Pai M. Mpox outbreaks in Africa—we must avert another failure of global solidarity. *BMJ* 2024; 386:q1803.
137. Pai M, Bandara S, Kyobutungi C. Shifting power in global health will require leadership by the Global South and allyship by the Global North. *The Lancet* 2024;404:1711-13.

G4e. Guidelines, Standards & Policy Recommendations

1. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione M. International Standards for Tuberculosis Care. *Lancet Infect Dis* 2006;6:710-25. [Contributor].
2. Gardam M, Kunimoto D, Long R, Menzies D, Pai M. Canadian Tuberculosis Committee. Interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). *Can Commun Dis Rep*. 2007 Nov 1;33(ACS-10):1-18. [Contributor].
3. Pai M, Gardam M, Haldane D, Kitai I, Kunimoto D, Long R, Menzies D, Morshed M, Ward H, Wobeser W. Canadian Tuberculosis Committee. Updated Recommendations on Interferon Gamma Release Assays for Latent Tuberculosis Infection. An Advisory Committee Statement (ACS). *Can Commun Dis Rep* 2008;34 (ACS-6):1-13. [Lead Author].

4. World Health Organization. Policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva, WHO, 2008. URL: http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel].
5. World Health Organization. Treatment of tuberculosis: Guidelines. 4th Edition. Geneva, WHO, 2010. URL: http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html [Member, Technical Guideline Development Group].
6. World Health Organization. WHO policy on tuberculosis infection control in health-care facilities, congregate settings and households. Geneva, WHO, 2009. URL: http://whqlibdoc.who.int/publications/2009/9789241598323_eng.pdf [Member, Systematic Reviews Panel].
7. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care. 2nd Edition. TBCTA, The Hague, 2009. URL: http://www.istcweb.org/ISTC_Documents.html [Member, Steering Committee].
8. Al Jahdali H, Baharoon S, Abba A, Memish Z, Alrajhi AA, Barrak AA, Haddad Q, Al Hajjaj M, Pai M, Menzies D. Saudi guidelines for testing and treatment of latent tuberculosis infection. *Ann Saudi Med* 2010;30:38-49 [Contributor].
9. Kunitomo D, Gardam M, Kitai I, Menzies D, Morshed M, Pai M, Ward H, Webster D, Wobeser W. Canadian Tuberculosis Committee. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection - 2010 Update. *Can Commun Dis Rep* 2010;36 (ACS-5):1-21 [Contributor].
10. World Health Organization. Policy statement: Fluorescent light emitting diode (LED) microscopy for diagnosis of tuberculosis. Geneva, WHO, 2010. URL: http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel].
11. World Health Organization. Policy statement: Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multidrug-resistant tuberculosis. Geneva, WHO, 2010. URL: http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel].
12. Kakkar F, Allen UD, Ling D, Pai M, Kitai IC; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Position statement: Tuberculosis in Children: New diagnostic blood tests. *Paediatr Child Health* 2010;15(8):529-33 [Contributor].
13. Tuberculosis Coalition for Technical Assistance (TBCTA). Implementing the WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. TBCTA, The Hague, 2010 [Contributor].
14. World Health Organization. Policy statement: Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. Geneva, WHO, 2011. URL: http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel].
15. World Health Organization. Policy statement: The use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. Geneva, WHO, 2011. URL:

- http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel].
16. Stop TB Partnership & World Health Organization. An international roadmap for tuberculosis research: towards a world free of tuberculosis. Geneva, WHO, 2011 [Contributor].
 17. Pai M, Minion J, Jamieson F, Wolfe J, Behr M. Diagnosis of active tuberculosis and drug resistance. Canadian TB Standards, 7th Edition. *Canadian Resp Journal* 2013; 20 (Suppl A): 16A-22A.
 18. Pai M, Kunimoto D, Jamieson F, Menzies D. Diagnosis of latent tuberculosis infection. Canadian TB Standards, 7th Edition. *Canadian Resp Journal* 2013; 20 (Suppl A): 23A-34A.
 19. Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization. Priorities for tuberculosis research. A report of the TDR Disease reference group on TB, leprosy and Buruli. Geneva, WHO, 2013 [Contributor].
 20. TB CARE I. International Standards for Tuberculosis Care, Edition 3. TB CARE I, The Hague, 2014. URL: <http://www.istcweb.org> [Member, Expert Committee].
 21. World Health Organization. Meeting Report: High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. 2014, World Health Organization, Geneva, Switzerland [Member, Expert Committee].
 22. World Health Organization. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. WHO, Geneva, 2016 [Member, Steering Group].
 23. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek G, O’Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick T, Sterling T, Warshauer D, Woods G. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clinical Infectious Diseases* 2017; 64(2):111-115.
 24. World Health Organization. Public-private mix for TB prevention and care: a roadmap. World Health Organization, Geneva, 2018 [Member, Expert Committee].
 25. World Health Organization. Engaging private healthcare providers in TB care and prevention: a landscape analysis. WHO, Geneva, 2018 [Member, Expert Committee]
 26. Economist Intelligence Unit. It’s time to end drug-resistant tuberculosis. A case for action. Report by The Economist, 2019 [Member, Expert Committee].

G4f. Books, Monographs and Book Chapters

Book (as Associate Editor)

Tuberculosis: A Comprehensive Clinical Reference. H. Simon Schaaf & Alimuddin I. Zumla [Editors], John Grange, Mario Raviglione, Wing Wai-Yew, Peter Donald, Madhukar Pai, and Jeffrey Starke [Associate Editors], 2009. London, UK: WB Saunders Elsevier, ISBN 9781416039884 (hardback) and ISBN 9788131221518 (international edition).

Canadian Tuberculosis Standards. 7th Edition. Dick Menzies [Editor], Edward Ellis, Richard Long, Madhukar Pai, and Tom Wong [Associate Editors], 2013. Ottawa, Canada: Canadian Thoracic Society and Lung Association. <http://www.respiratoryguidelines.ca/tb-standards-2013>

Monographs (as Contributor)

1. Francis J Curry National TB Center & California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 2nd edition, 2008. [Contributor].
2. Stop TB Partnership & World Health Organization. Pathways to better diagnostics for tuberculosis. WHO, Geneva, 2009. [Contributor].
3. Peter J, van-zyl Smit R, Denkinger CM, Pai M. Diagnosis of tuberculosis: state-of-the-art. *European Respiratory Society Monograph* 2012; 58 (Tuberculosis): 124-143. [Co-author].
4. Boyle D, Pai M. Tuberculosis diagnostic technology landscape. UNITAID, Geneva, 2012. [Co-author].
5. Boyle D, Pai M. Tuberculosis diagnostics technology and market landscape. 2nd Edition. UNITAID, Geneva, 2013. [Co-author].
6. Boyle D, Pai M. Tuberculosis diagnostics technology and market landscape. 3rd Edition. UNITAID, Geneva, 2014. [Co-author].
7. Boyle D, Pai M. Tuberculosis diagnostics technology and market landscape. 4th Edition. UNITAID, Geneva, 2015. [Co-author].
8. Jefferson C, Denkinger CM, Ginnard J, Kik S, Pai M. TB diagnostics market in select high-burden countries: Current market and future opportunities for novel diagnostics. FIND; McGill International TB Centre; UNITAID, Geneva, 2016. [Co-author].

Book Chapters (as Contributor)

1. Pai M. Ethics and epidemiological research. In: Ethics in Health Research: A Social Science Perspective. Jesani A, Barai-Jaitley T (editors). Center for Studies in Ethics and Rights. Bombay, 2005.
2. Hopewell PC, Fair E, Pai M. International Standards for Tuberculosis Care. Integrating tuberculosis care and control. In: Clinical Tuberculosis, 4th Edition. (Editors: Davies PDO, Barnes P and Gordon SB). Hodder Arnold, London, UK, 2008.
3. Pai M, Joshi R, Kalantri S. Diagnosis of latent tuberculosis infection: recent advances and future directions. In: Tuberculosis. 2nd Edition. Editors: SK Sharma & A Mohan. Jaypee Brothers Medical Publishers, New Delhi, India, 2009.
4. Marais BJ, Pai M. Diagnosis of childhood tuberculosis. Recent advances and applicability of new tools. In: Tuberculosis. 2nd Edition. Editors: SK Sharma & A Mohan. Jaypee Brothers Medical Publishers, New Delhi, India, 2009.
5. Menzies D, Schwartzman K, Pai M. Immune-based tests for tuberculosis. In: Tuberculosis: A Comprehensive Clinical Reference. Editors: Schaaf HS & Zumla AI. WB Saunders Elsevier, 2009.
6. Hopewell PC, Fair E, Pai M. International Standards for Tuberculosis Care. In: Tuberculosis: A Comprehensive Clinical Reference. Editors: Schaaf HS & Zumla AI. WB Saunders Elsevier, 2009.

7. Pai M, Menzies D. Diagnosis of latent tuberculosis infection in adults. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2014. URL: <http://www.uptodate.com>
8. Pai M, Menzies D. Interferon-gamma release assays for latent tuberculosis infection. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2014. URL: <http://www.uptodate.com>
9. Pai M, Menzies D. Diagnosis of latent tuberculosis infection in HIV-infected patients. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2014. URL: <http://www.uptodate.com>
10. Marais B, Ling D, Pai M. New approaches to TB diagnosis in children. In: Essentials of tuberculosis in children. 4th edition. Editors: Vimlesh Seth & SK Kabra. Jaypee Brothers Medical Publishers, New Delhi, India, 2011.
11. Pai M, Schumacher S, Sohn H, Denkinger CM. TB diagnostics: current pipeline, new developments and unmet needs. In: Current & Emerging Diagnostics, Therapeutics & Vaccines for Tuberculosis. Editor: Stefan HE Kaufmann. Future Medicine Ltd, October, 2011. DOI: 10.2217/9781780840239.
12. Ramsay A, Steingart K, Pai M. Improving on sputum smear microscopy for diagnosis of tuberculosis in resource-poor settings. In: Tuberculosis: Laboratory Diagnosis and Treatment Strategies. Edited by T D McHugh. CAB International, UK, 2013. (H ISBN 9781845938079).
13. Kik S, Qin ZZ, Pai M. Optimal diagnosis: how early and improved diagnosis can help prevent TB transmission. In: Clinical Insights: Tuberculosis Prevention. Future Medicine Ltd, 2014. DOI: 10.2217/9781780843810. eISBN (PDF): 978-1-78084-381-0.
14. Engel N, Pai M. Tuberculosis, Drug-resistant. In: Science and Politics: An A-to-Z Guide to Issues and Controversies. Editor: Brent S. Steel, Oregon State University. CQ Press, an imprint of SAGE. Thousand Oaks, CA, 2014. ISBN. 978-1-4833-4632-8.
15. *Satyanarayana S, Pai M. Enhancing the quality of tuberculosis care in India. In: Eradicating TB in India. Challenges, Prospective, Solutions. Global Policy & Observer Research Foundation. Editor: Harsh Sethi. Durham University and Wiley Blackwell, UK, 2015. E-book: <http://www.globalpolicyjournal.com/sites/default/files/GP-ORF%20TB%20EPDF.pdf>
16. Strnad L, Denkinger CM, Pai M. Effusions from Infections: Tuberculosis. In: Textbook of Pleural Diseases, Third Edition. Editors: Richard W. Light, Y C Gary Lee. CRC Press, 2016. ISBN 9781482222500.
17. Hogan C, Pai M. Point-of-care testing for active tuberculosis. In: A practical guide to global point-of-care testing. Editor: Mark Sheppard. ISBN: 9781486305186. CSIRO Publishing, 2016.
18. Denkinger CM, Pai M. Diagnosis of Tuberculosis: Current Pipeline, Unmet Needs, and New Developments. In: Handbook of Global Tuberculosis Control. Editors: Lu, Y., Wang, L., Duanmu, H., Chanyasulkit, C., Strong, A.J., Zhang, H. Springer, 2017. ISBN 978-1-4939-6665-3.
19. Engel N, Yellapa V, David M, Dheda K, Pai NP, Pai M. Barriers to Point of Care Testing in India and South Africa. In: Technologies for Development. From Innovation to Social Impact. Editors: Silvia Hostettler, Samira Najih Besson & Jean-Claude Bolay. Springer, 2018. ISBN 978-3-319-91067-3.
20. Koum Besson E, Pai M. Rethinking knowledge in global health. In: Global Health Essentials. Editors: Mario C. B. Raviglione, Fabrizio Tediosi, Simone Villa, N ria Casamitjana, Antoni Plas ncia. Springer, 2023. ISBN: 978-3-031-33850-2.

G4g. Letters, Book Reviews, and Notes

1. Pai M. A debate is needed on caesarean section rates in India. *BMJ*, 2000;320:1072.
2. Pai M, McCulloch M, Colford JM Jr. Meta-analysis of the impact of HIV on the infectiousness of tuberculosis: methodological concerns. *Clin Infect Dis* 2002;34:1285-87. [letter]
3. Pai M, McCulloch M. Book review: Computer programs for epidemiologists: PEPI v.4.0, fourth edition. Salt Lake City, UT: Sagebrush Press, 2001. *Am J Epidemiol* 2002;155(8):776-77. [book review]
4. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM. Nucleic acid amplification tests for diagnosis of tuberculous meningitis (Author Reply). *Lancet Infect Dis* 2004;4:11-12.
5. Pai M. Interpreting diagnostic evidence: fundamental principles. *Ind J Medical Ultrasound* 2004;2(3): 79-84.
6. Pai M, Riley LW, Colford JM. Interferon gamma assays for tuberculosis (Author Reply). *Lancet Infect Dis* 2005;5:325-327.
7. Pai M, Kalantri S, Menzies D. Discordance between tuberculin skin test and interferon-gamma assays. *Int J Tuberc Lung Dis* 2006;10(8):942-43.
8. Pai M, Dogra S, Narang P. Interferon-gamma release assays in children – no better than tuberculin skin testing. Response to Ranganathan S et al. *J Infect* 2007;54(4):412-13.
9. Steingart KR, Ramsay A, Pai M. Fluorescence microscopy for tuberculosis diagnosis (Author Reply). *Lancet Infect Dis* 2007;7:239-240.
10. Bates MN, Khalakdina A, Pai M, Smith KR. Smoking and Tuberculosis: Infection, Disease, and Mortality—Reply. *Arch Intern Med*. 2007;167:2009.
11. Menzies D, Pai M. New tests for the diagnosis of latent tuberculosis infection. *Ann Intern Med* 2007;147(9):673-74.
12. Perkins MD, Pai M. Biomarkers and diagnostics for tuberculosis. *Lancet* 2010;376:1540.
13. Minion J, Pai M. Assays for drug resistant tuberculosis in high burden countries – Authors' reply. *Lancet Infect Dis* 2011;11(3):162.
14. Baloch NA, Pai M. Public-private mix in tuberculosis – Author's reply. *Lancet Infect Dis* 2012;12:910-11.
15. Behr M, Schwartzman K, Pai M. Tuberculosis vaccine trials. *Lancet* 2013;381:2252-53.
16. Grenier J, Pai M. Book review: The plague that refuses to go away. Speaking of Medicine 2013. URL: <http://blogs.plos.org/speakingofmedicine/2013/05/15/book-review-the-plague-that-refuses-to-go-away/>
17. Pai M, Yadav P, Anupindi R. The need to further augment the public health system to control tuberculosis — Authors' reply. *Lancet Global Health* 2014;2(7):e389.
18. Denkinger CM, Pai M. Performance of Xpert MTB/RIF in induced sputum samples at detecting Mycobacterium tuberculosis. Response to Hana M. El Sahly. *Clin Infect Dis* 2014 May 22. pii: ciu376.

19. Ghiasi M, Pai M. Book review: The adventure of the cure that wasn't. *Speaking of Medicine* 2014. <http://blogs.plos.org/speakingofmedicine/2014/06/16/book-review-adventure-cure-wasnt/>
20. Denkinger CM, Pai M. Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert. *Eur Resp J* 2014;44:1095-96.

G4h. Conference Presentations/Abstracts/Posters

1. Pai M, McCulloch M, Colford JM, Bero L. Evaluation of study quality, heterogeneity, and publication bias: a survey of systematic reviews on HIV/AIDS. Oral presentation at the conference on "Statistical challenges for meta-analysis of medical and health policy data," Mathematic Sciences Research Institute, Berkeley, USA, 11 May 2002.
2. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM. Quality of studies evaluating the accuracy of nucleic acid amplification tests (NAAT) for tuberculosis. Poster presented at the 4th National Conference on Laboratory Aspects of Tuberculosis, San Francisco, USA, 10-13 December 2002.
3. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a meta-analysis. Poster presented at the California Tuberculosis Controllers Association Spring 2003 Conference, Oakland, USA, 24-25 April 2003.
4. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM. Comparison of Diagnostic Accuracy of Commercial and In-house Nucleic Acid Amplification Tests for Tuberculous Meningitis: a Meta-analysis. Poster presented at the American Society for Microbiology 103rd General Meeting, Washington D.C., USA, 18-22 May 2003.
5. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM. Quality assessment in meta-analyses of diagnostic studies: what difference does email contact with authors make? Poster presented at the XI Cochrane Colloquium, Barcelona, Spain, 26-31 October 2003.
6. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM. Use of meta-regression methods in the evaluation of heterogeneity in meta-analyses of diagnostic studies. Oral presentation at the XI Cochrane Colloquium, Barcelona, Spain, 26-31 October 2003.
7. Pai N, Tulsy JP, Pai M, Colford JM, Sheppard HW, Reingold AL. Structured treatment interruption of antiretroviral treatment in the management of HIV infection in adults. Presented at 15th International Conference on AIDS, Bangkok, Thailand, 11-16 July 2004.
8. Bitarakwate E, Hwang J, Dorsey G, Rosenthal P, Reingold A, Pai M. Efficacy of chloroquine or amodiaquine combined with sulfadoxine/pyrimethamine for treating uncomplicated malaria – a meta-analysis. Presented at the American Society of Tropical Medicine & Hygiene 53rd Annual Meeting, Miami Beach, USA, 7-11 November 2004.
9. Pai N, Joshi R, Wankhade A, Dogra S, Pai M, Mendiratta DK, et al. Evaluation of the diagnostic accuracy of OraQuick HIV1/2 rapid test in a rural patient population in central India. Presented at the CDC HIV Diagnostics Conference: New Developments and Challenges, Orlando, USA, 28 February-1 March 2005.
10. Pai N, Joshi R, Wankhade A, Dogra S, Pai M, Mendiratta DK, et al. Evaluation of the acceptability, feasibility, patient preference for OraQuick rapid HIV tests in a rural patient population in India. Presented at the CDC HIV Diagnostics Conference: New Developments and Challenges, Orlando,

- USA, 28 February-1 March 2005.
11. Pai M, Riley LW, Colford, JM. Interferon-g assays in the diagnosis of tuberculosis: impact of antigens on diagnostic accuracy. *Proceedings of the American Thoracic Society 2005(2):A270*.
 12. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis in health care workers in India: comparison of a whole-blood interferon-gamma assay with tuberculin skin testing. *Proceedings of the American Thoracic Society 2005(2):A20*.
 13. Morrison JL, Pai M, Hopewell P. Yield of tuberculosis contact investigations within households in high incidence countries: a systematic review. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, USA, 6-9 October 2005.
 14. Pai M, Joshi R, Dogra S, et al. Preliminary results from an evaluation of a whole-blood, interferon-gamma assay in individuals with tuberculosis infection and disease in a rural Indian hospital. Presented at the 36th Union World Conference on Lung Health, Paris, France, 18-22 October 2005.
 15. Dogra S, Narang P, Mendiratta DK, Chaturvedi P, Reingold AL, Colford JM, Riley LW, Pai M. Interferon-gamma assay for the detection of tuberculosis infection among children in a rural Indian hospital. Presented at the 36th Union World Conference on Lung Health, Paris, France, 18-22 October 2005.
 16. Mase S, Ng V, Henry M, Hopewell P, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz M, Pai M. Yield of Serial Sputum Smear Examinations in the Evaluation of Pulmonary Tuberculosis Suspects. 10th Annual Conference of the International Union Against Tuberculosis and Lung Disease - North American Region, Chicago, USA, 2-4 March 2006.
 17. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri SP, Reingold AL, Colford JM, Riley LW, Menzies D. Quantiferon-TB Gold Assay for Serial Testing in Health Care Workers: Boosting, Conversions, and Reversions. 10th Annual Conference of the International Union Against Tuberculosis and Lung Disease - North American Region, Chicago, USA, 2-4 March 2006.
 18. Steingart K, Ng V, Henry M, Hopewell P, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Sputum Processing Methods to Improve Sensitivity and Yield of Smear Microscopy for Tuberculosis: A Systematic Review. 10th Annual Conference of the International Union Against Tuberculosis and Lung Disease - North American Region, Chicago, USA, 2-4 March 2006.
 19. Steingart K, Henry M, Ng V, Hopewell P, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence Versus Conventional Sputum Microscopy for Tuberculosis. 10th Annual Conference of the International Union Against Tuberculosis and Lung Disease - North American Region, Chicago, USA, 2-4 March 2006.
 20. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri SP, Reingold AL, Colford JM, Riley LW, Menzies D. Performance of the Quantiferon-TB Gold In Tube Assay in Serial Testing of Health Care Workers. Oral presentation at the 27th Annual Conference of the European Society of Mycobacteriology, London, UK, 9-12 July 2006.
 21. Pai N, Joshi R, Mendiratta DK, Taksande B, Kalantri SP, Pai M, Narang P, Tulsy JP, Reingold AL. Differential in HIV seropositivity by gender and marital status: results from a cross sectional study from a rural hospital in India. Presented at the XVI International AIDS Conference, Toronto, Canada, 13-18 August 2006.
 22. Pai N, Joshi R, Mendiratta DK, Taksande B, Kalantri SP, Pai M, Narang P, Tulsy JP, Reingold AL.

- Comparable high accuracy of the OraQuick Rapid HIV-1/2 test with oral fluid and finger-stick specimens in patients with suspected HIV infection in a rural Indian hospital. Presented at the XVI International AIDS Conference, Toronto, Canada, 13-18 August 2006.
23. Pai M, Dendukuri N, Wang L, Joshi R, Dogra S, Kalantri SP, Mendiratta DK, Narang P, Menzies D, Rieder HL. Estimation of prevalence of tuberculosis infection among Indian healthcare workers: a comparison of conventional and model-based approaches. Presented at the 37th Union World Conference on Lung Health, Paris, France, 1-4 November 2006.
 24. Pai M, Joshi R, Bandopadaya M, Mendiratta DK, Narang P, Dogra S, Taksande B, Kalantri SP. Longitudinal changes in T cell interferon-gamma responses during anti-tuberculosis treatment. Presented at the 37th World Conference on Lung Health, Paris, France, 1-4 November 2006.
 25. Morrison J, Pai M, Hopewell PC. Yield of tuberculosis contact investigations in high income countries: a systematic review and meta-analysis. Poster (PS-71957-10) Presented at the 38th World Conference on Lung Health, Cape Town, South Africa, 9-12 November 2007.
 26. Michael JS, Daley P, Armstrong L, Kalaiselvan S, Chordia P, Asha M, Mathai D, John KR, Pai M. Comparison of QuantiFERON-TB Gold In-Tube to Tuberculin Skin Test for the Diagnosis of Active Tuberculosis (TB) in India - Preliminary Analysis. *Int J Infect Dis* 2008; Suppl. 1;12: E323-E324.
 27. Michael JS, Daley P, Armstrong L, Kalaiselvan S, Chordia P, Asha M, Mathai D, John KR, Pai M. Prospective Evaluation of Microscopic Observation drug-susceptibility (MODS) assay for the Diagnosis of Active Tuberculosis (TB) in India - Preliminary Analysis. *Int J Infect Dis* 2008; Suppl. 1;12: E324-E324.
 28. Zwerling AA, Menzies D, Pai M. T-cell based assays for the diagnosis of latent tuberculosis infection: updated meta-analysis. Thematic slide presentation at the 39th World Conference on Lung Health, Paris, France, 16-20 October 2008.
 29. Zwerling AA, Ladurantaye J, Menzies D, Pai M. T-cell IFN-gamma responses in patients treated for LTBI. Presented at 2nd Global Symposium on IGRAs, Dubrovnik, Croatia, 30 May 2009.
 30. Zwerling AA, Ladurantaye J, Pietrangelo F, Behr M, Schwartzman K, Dendukuri N, Menzies D, Pai M. Conversions and Reversions in Health Care Workers in Montreal, Canada Using QuantiFERON-TB-Gold In-Tube. *Am J Respir Crit Care Med*, Apr 2009; 179: A1012.
 31. Zwerling AA, M Behr, T Brewer, D Menzies, M Pai. Which Countries Are Most Likely To Benefit from Highly Specific IGRAs? Findings from the World Atlas of BCG Policies and Practices. *Am J Respir Crit Care Med*, Apr 2009; 179: A4773.
 32. RN van Zyl-Smit, M Pai, K Peprah, R Meldau, J Kieck, J Juritz, M Badri, A Zumla, ED Bateman, and K Dheda. Within-Subject Variability and Boosting of T-Cell IFN-g Responses Following Tuberculin Skin Testing. *Am J Respir Crit Care Med*, Apr 2009; 179: A1013.
 33. Brunet L, Minion J, Lienhardt C, Pai M. Mapping The Landscape Of Tuberculosis Diagnostic Research. *Am J Respir Crit Care Med*, May 2010; 181: A2255.
 34. Ling D, Pai M, Davids V, Brunet L, Lenders L, Meldau R, van Zyl-smit R, Peter J, Dawson R, Zumla A, Dheda KUJ. Incremental Value Of Interferon-Gamma Release Assays For Diagnosis Of Active Tuberculosis In Smear-Negative Patients In A High-Burden Setting: A Multivariable Analysis. *Am J Respir Crit Care Med*, May 2010; 181: A2262.

35. Smith RM, Cattamanchi A, Metcalfe J, Steingart K, Hopewell PC, Pai M. Systematic Review Of Sensitivity Of Interferon-gamma Release Assays For Detection Of M. Tuberculosis Infection In HIV-infected Patients. *Am J Respir Crit Care Med*, May 2010; 181: A2264.
36. Brunet L, Pai M, Davids V, Ling DI, Lenders L, Meldau R, van Zyl-smit R, Dawson R, Zumla A, Dheda KUJ. Tobacco Smoking And Spectrum Of Tuberculosis Infection And Disease In South African Patients With Suspected Tuberculosis. *Am J Respir Crit Care Med*, May 2010; 181: A4758.
37. Ling DI, Crepeau C, Dufresne M, Quach C, Lands LC, Pai M. Interferon-gamma release assay for pediatric tuberculosis: does it impact diagnostic and treatment decisions? *Am J Respir Crit Care Med*, May 2010; 181: A4776.
38. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-g Release Assays For TB Screening Of Healthcare Workers: A Systematic Review. *Am J Respir Crit Care Med*, May 2010; 181: A1764.
39. Leung E, Minion J, Pai M, Menzies D. Using MODS And/or TLA Techniques For Active Tuberculosis Diagnosis: A Systematic Review And Meta-Analysis. *Am J Respir Crit Care Med*, May 2010; 181: A1768.
40. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treating Active Tuberculosis In HIV Co-infected Patients: A Systematic Review And Meta-analysis. *Am J Respir Crit Care Med*, May 2010; 181: A5196.
41. DJ Christopher, Prince James, Peter Daley, Lois Armstrong, Beulah Premkumar, Joy Sarojini Michael, Alice Zwerling, Madhukar Pai. Serial testing for tuberculosis infection in a cohort of Indian nursing students: QFT conversions and reversions. Presented at the European Respiratory Society Annual Congress, 2010, E269.
42. Christopher DJ, James P, Michael JS, Zwerling A, Pai M. Serial testing using IGRAs in a cohort of Indian nursing students. Presented at the European Respiratory Society Annual Congress, Amsterdam, Netherlands, 2011, P2654.
43. Christopher DJ, James P, Michael JS, Shankar D, Zwerling A, Pai M. Prevalence of LTBI using IGRA and TST in a cohort of health professional trainees from India. Presented at the European Respiratory Society Annual Congress, Amsterdam, Netherlands, 2011, P2652.
44. Christopher DJ, James P, Michael JS, Zwerling A, Pai M. Concordance between IGRA and TST in a cohort of health professional trainees from India. Presented at the European Respiratory Society Annual Congress, Amsterdam, Netherlands, 2011, P2657.
45. Dendukuri N, Pai M, Ling D, Schiller I. Bayesian Framework for Estimating the Incremental Value of a Diagnostic Test in the Absence of a Gold Standard. Presented at the Joint Statistical Meetings, Montreal, Canada, 2013.
46. Tagmouti S, Slater M, Kik S, Banaei N, Cattamanchi A, Metcalfe J, Dowdy D, van Zyl-smit R, Dendukuri N, Pai M, Denkinger CM. Reproducibility of Quantiferon-TB Gold assay: a systematic review. *Am J Respir Crit Care Med* 2014;189:A2557.

G4i. Media citations, op-eds, and expert interviews

1. Asian Age, November 13, 2010

2. The New Yorker, November 15, 2010
3. India Today, March 14, 2011
4. Hindustan Times, March 24, 2011
5. The Hindu, March 26, 2011
6. Globalpost, March 31, 2011
7. Times of India, July 3, 2011
8. Nature News, August 23, 2011
9. Down To Earth, September 1, 2011
10. SciDev, January 19, 2012
11. CBC News, January 30, 2012
12. Scientific American, January 30, 2012
13. Huffington Post, January 30, 2012
14. NBR – National Bureau of Asian Research, February 16, 2012
15. L'Actualite, May 15, 2012
16. Deccan Herald, May 16, 2012
17. Express Pharma, July 1, 2012
18. SciBX, September 13, 2012
19. The Telegraph, December 6, 2012
20. BioSpectrum, February, 2013
21. The Indian Express, February 1, 2013
22. Business Standard, March 16, 2013
23. The Wall Street Journal, March 18, 2013
24. NBR – National Bureau of Asian Research, March 20, 2013
25. The Sunday Guardian, March 24, 2013
26. The Tribune, August 6, 2013
27. Next Billion, September 24, 2013
28. The Hindu, January 9, 2014
29. Al Jazeera, February 17, 2014
30. Deutsche Welle, February 27, 2014
31. Inter Press Service, March 5, 2014
32. Times of India, March 22, 2014
33. Business Line, March 23, 2014
34. Daily Pioneer, March 24, 2014
35. Express Healthcare, May 2014
36. The Week, July 2014
37. The Telegraph, August 30, 2014
38. Hindu Business Line, October 20, 2014
39. Hindu Business Line, March 20, 2015
40. The Tribune, March 24, 2015
41. Slate, March 24, 2015
42. Ottawa Citizen, March 23, 2015
43. Financial Times, April 7, 2015
44. New York Times, June 12, 2015
45. Scientific American, July 6, 2015
46. The Hindu, January 26, 2016
47. CNN IBN, IBN Live, Feb 18, 2016

48. Scientific American, March 9, 2016
49. Hindu Business Line, March 19, 2016
50. Huffington Post Blog, March 23, 2016
51. Huffington Post Blog, June 8, 2016
52. Huffington Post Blog, July 13, 2016
53. Forbes, Aug 4, 2016
54. Huffington Post Blog, September 17, 2016
55. Huffington Post Blog, September 20, 2016
56. Scroll.in, September 28, 2016
57. Toronto Star, September 29, 2016
58. Huffington Post Blog, October 4, 2016
59. Huffington Post Blog, October 13, 2016
60. Huffington Post Blog, October 17, 2016
61. The Globe and Mail, January 4, 2017
62. Forbes, Feb 13, 2017
63. Huffington Post Blog, 22 Feb, 2017
64. The Wire, March 2, 2017
65. Devex, March 23, 2017
66. Hindustan Times, 22 March, 2017
67. STAT News, 29 March, 2017
68. Huffington Post, 2 May, 2017
69. Huffington Post, 29 June, 2017
70. Huffington Post, 5 July, 2017
71. The Wire, 21 September, 2017
72. Devex, 22 September, 2017
73. The Conversation, 3 October, 2017
74. The Conversation, 20 March, 2018
75. The Conversation, 16 May, 2018
76. Huffington Post, 7 June, 2018
77. Huffington Post, 24 June, 2018
78. The Conversation, 17 Oct, 2018
79. The Indian Express, 29 Oct 2018
80. Scientific American, 11 Feb 2019
81. Huffington Post, 21 March 2019
82. The Conversation, 21 March 2019
83. Forbes, 7 May 2019
84. Forbes, 8 May 2019
85. Forbes, 15 May 2019
86. STAT News, 20 May 2019
87. Forbes, 9 July 2019
88. Forbes, 15 Aug 2019
89. Global Health NOW, 12 Aug 2019
90. The Conversation, 18 Aug 2019
91. Forbes, 17 Oct 2019
92. Forbes, 10 Nov 2019
93. Forbes, 30 Nov 2019

94. Forbes, 29 Jan 2020
95. Forbes, 17 Feb 2020
96. Forbes, 1 March 2020
97. Forbes, 6 March 2020
98. Forbes, 8 March 2020
99. Forbes, 17 March 2020
100. Forbes, 29 March 2020
101. Forbes, 6 April 2020
102. Forbes, 12 April 2020
103. Forbes, 22 April 2020
104. Forbes, 1 May 2020
105. Forbes, 3 June 2020
106. Forbes, 13 July 2020
107. Forbes, 20 July 2020
108. Forbes, 26 July 2020
109. Forbes, 9 Aug 2020
110. Forbes, 26 Sept 2020
111. Forbes, 22 Oct 2020
112. Forbes, 9 Nov 2020
113. New York Times, 20 Nov 2020
114. Forbes, 30 Nov 2020
115. The Atlantic, 14 Dec 2020
116. Forbes, 1 Jan 2021
117. Forbes, 17 Jan 2021
118. Forbes, 20 Jan 2021
119. Forbes, 28 Jan 2021
120. Forbes, 1 Feb 2021
121. Forbes, 15 Feb 2021
122. Forbes, 8 March 2021
123. Telegraph, 22 March 2021
124. Forbes, 22 July 2021
125. Forbes, 23 September 2021
126. Forbes, 6 October 2021
127. Forbes, 6 Jan 2022
128. Forbes, 25 Jan 2022
129. Forbes, 6 Feb 2022
130. The Atlantic, 4 March 2022
131. Forbes, 15 March 2022
132. Forbes, 22 May 2022
133. Forbes, 6 June 2022
134. Forbes, 28 July 2022
135. Forbes, 27 Oct 2022
136. Devex, 22 March 2023
137. Forbes, 13 July 2023
138. New York Times, 7 November 2023
139. Forbes, 19 Feb 2024

140. Forbes, 8 May 2024